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Abstract 
Cytokinesis involves abscission of the intracellular bridge between two daughter 
cells, thus completing mitosis. Membrane traffic is at the heart of mammalian 
cytokinesis. Rab11-FIP3 (also referred to as FIP3) in complex with Rab11 plays a 
key role in the delivery and targeting of recycling endosomes to the furrow; this 
is essential for completion of cytokinesis. FIP3 undergoes spatial and temporal 
dynamics during mitosis. During metaphase and early anaphase, FIP3 is largely 
cytosolic, with some localised to endosomal membrane structures. During late 
anaphase, following furrow initiation, FIP3 localises to the centrosome. At late 
cytokinesis, FIP3 relocates to the cleavage furrow and midbody. On separation of 
the daughter cells, FIP3 returns to the centrosome. The regulatory mechanisms 
governing the dynamics of FIP3 during mitosis are unknown. This work aims to 
determine if FIP3 can be phosphorylated by the cell-cycle kinases which regulate 
mitosis, and whether this has an impact on the spatial and temporal dynamics of 
FIP3.  
In vitro phosphorylation assays show that FIP3 can be phosphorylated by cyclin 
B-CDK1, Plk1, Aurora A and weakly by Aurora B. A proteomic approach revealed 
that, within the limits of our experimental approach, only cyclin B-CDK1 
phosphorylated FIP3 significantly, at serine 102. Interestingly, proteomic analysis 
of FIP3 immunoprecipitated from metaphase cells has identified serine 102, 281, 
348 and 451 as sites of potential phosphorylation. Data from this and a 
collaborating lab offers the hypothesis that FIP3 is phosphorylated during the 
early stages of the cell-cycle, and that dephosphorylation of FIP3 is the trigger 
for the association of FIP3 with membranes. A phospho-specific antibody to 
serine 102 (pS102) detects CDK1 phosphorylated FIP3. Serine 102 is 
phosphorylated in metaphase and becomes dephosphorylated as the cell 
progresses through to telophase. Further analysis reveals that cytosolic levels of 
pS102 peak in metaphase and decrease towards telophase to negligible levels. 
pS102 is absent in the membrane fraction. This work suggests that FIP3 may be 
directly phosphorylated by CDK1, at serine 102, in early mitosis. Kinase 
inhibition studies show that inhibition of CDK1, by the inhibitor BMI-1026, results 
in a mis-localisation of GFP-FIP3 in HeLa cells. This could also be interpreted as 
a delay in cytokinesis, since CDK1 inhibition resulted in more cells in telophase 
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displaying GFP-FIP3 in a localisation characteristic of an earlier stage of 
telophase, compared to the controls.  
The role of phosphorylation at serines 102, 281, 348 and 451 of FIP3 was 
investigated by creating phospho-null and phospho-mimetic mutants in the 
context of GFP-FIP3. It would appear that when mutated singly, the potential 
phospho-sites of serines 102, 281, 348 and 451 (phospho-mimetic mutant only for 
serine 451) have no significant effect on the localisation of FIP3 during mitosis, 
nor do they affect cytokinesis. A phospho-null mutation of serine 451 resulted in 
poor expression of the protein and an unhealthy population of cells.  
In summary, the spatial and temporal dynamics of FIP3 may be regulated by 
phosphorylation. We hypothesise that during prometaphase and metaphase FIP3 
is phosphorylated, preventing its association with endosomes. FIP3 is 
dephosphorylated in late anaphase, allowing it to associate with endosomes and 
subsequently traffic to the furrow and midbody. We suggest that CDK1 
phosphorylates FIP3 in the early stages of mitosis, at serine 102. In conclusion, 
membrane traffic is central to mammalian cytokinesis and data from this thesis 
suggests that it may be regulated by the cell-cycle kinases. 
4 
Table of Contents 
Chapter 1 Introduction 
1 Introduction........................................................................... 17 
1.1 Cell division ..................................................................... 18 
1.2 Cytokinesis....................................................................... 20 
1.2.1 Cytokinesis specialisations ............................................... 20 
1.2.1.1 Animal cells........................................................... 20 
1.2.1.2 Plant cells............................................................. 20 
1.2.1.3 Fission Yeast .......................................................... 21 
1.2.1.4 Budding Yeast ........................................................ 21 
1.2.1.5 Drosophila melanogaster cellularisation ......................... 21 
1.2.2 Stages of mammalian cytokinesis ....................................... 22 
1.2.2.1 Cleavage plane specification....................................... 22 
1.2.2.2 Contractile ring assembly........................................... 23 
1.2.2.3 Molecular mechanisms of furrow ingression ..................... 24 
1.2.2.4 The midbody.......................................................... 26 
1.2.2.5 Completion of cytokinesis .......................................... 27 
1.3 Membrane trafficking .......................................................... 27 
1.3.1 Intracellular membrane-trafficking pathways ........................ 27 
1.3.2 Rab GTPase family ........................................................ 28 
1.3.3 The ADP-ribosylation factor (ARF) family.............................. 29 
1.3.4 SNARE proteins ............................................................ 29 
1.3.5 Vesicle-tethering factors................................................. 30 
1.4 Membrane trafficking in cytokinesis ......................................... 30 
1.4.1 The role of membrane trafficking in cytokinesis ..................... 30 
1.4.2 Origin of the membrane delivered to the cleavage furrow ......... 32 
1.4.2.1 The secretory pathway.............................................. 32 
1.4.2.2 The endosomal pathway ............................................ 33 
1.5 Rab11-FIP3....................................................................... 36 
1.5.1 Rab11-family interacting proteins (Rab11-FIPs) ...................... 36 
1.5.2 Nuf protein is a D. melanogaster homologue of FIP3 ................ 37 
1.5.3 Cellular functions of FIP3 ................................................ 38 
1.5.4 Subcellular localisation of FIP3 ......................................... 39 
1.5.5 Structure of FIP3 .......................................................... 40 
1.5.6 Interacting partners of FIP3 ............................................. 41 
1.5.6.1 FIP3 interacts with members of the Rab GTPase family ....... 41 
1.5.6.2 FIP3 interacts with members of the ARF GTPase family ....... 42 
1.5.6.3 FIP3 interacts with CYK-4........................................... 43 
1.5.6.4 FIP3 interacts with ASAP1 .......................................... 44 
1.5.6.5 FIP3 interacts with molecular motor proteins ................... 44 
1.5.7 Model for membrane traffic during cytokinesis....................... 45 
1.5.8 Regulation of FIP3......................................................... 48 
1.6 Cell-cycle kinases............................................................... 49 
1.6.1 Cell-cycle overview ....................................................... 49 
1.6.2 Cyclin-dependent kinase 1 (CDK1)...................................... 50 
1.6.3 Polo-like kinase 1 (Plk1).................................................. 54 
1.6.4 Aurora A kinase ............................................................ 56 
1.6.5 Aurora B kinase ............................................................ 57 
5 
1.7 Aims .............................................................................. 59 
 
 
Chapter 2 Materials and Methods 
2 Materials and Methods............................................................... 60 
2.1 Materials ......................................................................... 61 
2.1.1 General reagents .......................................................... 61 
2.1.2 Cell culture reagents ..................................................... 66 
2.1.3 Primary antibodies ........................................................ 66 
2.1.4 Escherichia coli (E. coli) strains......................................... 67 
2.1.5 Plasmids .................................................................... 67 
2.1.6 Primers...................................................................... 68 
2.1.7 Rab11-FIP3 phospho-peptides ........................................... 69 
2.1.8 Radiochemicals ............................................................ 70 
2.1.9 Kinase Inhibitors........................................................... 70 
2.1.10 General solutions.......................................................... 71 
2.2 General laboratory procedures ............................................... 73 
2.2.1 Protein assays.............................................................. 73 
2.2.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)................. 73 
2.2.3 Western blotting .......................................................... 74 
2.2.4 Immunodetection of proteins............................................ 74 
2.2.5 Stripping of nitrocellulose membranes................................. 75 
2.2.6 Coomassie blue staining of SDS polyacrylamide gels................. 75 
2.2.7 Brilliant Blue G-Colloidal Coomassie ................................... 75 
2.3 General molecular biology .................................................... 76 
2.3.1 Site directed mutagenesis ............................................... 76 
2.3.2 Transformation of Escherichia coli ..................................... 77 
2.3.3 Small scale DNA preparations (miniprep).............................. 77 
2.3.4 Large-scale DNA preparation (maxiprep) .............................. 78 
2.3.5 DNA restriction digests ................................................... 79 
2.3.6 Ligation ..................................................................... 79 
2.3.7 Agarose gel electrophoresis ............................................. 80 
2.3.8 Gel extraction of DNA .................................................... 80 
2.3.9 Alkaline phosphatase treatment of linearised plasmid DNA ........ 81 
2.3.10 DNA sequencing............................................................ 81 
2.4 Mammalian cell culture........................................................ 81 
2.4.1 Cell culture conditions ................................................... 81 
2.4.2 Passage of cells............................................................ 82 
2.4.3 Cryopreservation of cells................................................. 82 
2.4.4 Resurrecting cells ......................................................... 83 
2.4.5 HeLa cell synchronisation ................................................ 83 
2.4.5.1 Thymidine, nocodazole block ...................................... 83 
2.4.5.2 Thymidine, nocodazole and MG132 block ........................ 83 
2.4.6 Plasmid DNA transfection ................................................ 84 
2.4.7 Cell lysis .................................................................... 84 
2.4.8 Membrane and cytosol fractionation ................................... 85 
2.4.9 Density gradient fractionation .......................................... 86 
2.5 Immunofluorescence ........................................................... 88 
2.5.1 Immunofluorescence...................................................... 88 
2.5.2 Confocal microscopy...................................................... 89 
6 
2.6 In vitro phosphorylation assays ............................................... 89 
2.7 Proteomics....................................................................... 90 
2.7.1 Phosphorylation site mapping of Rab11-FIP3.......................... 90 
2.7.2 Proteomic analysis of recombinant Rab11-FIP3....................... 91 
2.8 Phospho-specific antibody production....................................... 92 
2.8.1 Phospho-specific antibody generation ................................. 92 
2.8.2 Phospho-specific antibody purification ................................ 93 
2.8.3 Peptide competition assay (PCA) ....................................... 93 
 
 
Chapter 3 In vitro phosphorylation of Rab11-FIP3 
3 In vitro phosphorylation of Rab11-FIP3 ........................................... 95 
3.1 Introduction ..................................................................... 96 
3.2 Aims .............................................................................. 97 
3.3 Results............................................................................ 99 
3.3.1 Generic (non kinase specific) phosphorylation predictions ......... 99 
3.3.2 Kinase specific phosphorylation predictions .........................101 
3.3.3 In vitro phosphorylation of FIP3 by mitotic kinases.................102 
3.3.4 Analysis of recombinant FIP3’s capacity to autophosphorylate ...104 
3.3.5 In vitro phosphorylation of heat-treated FIP3 by mitotic kinases.106 
3.3.6 Phosphorylation site mapping of FIP3 .................................107 
3.3.7 In vitro phosphorylation of FIP3 by Aurora B (co-expressed with 
INCENP and survivin).....................................................113 
3.3.8 In vitro phosphorylation of CDK1 and Aurora A primed FIP3.......113 
3.3.9 In vitro phosphorylation of Alkaline Phosphatase treated FIP3 by 
mitotic kinases............................................................116 
3.3.10 Proteomic analysis of recombinant FIP3 ..............................117 
3.3.11 Immunoblot analysis of recombinant FIP3............................121 
3.3.12 FIP3 autophosphorylation in the presence of kinase inhibitors....123 
3.3.13 HeLa cytoplasmic S100 fraction phosphorylation of FIP3 ..........124 
3.4 Conclusions .....................................................................126 
 
 
Chapter 4 Consequences of Rab11-FIP3 phosphorylation  
4 Consequences of Rab11-FIP3 phosphorylation ..................................130 
4.1 Introduction ....................................................................131 
4.2 Aims .............................................................................133 
4.3 Results...........................................................................133 
4.3.1 Membrane and cytosol fractionation of synchronised GFP-FIP3 
expressing HeLa cells ....................................................133 
4.3.2 Phospho-specific antibody validation via peptide competition assays 
(PCAs) ......................................................................136 
4.3.3 Phospho-specific antibody analysis of membrane and cytosol 
fractions from synchronised GFP-FIP3 expressing HeLa cells ......143 
4.3.4 Density gradient analysis of FIP3’s association with HeLa 
membranes................................................................147 
4.3.5 Effect of kinase inhibition on GFP-FIP3 localisation in HeLa cells 149 
4.4 Conclusions .....................................................................154 
7 
Chapter 5 Analysis of Rab11-FIP3 phosphosites 
5 Analysis of Rab11-FIP3 phosphosites .............................................158 
5.1 Introduction ....................................................................159 
5.2 Aims .............................................................................159 
5.3 Methods .........................................................................159 
5.3.1 Site directed mutagenesis ..............................................159 
5.3.2 Validation of mutant plasmids .........................................161 
5.3.3 Cloning of BamHI fragments into GFP-FIP3 or pCR3.1 ..............161 
5.3.4 Generation of phospho-mutant GFP-FIP3 plasmids..................163 
5.3.4.1 Generation of GFP-FIP3-S102A and GFP-FIP3-S102D plasmids163 
5.3.4.2 Generation of GFP-FIP3-S281A and GFP-FIP3-S281D plasmids163 
5.3.4.3 Generation of GFP-FIP3-S348A and GFP-FIP3-S348D plasmids165 
5.3.4.4 Generation of GFP-FIP3-S451A and GFP-FIP3-S451D plasmids166 
5.4 Results...........................................................................167 
5.4.1 Restriction digest analysis of phospho-mutant GFP-FIP3 plasmids167 
5.4.2 Immunoblot analysis of HeLa lysates from cells expressing phospho-
mutant GFP-FIP3 plasmids ..............................................169 
5.4.3 Immunofluorescence analysis of HeLa cells expressing phospho-
mutant GFP-FIP3 plasmids ..............................................172 
5.4.4 Binuclear cell count analysis of HeLa cells expressing phospho-
mutant GFP-FIP3 plasmids ..............................................174 
5.5 Conclusions .....................................................................178 
 
 
Chapter 6 Discussion 
6 Discussion ............................................................................201 
 
 
Chapter 7 Appendix 
7 Appendix .............................................................................206 
7.1 Rab11-FIP3 Proteomic Data ..................................................206 
7.1.1 Rab11-FIP3 solution analysed via nLC-ESI-MS/MS by Sir Henry 
Wellcome Functional Genomics Facility (SHWFGF), University of 
Glasgow....................................................................206 
7.1.2 Rab11-FIP3 gel slices analysed via nLC-ESI-MS/MS by Sir Henry 
Wellcome Functional Genomics Facility (SHWFGF), University of 
Glasgow....................................................................209 
7.1.3 Rab11-FIP3 gel slices analysed via LC-MS/MS by Aberdeen 
Proteomics, University of Aberdeen...................................219 
 
List of References ....................................................................... 221 
 
8 
List of Tables 
Table 3.1 Generic (non kinase specific) phosphorylation predictions for serine 
residues of human Rab11-FIP3..........................................................101 
 
Table 7.1 Protein identification of recombinant FIP3 solution by nLC-ESI-MS/MS, 
searching the Mammalia database, performed by SHWFGF, University of 
Glasgow. ...................................................................................208 
Table 7.2 Protein identification of recombinant FIP3 solution by nLC-ESI-MS/MS, 
searching the Drosophila database, performed by SHWFGF, University of 
Glasgow. ...................................................................................209 
Table 7.3 Protein identification of recombinant FIP3 gel slice 1 by nLC-ESI-MS/MS 
searching the Mammalia database, performed by SHWFGF, University of 
Glasgow. ...................................................................................210 
Table 7.4 Protein identification of recombinant FIP3 gel slice 1 by nLC-ESI-MS/MS 
searching the Drosophila database, performed by SHWFGF, University of 
Glasgow. ...................................................................................211 
Table 7.5 Protein identification of recombinant FIP3 gel slice 2 by nLC-ESI-MS/MS 
searching the Mammalia database, performed by SHWFGF, University of 
Glasgow. ...................................................................................213 
Table 7.6 Protein identification of recombinant FIP3 gel slice 2 by nLC-ESI-MS/MS 
searching the Drosophila database, performed by SHWFGF, University of 
Glasgow. ...................................................................................213 
Table 7.7 Protein identification of recombinant FIP3 gel slice 3 by nLC-ESI-MS/MS 
searching the Mammalia database, performed by SHWFGF, University of 
Glasgow. ...................................................................................215 
Table 7.8 Protein identification of recombinant FIP3 gel slice 3 by nLC-ESI-MS/MS 
searching the Drosophila database, performed by SHWFGF, University of 
Glasgow. ...................................................................................215 
Table 7.9 Protein identification of recombinant FIP3 gel slice 4 by nLC-ESI-MS/MS 
searching the Mammalia database, performed by SHWFGF, University of 
Glasgow. ...................................................................................216 
Table 7.10 Protein identification of recombinant FIP3 gel slice 4 by nLC-ESI-
MS/MS searching the Drosophila database, performed by SHWFGF, University of 
Glasgow. ...................................................................................217 
Table 7.11 Protein identification of recombinant FIP3 gel slice 5 by nLC-ESI-
MS/MS searching the Mammalia database, performed by SHWFGF, University of 
Glasgow. ...................................................................................218 
Table 7.12 Protein identification of recombinant FIP3 gel slice 5 by nLC-ESI-
MS/MS searching the Drosophila database, performed by SHWFGF, University of 
Glasgow. ...................................................................................218 
Table 7.13 Protein identification of recombinant FIP3 gel slices by LC-MS/MS 
searching Human and Spodoptera Frugiperda databases, performed by Aberdeen 
Proteomics at the University of Aberdeen............................................220 
 
9 
List of Figures 
Figure 1-1 The stages of cell division................................................... 19 
Figure 1-2 Schematic diagram of the molecular mechanisms of furrow ingression
............................................................................................... 25 
Figure 1-3 Schematic representation of predicted domains and classification of 
the FIPs ..................................................................................... 37 
Figure 1-4 Temporal and spatial dynamics of GFP-FIP3 during mitosis............ 40 
Figure 1-5 Model for membrane traffic during cytokinesis .......................... 48 
Figure 1-6 Cell-cycle regulation of the central spindle. ............................. 50 
 
Figure 3-1 Identification of FIP3 phosphosites from metaphase HeLa lysates.... 98 
Figure 3-2 In vitro phosphorylation of FIP3 by mitotic kinases ....................103 
Figure 3-3 Analysis of recombinant FIP3’s capacity to autophosphorylate ......105 
Figure 3-4 In vitro phosphorylation of heat-treated FIP3 by mitotic kinases....107 
Figure 3-5 Phosphorylation site mapping of non-phosphorylated FIP3 ...........109 
Figure 3-6 In vitro phosphorylation of CDK1 and Aurora A primed FIP3..........115 
Figure 3-7 Recombinant FIP3 separated by SDS-PAGE and stained with Coomassie 
Blue Stain. .................................................................................117 
Figure 3-8 Immunoblot analysis of recombinant FIP3 ...............................122 
Figure 3-9 FIP3 autophosphorylation in the presence of kinase inhibitors.......124 
Figure 3-10 HeLa cytoplasmic S100 fraction phosphorylation of FIP3 ............126 
 
Figure 4-1 Analysis of the role of phosphorylation in the membrane and cytosol 
distribution of FIP3 throughout the cell-cycle. ......................................132 
Figure 4-2 Membrane and cytosol fractionation of synchronised GFP-FIP3 
expressing HeLa cells ....................................................................135 
Figure 4-3 Quantification of GFP levels in the membrane and cytosol fractions of 
synchronised GFP-FIP3 expressing HeLa cells.. ......................................136 
Figure 4-4 FIP3 pS102 peptide competition assay ...................................139 
Figure 4-5 FIP3 pS281 peptide competition assay ...................................140 
Figure 4-6 FIP3 pS348 peptide competition assay ...................................141 
Figure 4-7 FIP3 pS451 peptide competition assay ...................................142 
Figure 4-8 Analysis of phosphorylated serine 102 in membrane and cytosol 
fractionated synchronised GFP-FIP3 expressing HeLa cells ........................144 
Figure 4-9 Quantification of pS102 expression in the input, membrane and 
cytosol fractions of synchronised GFP-FIP3 expressing HeLa cells. ...............145 
Figure 4-10 Phospho-specific antibody analysis of crude cell homogenate from 
synchronised GFP-FIP3 expressing HeLa cells ........................................146 
Figure 4-11 Density gradient analysis of FIP3’s association with HeLa membranes
..............................................................................................148 
Figure 4-12 Telophase localisations of GFP-FIP3 in HeLa cells ....................150 
Figure 4-13 Effect of kinase inhibition on the localisation of GFP-FIP3 in non-
synchronised HeLa cells .................................................................151 
Figure 4-14 Effect of kinase inhibition on the localisation of GFP-FIP3 in 
synchronised HeLa cells .................................................................153 
 
Figure 5-1 Schematic figure of the GFP-FIP3 plasmid...............................160 
Figure 5-2 Restriction digest analysis of GFP-FIP3-S102A and GFP-FIP3-S102D 
plasmids....................................................................................168 
10 
Figure 5-3 Immunoblot analysis of HeLa lysates from cells expressing GFP-FIP3-
S102A and GFP-FIP3-S102D plasmids ..................................................170 
Figure 5-4 Immunoblot analysis of HeLa lysates from cells expressing GFP-FIP3-
S281A and GFP-FIP3-S281D plasmids...................................................171 
Figure 5-5 Immunoblot analysis of HeLa lysates from cells expressing GFP-FIP3-
S348A and GFP-FIP3-S348D plasmids ..................................................171 
Figure 5-6 Immunoblot analysis of HeLa lysates from cells expressing GFP-FIP3-
S451A and GFP-FIP3-S451D plasmids...................................................172 
Figure 5-7 Binuclear cell count of HeLa cells expressing GFP-FIP3-S102A and GFP-
FIP3-S102D plasmids for 48 hours ......................................................176 
Figure 5-8 Binuclear cell count of HeLa cells expressing GFP-FIP3-S281A and GFP-
FIP3-S281D plasmids for 24 hours ......................................................176 
Figure 5-9 Binuclear cell count of HeLa cells expressing GFP-FIP3-S348A and GFP-
FIP3-S348D plasmids for 72 hours ......................................................177 
Figure 5-10 Binuclear cell count of HeLa cells expressing GFP-FIP3-S451A and 
GFP-FIP3-S451D plasmids for 24 hours ................................................177 
Figure 5-11 Immunofluorescence analysis of HeLa cells in interphase expressing 
GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. ................183 
Figure 5-12 Immunofluorescence analysis of HeLa cells in interphase expressing 
GFP-FIP3-S348A/D and GFP-FIP3-S451A/D plasmids for 48 hours. ................184 
Figure 5-13 Immunofluorescence analysis of HeLa cells in interphase expressing 
wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to Lipofectamine 
2000 only and untransfected controls, for 48 hours.................................185 
Figure 5-14 Immunofluorescence analysis of HeLa cells in metaphase expressing 
GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. ................186 
Figure 5-15 Immunofluorescence analysis of HeLa cells in metaphase expressing 
GFP-FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 hours. ...................187 
Figure 5-16 Immunofluorescence analysis of HeLa cells in metaphase expressing 
wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to Lipofectamine 
2000 only and untransfected controls, for 48 hours.................................188 
Figure 5-17 Immunofluorescence analysis of HeLa cells in anaphase expressing 
GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. ................189 
Figure 5-18 Immunofluorescence analysis of HeLa cells in anaphase expressing 
GFP-FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 hours. ...................190 
Figure 5-19 Immunofluorescence analysis of HeLa cells in anaphase expressing 
wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to Lipofectamine 
2000 only and untransfected controls, for 48 hours.................................191 
Figure 5-20 Immunofluorescence analysis of HeLa cells in early telophase 
expressing GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. ...192 
Figure 5-21 Immunofluorescence analysis of HeLa cells in early telophase 
expressing GFP-FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 hours. ......193 
Figure 5-22 Immunofluorescence analysis of HeLa cells in early telophase 
expressing wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to 
Lipofectamine 2000 only and untransfected controls, for 48 hours. .............194 
Figure 5-23 Immunofluorescence analysis of HeLa cells in late telophase 
expressing GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. ...195 
Figure 5-24 Immunofluorescence analysis of HeLa cells in late telophase 
expressing GFP-FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 hours. ......196 
Figure 5-25 Immunofluorescence analysis of HeLa cells in late telophase 
expressing wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to 
Lipofectamine 2000 only and untransfected controls, for 48 hours. .............197 
Figure 5-26 Immunofluorescence analysis of HeLa cells expressing GFP-FIP3-
S451A/D plasmids for 48 hours .........................................................198 
11 
Figure 5-27 Immunofluorescence analysis of HeLa cells expressing wild-type GFP-
FIP3 and GFP-FIP3-I737E plasmids for 48 hours. .....................................199 
Figure 5-28 Immunofluorescence analysis HeLa cells treated with control 
transfections for 48 hours ...............................................................200 
 
12 
Acknowledgements 
First and foremost I’d like to thank Prof. Gwyn W. Gould for giving me the 
opportunity to work in his lab and for his patience, support and encouragement 
throughout my PhD. I’d also like to thank him for his faith in my abilities and 
giving me the opportunity to continue my work in his lab. 
I’d also like to thank Dr. Nia J. Bryant for her encouragement throughout my 
time in the lab. Dr. Johanne Matheson provided great friendship and support 
throughout my PhD which I value greatly. I’m indebted to Dr. Hélia Neto for her 
advice, encouragement and scientific discussion throughout this work, for which 
I am truly grateful. I’d like to thank all members of lab 241, past and present, 
for their technical help and moral support. In particular I’d like to thank Dr. 
Scott Shanks for his help and friendship throughout my PhD. 
I’d like to thank all my lovely friends who have helped me along the way. I’d 
especially like to thank Aparna Barua, Sara Stevenson, Helen McArdle and Sarah 
Jones for their friendship. 
Finally, I’m indebted to my parents for their patience, understanding and 
support, not only during my PhD, but throughout my lifetime. None of this would 
have been possible without them and I would like to take this opportunity to 
thank them with all my love. It remains for me to thank Sunny, Bailey and Finty, 
without whom none of this work would have been possible. 
13 
Author's declaration 
I declare that the work described in this thesis has been carried out by myself 
unless otherwise cited or acknowledged. It is entirely of my own composition 
and has not, in whole or in part, been submitted for any other degree. 
 
 
Louise Larmour Collins 
2009 
 
14 
Abbreviations 
 
Ab   Antibody 
ABD   ARF-binding domain 
ADP   Adenosine 5’-diphosphate 
AIS   Aurora B-INCENP-Survivin complex 
APC/C  Anaphase promoting complex/cyclosome 
APS   Ammonium persulphate 
ARF   ADP-ribosylation factor 
ATP   Adenosine 5’-triphosphate 
ATP-γ-32P  Adenosine 5’-triphosphate [γ-32P]  
ATP.Mg2+   Adenosine 5′-triphosphate magnesium salt  
bp   Base pair 
BFA   Brefeldin A 
BSA   Bovine serum albumin 
Cdc   Cell division control protein 
CDK   Cyclin-dependent kinase 
C. elegans   Caenorhabditis elegans 
CHO   Chinese hamster ovary cells 
CK2   Casein kinase 2 
CPC   Chromosomal passenger complex 
Da   Dalton 
DAPI  4′,6-Diamidino-2-phenyindole, dilactate 
DEPC  Diethylpyrocarbonate 
DMEM  Dulbecco's Modified Eagle's Medium 
DMSO  Dimethyl sulphoxide 
DNA   Deoxyribonucleic acid 
dNTP  Deoxynucleoside 5’-triphosphate 
DOPS  1,2-dioleoyl phosphatidylserine  
DTT   Dithiothreitol 
ECL   Enhanced chemiluminescence 
E. coli  Escherichia coli 
EDTA  Ethylenediaminetetraacetic acid 
EE   Early endosome 
Eferin  EF-hands-containing Rab11-interacting protein 
EGFP  Enhanced green fluorescence protein 
15 
EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic 
acid  
ER   Endoplasmic reticulum 
FIP   Rab11-family interacting protein  
FIP3   Rab11-FIP3 
GAP   GTPase activating protein 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GEF   Guanine nucleotide exchange factor 
GFP   Green fluorescent protein 
GTP   Guanosine 5’-triphosphate 
HEPES  N-(2-Hydroxyethyl)piperazine-N'-2-ethanesulphonic acid 
HCl   Hydrochloric acid 
HIS-tag  Hexa-histidine tag 
HRP   Horseradish peroxidase  
IgG   Immunoglobulin G 
INCENP  Inner centromere protein 
kb   Kilobase 
kDa   Kilo Dalton 
LE   Late endosome 
m   Milli 
M   Molar 
mA   Milliamps 
MAP   Microtubule-associated protein 
MBP   Myelin basic protein 
MEM   Minimum Essential Medium 
MES   2-(N-Morpholino)ethanesulphonic acid 
MG132   Z-Leu-Leu-Leu-al 
min   Minute 
MKLP  Mitotic kinesin-like protein  
MOPS  3-(N-Morpholino)propanesulphonic acid 
MT   Microtubule 
MTOC  Microtubule-organising centre 
nLC-ESI-MS/MS Nanoflow HPLC electrospray tandem mass spectrometry 
nLC-MS/MS  Nano-liquid chromatography-tandem mass spectrometry  
Nuf   Nuclear-fallout 
Nycodenz® 5-(N-2,3-Dihydroxypropylacetamido)-2,4,6-triiodo-N,N′-
bis(2,3-dihydroxypropyl)isophthalamide  
OD   Optical density 
16 
PAGE  Polyacrylamide gel electrophoresis 
PBS   Phosphate buffered saline  
PBST  Phosphate buffered saline with Tween20 
PCA   Peptide competition assay 
PCR   Polymerase chain reaction 
Plk   Polo-like kinase  
PM   Plasma membrane 
POPC  1-palmitoyl-2-oleoyl phosphatidylcholine  
PRC1  MAP protein regulator of cytokinesis 1  
Rab   Ras protein in brain 
Rab11-FIP  Rab11-family interacting protein  
Ras   Rat Sarcoma 
RBD   Rab11-binding domain 
RCP   Rab-coupling protein 
RE   Recycling endosome 
RNAi  RNA interference  
ROCK  Rho-associated kinase 
rpm   Revolutions per minute 
SAP   Shrimp alkaline phosphatase 
S. cerevisiae   Saccharomyces cerevisiae  
SDM   Site directed mutagenesis 
SDS   Sodium dodecyl sulphate  
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sf   Spodoptera frugiperda 
S. pombe   Schizosaccharomyces pombe  
SNARE Soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor 
TAE   Tris-acetate-EDTA 
TCA   Trichloroacetic acid  
TEMED  N,N,N′,N′-Tetramethylethylenediamine   
Tf   Transferrin 
TfR   Transferrin Receptor 
TGN   Trans-Golgi network  
Tris   Tris(hydroxymethyl)aminoethane  
Tween 20  Polyethylene glycol sorbitan monolaurate 
v/v   volume/volume ratio 
w/v   weight/volume ratio 
   17 
1 Introduction 
Louise L. Collins, 2010  Chapter 1, 18 
 
1.1 Cell division 
Cell division involves two key stages. Firstly the nucleus divides through a 
process known as mitosis, separating replicated chromosomes into two daughter 
nuclei. This is directly followed by partitioning of the cytoplasm via cytokinesis, 
forming two daughter cells (Barr and Gruneberg, 2007). 
A cell divides via a series of stages, as shown in figure 1.1 (reproduced from 
Scholey et al., 2003). Interphase is the period in the cell-cycle between one 
mitotic cycle and the next. At this stage chromosomes are uncondensed, 
allowing replication of genetic material, thus producing two copies of each 
chromosome, known as sister chromatids. The centrosome is also duplicated 
during interphase. The centrosome is composed of a pair of centrioles 
surrounded by pericentriolar material. This structure is the microtubule-
organising centre (MTOC), responsible for microtubule nucleation leading to the 
formation of the spindle poles during mitosis. Prophase (figure 1.1A) follows, 
where replicated chromosomes, each consisting of two sister chromatids, 
condense. Outside of nucleus, the replicated centrosomes migrate around the 
nucleus. The cytoskeleton reorganises, allowing the microtubules of the mitotic 
spindle to assemble between the two centrosomes. During prometaphase (figure 
1.1B), the nuclear envelope breaks down, allowing the spindle microtubules to 
interact with the fully condensed chromosomes via their kinetochores. Under the 
influence of the mitotic spindle, chromosomes align to the equator of the cell, 
in a process termed congression. At metaphase the chromosomes are aligned at 
the equator of the cell (indicated in figure 1.1C as ‘e’), midway between the 
spindle poles (indicated in figure 1.1C as ‘p’). During anaphase A (figure 1.1D), 
cohesion is lost between sister chromatids and they are pulled towards either 
pole of the cell under the influence of the spindle microtubules. In anaphase B 
(figure 1.1E), the spindle poles move apart which also aids chromosome 
separation. During anaphase the division plane is determined by the spindle 
which sends a signal to the cortex, marking the location for contractile ring 
assembly. Constriction of this structure in late anaphase forms a cleavage 
furrow, thus driving cytokinesis. At telophase (figure 1.1F), the two sets of 
Louise L. Collins, 2010  Chapter 1, 19 
daughter chromosomes arrive at the poles of the spindle and decondense. A new 
nuclear envelope reassembles around each set, completing the formation of two 
daughter nuclei. The cleavage furrow continues to ingress, forming a barrier 
between the two daughter cells. Abscission occurs to seal the furrow, thus 
creating two separate daughter cells, each with one complement of 
chromosomes. Cytokinesis is complete by the end of telophase; the nucleus and 
cytoplasm of each of the daughter cells then return to interphase, marking the 
end of mitosis. 
 
Figure 1-1 The stages of cell division (modified from Scholey et al., 2003) 
a, Prophase; b, Prometaphase; c, Metaphase; d, Anaphase A; e, Anaphase B; f, 
telophase/cytokinesis. Key: ‘e’ denotes the equator and ‘p’ marks each pole of the cell. 
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1.2 Cytokinesis 
1.2.1 Cytokinesis specialisations 
The overall approach to cell division is well conserved. However, species specific 
variations exist in the mechanics of cytokinesis. Plant cells divide by creating a 
Golgi-derived membrane partition between separating nuclei, known as the 
phragmoplast. Animal cells and yeast both employ an actomyosin based-
contractile ring to separate dividing cells (Guertin et al., 2002).  
1.2.1.1 Animal cells 
In animal cells, cytokinesis commences with the formation of the actomyosin 
contractile ring. The contractile ring is composed of actin, myosin-II and other 
structural and regulatory proteins. It forms beneath the plasma membrane, 
around the equator of the cell, at the mid-point between the two mitotic 
spindle poles. This structure constricts at the end of anaphase, inducing 
invagination of the cell membrane. This forms a cleavage furrow which 
continues to ingress until the two daughter cells are pinched apart (Eggert et 
al., 2006). The mechanics of animal cell cytokinesis will be discussed in more 
detail in section 1.2.2. 
1.2.1.2 Plant cells 
Plant cells are surrounded by a rigid cell wall, thus cell division cannot occur via 
the formation of an actomyosin-contractile ring or furrow ingression. Indeed, it 
has been found that the Arabidopsis genome sequence lacks the gene for myosin 
II (The Arabidopsis Genome Initiative, 2000). Instead plant cells divide by 
forming a new membrane compartment between the two daughter nuclei. In 
somatic cells, a structure known as the phragmoplast forms between divided 
nuclei and is believed to guide the formation of the membrane partition and the 
new cell wall (Jürgens, 2005). The phragmoplast is a cylindrical structure 
containing two opposing groups of actin filaments and microtubules. It forms in 
late anaphase. The phragmoplast is formed by the fusion of Golgi-derived 
vesicles, containing cell wall material, which have been transported along the 
microtubules to the plane of cell division. The continuous fusion of vesicles 
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generates a membrane compartment at the plane of division, forming a 
structure known as the cell plate. During cytokinesis the cell plate grows from 
the interior of the cell, outwards to the cell cortex. The fusion of later-arriving 
vesicles with the margin of the cell plate causes it to expand towards the 
periphery of the cell, resulting in the fusion of the cell plate with the plasma 
membrane, thus dividing the cytoplasm of the cell (Otegui et al., 2005).   
1.2.1.3 Fission Yeast  
Fission yeast Schizosaccharomyces pombe (S. pombe) divides by employing the 
actomyosin-contractile ring, which is positioned at the equator of the dividing 
yeast. As the contractile ring constricts, S. pombe synthesises a division septum 
behind the ring. This leads to the formation of a cell wall and membrane 
between the two daughter cells. Digestive enzymes then degrade the septum, 
thus completing cytokinesis and separating the daughter cells (Guertin et al., 
2002). 
1.2.1.4 Budding Yeast 
Contrastingly, Saccharomyces cerevisiae (S. cerevisiae) division is asymmetric 
and occurs by budding. A bud grows out from the mother cell cortex via 
polarised cell growth. An actomyosin based-contractile ring is then formed at 
the bud neck, and similar to S. pombe, a division septum is formed behind the 
constricting ring (Guertin et al., 2002). 
1.2.1.5 Drosophila melanogaster cellularisation 
Drosophila melanogaster (D. melanogaster) cellularisation is a specialised form 
of cytokinesis. During early embryogenesis, the zygote undergoes 13 nuclear 
divisions without cytokinesis (syncytial divisions). The first nine occur in the 
interior of the embryo. This results in the synctial blastoderm containing 
approximately 6000 somatic nuclei, which migrate to the cortex during 
interphase of cycle 10. Four more synchronous divisions take place as a 
monolayer directly below the plasma membrane. During cycle 14, termed 
cellularisation, membrane furrows develop in between the cortical nuclei, 
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eventually compartmentalising each nuclei into separate cells (Mazumdar and 
Mazumdar, 2002).  
1.2.2 Stages of mammalian cytokinesis 
In mammalian cells, cytokinesis was thought to be driven by an actomyosin-
contractile ring. Constriction of the contractile ring induces invagination of the 
cell membrane into a cleavage furrow which continues to ingress until the two 
daughter cells are pinched apart (Eggert et al., 2006). However, animal cell 
cytokinesis is a far more intricate process, involving a series of stages which are 
precisely timed and a multitude of proteins which are meticulously regulated to 
ensure accurate cell division (Eggert et al., 2006). On initiation of cytokinesis, 
the position of the cleavage plane is first specified. Next the contractile ring is 
assembled and the cleavage furrow ingresses. This leads to the formation of a 
narrow intracellular bridge linking the two daughter cells, the central region of 
which is known as the midbody. Cytokinesis reaches completion upon abscission 
of the intracellular bridge, forming two separate daughter cells (Eggert et al., 
2006). Abscission itself is a complicated process, the mechanism of which is 
currently undergoing intense research (Steigemann and Gerlich, 2009). For 
cytokinesis to occur, the actomyosin contractile ring must disassemble. 
Additionally, recent research has placed membrane traffic to the midbody at the 
heart of abscission (Albertson et al., 2005;Glotzer, 2005;Barr and Gruneberg, 
2007;Prekeris and Gould, 2008). The current understanding of the mechanisms 
behind each stage of cytokinesis is discussed in the following sections. 
1.2.2.1 Cleavage plane specification 
The first step in cytokinesis is to specify the position of the cleavage plane, 
where the components of the contractile ring are destined to assemble (Eggert 
et al., 2006). Research performed by Rappaport has shown that the mitotic 
spindle specifies the location of the contractile ring, and thereby the position of 
the cleavage furrow during early anaphase (reviewed in Burgess and Chang, 
2005). The cell cleavage plane is perpendicular to the axis of chromosome 
segregation, usually midway between spindle poles. This ensures that the 
genome and cytoplasm are equally partitioned between cells. In some situations, 
the spindle is not positioned centrally, resulting in asymmetric divisions 
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important during embryonic and stem cell divisions (Siller and Doe, 
2009;Neumüller and Knoblich, 2009). 
Several models exist to explain which parts of the mitotic spindle define the site 
of cleavage furrow formation (Eggert et al., 2006). One area of research 
questions the nature of the signals delivered to the cortex by the astral 
microtubules. Firstly, the astral relaxation model suggests that astral 
microtubules, radiating out from the centrosome to the cortex, dampen down 
cortical contraction everywhere except the furrow. This is due to the greater 
density of microtubules interacting with the polar regions of the cortex than at 
the equator (reviewed in Glotzer, 2004). However, the astral stimulation model 
suggests that astral microtubules at the equatorial region signal the site of 
cleavage and recruit contractile components to this region. This is potentially 
due to the fact that the cortex at the equator interacts with two sets of astral 
microtubules, one from either pole, and therefore the strength of the stimulus is 
highest in this region (reviewed in Glotzer, 2004). Another area of research has 
focused on the type of microtubules delivering the signal: astral or central 
spindle. During anaphase, overlapping microtubules from opposing poles are 
bundled, forming a structure known as the central spindle, or spindle midzone. 
Research suggests that the anaphase spindle midzone microtubules are a 
principal regulator of furrow formation (reviewed in Glotzer, 2004). Interestingly 
many regulators of mitosis localise to the central spindle, as discussed in section 
1.2.2.2. Currently no consensus has been reached as to the mechanisms behind 
cleavage plane specification. It has been suggested that multiple, overlapping 
mechanisms function within the cell, but the relative contributions of each 
mechanism vary between cell type (Burgess and Chang, 2005). 
1.2.2.2 Contractile ring assembly 
The contractile ring generates the force required for membrane deformation, 
resulting in ingression of the cleavage furrow. Once the position of the cleavage 
furrow has been determined, the components of the contractile ring assemble in 
anaphase. The contractile ring is composed primarily of actin and the motor 
protein myosin II (Eggert et al., 2006). Actin forms two-stranded helical 
polymers beneath the plasma membrane. Myosin II is a dimer of two heavy 
chains. Each of these is associated with two proteins, namely the essential light 
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chain (ELC) and regulatory light chain (rMLC). Each myosin heavy chain has a 
globular head domain at the N-terminus which interacts with actin and also 
binds to and hydrolyses ATP (Matsumura, 2005). The activity of myosin II 
generates the force required for constriction of the actomyosin ring, but the 
arrangement of actin filaments and myosin II in the contractile ring is unknown. 
The generally accepted model for furrow ingression is the ‘purse string’ model 
(Wang, 2005). Myosin II forms long bipolar filaments via interaction of the tail 
regions of their heavy chains. Myosin II filaments cross link anti-parallel actin 
filaments into contractile bundles around the equator. Upon hydrolysis of ATP by 
myosin II, oppositely opposed actin filaments slide past each other, causing the 
actin filaments to overlap and as a result the bundles shorten (Wang, 2005). This 
causes the associated membrane to ingress, forming a cleave furrow.  
1.2.2.3 Molecular mechanisms of furrow ingression 
Actin and myosin II activity reshapes the cell during cytokinesis; this process is 
regulated by a network of molecular mechanisms. The main regulators of actin 
dynamics are the Rho family of small GTPases (Piekny et al., 2005). In animal 
cells, the role of RhoA is central to cytokinesis (Glotzer, 2005). RhoA 
accumulates at the future site of furrowing (Yüce et al., 2005;Bement et al., 
2005). Upon activation, RhoA interacts with and regulates a collection of specific 
effector proteins (Piekny et al., 2005). These in turn regulate the actomyosin 
contractile network. A schematic diagram of the molecular mechanisms of 
furrow ingression is provided in figure 1.2. 
Like other small GTPases, RhoA cycles between a GDP-bound inactive form and a 
GTP-bound active form. This cycle is regulated by various proteins, which are 
delivered to the correct region of the cortex by the central spindle. ECT2 is the 
guanine nucleotide exchange factor (GEF) primarily responsible for activation of 
RhoA. CYK-4 is the GTPase-activating protein (GAP) responsible for inactivation 
of RhoA. Centralspindlin is a heterotetrameric protein assembly consisting of 
parallel homodimers of both the kinesin-6 microtubule motor MKLP1 (mitotic 
kinesin-like protein) and CYK-4. At anaphase the centralspindlin complex 
interacts with ECT2, via CYK-4, and MKLP1 restricts this ternary complex to the 
central spindle (Yüce et al., 2005). Interaction of ECT2 with centralspindlin 
results in the release of ECT2 from its autoinhibitory state (Kim et al., 2005). 
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ECT2 then promotes the accumulation of RhoA in the regions of the cortex 
surrounding the central spindle, thus inducing the recruitment of actin and 
myosin II and assembly of the contractile ring (Werner and Glotzer, 2008). 
RhoA regulates contractile ring formation both directly and indirectly, by binding 
and regulating specific effector proteins. RhoA effectors include members of the 
formin family and Rho-associated kinase (ROCK) (Piekny et al., 2005). RhoA 
activates the actin assembly factor formin, thus promoting formation of the 
contractile ring (Glotzer, 2005). Myosin II is activated by phosphorylation of its 
regulatory light chain (rMLC) at a highly conserved serine residue at position 19. 
Upon phosphorylation of Ser19, myosin II assembles into filaments, interacts 
with actin and the actin-dependent ATPase activity of the motor domain is 
activated (Matsumura, 2005). RhoA activation results in the activation of ROCK, 
which phosphorylates rMLC at Ser19, thus activating myosin and furrow 
formation (Piekny et al., 2005). ROCK also phosphorylates and inhibits the 
myosin-binding subunit (MBS) of a phosphatase which dephosphorylates Ser19 of 
rMLC, thus activating myosin phosphorylation (Piekny et al., 2005).  
 
Figure 1-2 Schematic diagram of the molecular mechanisms of furrow ingression (modified 
from Werner and Glotzer, 2008) 
Centralspindlin is a heterotetrameric protein assembly consisting of both the microtubule 
motor MKLP1 and the RhoA GAP CYK-4. At anaphase the centralspindlin complex interacts 
with the RhoGEF ECT2, via CYK-4. MKLP1 restricts this ternary complex to the central 
spindle. Interaction of ECT2 with centralspindlin results in the release of ECT2 from its 
autoinhibitory state. ECT2 then promotes the accumulation of RhoA in the regions of the 
cortex surrounding the central spindle. RhoA activates the actin assembly factor formin, 
thus promoting formation of the contractile ring. RhoA activates of ROCK, which 
phosphorylates rMLC at Ser19, thus activating myosin II. As a result, the actomyosin 
contractile ring constricts and the cleavage furrow is formed. 
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1.2.2.4 The midbody 
In the later stages of telophase, the spindle midzone is compressed by the 
ingressing cleavage furrow to the point at which the furrow cannot ingress any 
further. As a result, the cytoplasm of the two daughter cells is connected by a 
narrow intracellular bridge. The spindle microtubules form tightly packed 
antiparallel bundles, which overlap at the central region of the intracellular 
bridge. This is known as the midbody, a compact electron-dense matrix of 
proteins from the spindle midzone and cleavage furrow, covering the 
overlapping microtubule bundles of the central spindle (Steigemann and Gerlich, 
2009). The midbody is also known as the Flemming body, stembody or midbody-
ring. This structure can persist for some time as a tether between the two 
daughter cells, before resolution of the bridge (Steigemann and Gerlich, 2009). 
An electron micrograph of the intracellular bridge is shown in figure 1.5A of 
section 1.5.7. 
The function of the midbody is largely unknown and is currently being intensely 
researched. Skop and co-workers used a proteomic approach to analyse the 
protein complement of the midbody, using midbodies purified from Chinese 
hamster ovary (CHO) cells (Skop et al., 2004). This study identified 160 
candidate midbody proteins and these were categorised into five groups. The 
largest class of proteins (33%) were involved in secretory or membrane-
trafficking; 29% were actin-associated proteins; 11% were microtubule-
associated proteins; and another 11% were protein kinases. The remaining 16% of 
the midbody proteins were not classified as they fell into multiple groups. Thus a 
host of proteins are found within the midbody and could potentially regulate 
cytokinesis. 
Interestingly, the largest class of proteins (33%) identified were involved in 
secretory or membrane trafficking pathways (Skop et al., 2004). This suggests 
that membrane trafficking may not only be involved in cytokinesis, but plays an 
essential role in it. As discussed in section 1.2.1.2, higher plant cells do not 
employ an actomyosin-contractile ring to drive cytokinesis. In plant cells, the 
phragmoplast created between divided nuclei, via vesicle trafficking, forms a 
membrane partition and a new cell wall, resulting in abscission (Jürgens, 2005). 
It is suggested that in that aspect, the midbody might be analogous to the 
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phragmoplast and that membrane delivery to the furrow plays a critical role in 
cytokinesis (Otegui et al., 2005).  
1.2.2.5 Completion of cytokinesis 
Cytokinesis reaches completion upon abscission of the intracellular bridge, 
forming two separate daughter cells (Steigemann and Gerlich, 2009). The 
cellular dynamics at the midbody resulting in abscission are the subject of 
intense research. Cytokinesis is a multi-step process: the intracellular bridge 
must be stabilised to prevent regression, following cleavage furrow ingression 
the contractile ring must be disassembled and the membrane must be remodeled 
for abscission of the two daughter cells (Schweitzer and D'Souza-Schorey, 2004). 
Current research has placed membrane trafficking at the heart of cytokinesis. 
Daughter cells separate via a more complicated process than a mechanical 
‘ripping’ of the cell in two. Membrane fusion events are thought to play a key 
role during abscission, when the intracellular bridge is resolved and the two 
daughter cells finally divide and seal (Barr and Gruneberg, 2007). The 
involvement of membrane trafficking in cytokinesis will be covered in depth, in 
section 1.4. 
1.3 Membrane trafficking 
1.3.1 Intracellular membrane-trafficking pathways 
Eukaryotic cells contain various distinct membrane-bound intracellular 
compartments, called organelles. These include the nucleus, endoplasmic 
reticulum (ER), Golgi apparatus, mitochondria, endosomes and lysosomes (van 
Vliet et al., 2003). This high degree of organisation allows biochemically discrete 
processes to be carried out in isolation, under the correct cellular conditions. 
There are two main vesicular trafficking pathways within the cell, the secretory 
pathway and the endocytic pathway, which communicate via vesicle trafficking. 
Membrane bound vesicles bud-off from the donor compartment membrane, 
translocate to their target compartment, tether with this compartment and 
finally dock and fuse with the target organelle membrane (Bonifacino and Glick, 
2004). 
Louise L. Collins, 2010  Chapter 1, 28 
Depending on their role in the cell, proteins within the secretory pathway can be 
secreted from the cell, become plasma membrane bound, trafficked to the 
lysosomes or retained within any of the organelles (reviewed in van Vliet et al., 
2003). For secretion, protein must traffic through various distinct organelles 
within the secretory pathway. Proteins are synthesised, folded and quality 
controlled within the ER. They are packaged into vesicles and trafficked to the 
Golgi apparatus. Secretory proteins are then transported through the Golgi 
cisternae, where they are processed and sorted before traffic to the trans-Golgi 
network (TGN). At the TGN proteins are sorted according to their final 
destinations and secretory proteins are packaged into vesicles which are 
transported to the cell surface prior to exocytosis and secretion (van Vliet et al., 
2003).  
Within the endocytic pathway, proteins on the plasma membrane can be 
internalised through the inward budding of endocytic vesicles (reviewed in 
Maxfield and McGraw, 2004;Grant and Donaldson, 2009). Following endocytosis, 
vesicles are incorporated into early endosomes where sorting occurs. Cargo can 
be directed to the recycling endosomes which subsequently directs vesicles back 
to the plasma membrane. From the early endosomes, cargo can also be targeted 
to the late endosomes and lysosomes for degradation or to the TGN. 
A host of proteins regulate intracellular membrane trafficking, including Rab 
GTPases, ARF GTPases, a variety of vesicle-tethering factors and SNARE proteins 
(Bonifacino and Glick, 2004). 
1.3.2 Rab GTPase family 
The Rab family of proteins is the largest group in the Ras superfamily of small 
GTPases; it comprises of approximately 60 family members in humans 
(Stenmark, 2009). Specific Rabs are localised to the cytosolic side of specific 
intracellular membrane compartments, where they regulate distinct steps in 
vesicular membrane traffic pathways and Rabs are considered to regulate 
specificity of membrane trafficking (reviewed in Zerial and McBride, 2001). Rab 
proteins exist in two distinct conformations: in the GTP-bound form, the Rab 
protein is active, enabling it to interact with downstream effectors; in the GDP-
bound form the protein is inactive. Rab proteins switch between these two 
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conformations, under the influence of two classes of protein: the guanine 
nucleotide exchange factors (GEFs) catalyse nucleotide exchange from the GDP-
to the GTP-bound state, thus activating the Rab protein; the GTPase activating 
proteins (GAPs) catalyse GTP hydrolysis from the GTP- to the GDP-bound state, 
thus inactivating the Rab protein (Lee et al., 2009).   
1.3.3 The ADP-ribosylation factor (ARF) family 
The ADP-ribosylation factor (ARF) family of proteins belongs to the Ras 
superfamily of small GTPases. They cycle between and active GTP-bound and 
inactive GDP-bound conformations, a process which is mediated by GAPs and 
GEFs, as discussed in section 1.3.2 (D'Souza-Schorey and Chavrier, 2006). Six 
mammalian ARFs have been identified, and based on amino-acid sequence they 
can be categorised into three classes: Class I includes ARF1, ARF2 and ARF3; 
Class II includes ARF4 and ARF5; Class III has only one member, ARF6. However, 
this classification has been disputed (Kahn et al., 2006). The ARF family of 
proteins is involved in regulating membrane trafficking by recruiting coat 
proteins, influencing phospholipid metabolism and actin dynamics (D'Souza-
Schorey and Chavrier, 2006).  
1.3.4 SNARE proteins 
SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) 
proteins were first characterised during the late 1980s. Since then it has been 
revealed that SNARE proteins form a superfamily which is conserved from yeast 
to humans. There are 25 members in S. cerevisiae, 36 members in humans and 
54 members in Arabidopsis thaliana (Jahn and Scheller, 2006). SNARE proteins 
are the key constituents of membrane fusion. Studies using reconstituted lipid 
vesicles show that purified SNARE proteins are the minimal machinery required 
for membrane fusion (Weber et al., 1998). SNAREs can be classified with regards 
to their function. The donor compartment, which gives rise to the vesicle, hosts 
the v-SNARE (vesicle-membrane SNARE); the acceptor, or target, compartment 
contains the t-SNARE (target-membrane SNARE) (Sollner et al., 1993). SNAREs 
play a central role in the final stages of vesicle trafficking; they are responsible 
for docking and fusion of vesicles in a wide array of vesicle-mediated transport 
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pathways and also help to achieve compartmentalisation specificity. For fusion 
to occur the v-SNARE must interact specifically with its cognate t-SNARE. On 
interaction of the v-SNARE with the appropriate t-SNARE, the two opposing 
membranes are brought together, resulting in membrane fusion (Sollner et al., 
1993). This is known as the SNARE hypothesis. 
1.3.5 Vesicle-tethering factors 
In eukaryotic cells, membranes are often initially attached by tethering factors, 
which brings donor and target membranes into close enough proximity to allow 
SNARE proteins to fuse the opposing membranes (Pfeffer, 1999). 
One protein family which function as membrane tethers is the Exocyst family 
(Munson and Novick, 2006). The Exocyst is a large octameric complex that 
contains subunits Sec3, Sec5, Sec6, Sec8, Sec10, Sec15 and Exo70 and Exo84. 
The Exocyst functions to tether transport vesicles to the docking site on the 
plasma membrane, enabling SNARE assembly to occur. Members of the Exocyst 
family have been implicated in cytokinesis (Gromley et al., 2005;Fielding et al., 
2005). 
1.4 Membrane trafficking in cytokinesis  
1.4.1 The role of membrane trafficking in cytokinesis 
As discussed in section 1.2.1.2, membrane trafficking has long been known to be 
central to plant cell cytokinesis (Jürgens, 2005). Mammalian cell cytokinesis was 
considered to be driven solely by constriction of the actomyosin-contractile ring. 
However, recent research has placed membrane traffic at the heart of 
mammalian cytokinesis (Albertson et al., 2005;Glotzer, 2005;Barr and 
Gruneberg, 2007;Prekeris and Gould, 2008).  
Membrane delivery to the cleavage furrow accommodates for the changes in 
surface area required to produce two daughter cells. Research using sea urchin 
embryos and Xenopus eggs has shown that membrane delivery is targeted to the 
cleavage furrow (Shuster and Burgess, 2002;Danilchik et al., 2003). This 
additional membrane is not derived from expansion of pre-existing plasma 
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membrane, but is delivered to the plasma membrane from internal stores 
(Bluemink and de Laat, 1973). D. melanogaster embryogenesis requires a large 
amount of new membrane to be synthesised and delivered to the ingressing 
furrow canals to allow for cellularisation (Strickland and Burgess, 2004). 
Secretory and endocytic vesicles have been found to accumulate adjacent to the 
midbody in mammalian cells (Gromley et al., 2005;Goss and Toomre, 2008). 
Various RNAi screens and proteomic analyses have revealed that a significant 
number of membrane trafficking proteins are essential for cytokinesis (Skop et 
al., 2004;Echard et al., 2004;Eggert et al., 2004). Skop and co-workers used a 
proteomic approach to analyse the protein complement of the midbody, using 
midbodies purified from CHO cells (Skop et al., 2004). Interestingly, the largest 
class of proteins (33%) identified were involved in secretory or membrane 
trafficking, suggesting that membrane trafficking may be involved in cytokinesis. 
Various protein families known for their roles in membrane trafficking pathways 
have been implicated in cytokinesis. For example, studies have demonstrated 
roles for SNARE proteins (Low et al., 2003) and the Rab GTPase family (Skop et 
al., 2001). 
The importance of membrane dynamics may impinge on a variety of processes 
involved in cytokinesis. Membrane delivery to the cleavage furrow 
accommodates for the change in cell shape required to produce two daughter 
cells. Studies have shown that the lipid and protein composition of the 
membrane at furrow is distinct (Ng et al., 2005). Proteins required for 
cytokinesis, such as structural and signalling proteins, may be delivered to the 
cleavage furrow in conjunction with the delivery of new membrane (Strickland 
and Burgess, 2004). Membrane dynamics are thought to play a key role when the 
intracellular bridge is resolved and the two daughter cells finally divide and seal. 
Vesicles are thought to accumulate at the furrow and eventually fuse with the 
plasma membrane, resulting in the abscission of the two daughter cells 
(Steigemann and Gerlich, 2009).  
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1.4.2 Origin of the membrane delivered to the cleavage furrow 
The origins of the membrane delivered to the cleavage furrow have been 
intensely studied and both the secretory and recycling endosomal pathways have 
been implicated (Albertson et al., 2005). 
1.4.2.1 The secretory pathway 
One model for the origin of the membrane delivered to the plasma membrane 
during cytokinesis suggests that the secretory pathway is involved. A variety of 
evidence suggests that the delivery of Golgi-derived membrane to the furrow 
and midbody is a requirement during cytokinesis (Albertson et al., 2005). In a 
variety of cell types the Golgi apparatus is disassembled as the cell enters 
mitosis (Colanzi et al., 2003) and it has been suggested that the Golgi not only 
provides membrane for the invagination of the cleavage furrow, but also 
releases protein required for cytokinesis into the cytoplasm (Altan-Bonnet et al., 
2003). 
In plant cytokinesis, Golgi-derived vesicles are known to be the major source of 
membrane in the cell plate (Jürgens, 2005). In animal cytokinesis, it has been 
demonstrated that Golgi-derived vesicles are essential for the terminal stages of 
cytokinesis. Brefeldin A (BFA) is an inhibitor of ARF GTPases and disrupts the 
secretory pathway by inhibiting the budding of vesicles from the Golgi 
apparatus, thus preventing anterograde transport from the ER to the plasma 
membrane. BFA was observed to inhibit D. melanogaster cellularisation (Sisson 
et al., 2000) and cytokinesis in C. elegans embryonic blastomeres (Skop et al., 
2001). Using time-lapse microscopy, secretory vesicles have been found to 
accumulate adjacent to the midbody in mammalian cells (Gromley et al., 
2005;Goss and Toomre, 2008). 
Research has uncovered a variety of Golgi-associated proteins which are 
essential for cytokinesis. One quarter of the proteins identified by Skop et al. in 
midbodies was Golgi-associated proteins. RNAi-based function analysis in C. 
elegans embryos found that many of these proteins are essential in early and 
late stages of cytokinesis (Skop et al., 2004). A host of Golgi-associated proteins 
has been identified as required for cytokinesis in D. melanogaster. For example, 
Louise L. Collins, 2010  Chapter 1, 33 
on injection of embryos with antibodies directed against the D. melanogaster 
Golgi-associated protein, Lava Lamp, it was revealed that, in addition to 
disruption of Golgi morphology, furrow formation during cellularisation was also 
inhibited (Sisson et al., 2000). Mutations in the D. melanogaster Syntaxin 5 
homologue, a Golgi-localised SNARE, resulted in male sterility due to a failure in 
cytokinesis (Xu et al., 2002). 
1.4.2.2 The endosomal pathway 
One model for the origin of the membrane delivered to the plasma membrane 
during cytokinesis suggests that the endocytic pathway also plays a role in this 
process (Prekeris and Gould, 2008;Montagnac et al., 2008;Fürthauer and 
González-Gaitán, 2009;Ai and Skop, 2009). As discussed in section 1.3.1, proteins 
on the plasma membrane can be internalised through the inward budding of 
endocytic vesicles and incorporated into early endosomes where sorting occurs. 
Cargo can be directed to the recycling endosomes which subsequently directs 
vesicles back to the plasma membrane (Maxfield and McGraw, 2004;Grant and 
Donaldson, 2009). Studies have highlighted the potential importance of the 
endocytic recycling pathway in cytokinesis. Membrane delivery to the cleavage 
furrow originates from internal stores (Shuster and Burgess, 2002;Danilchik et 
al., 2003) and it has been suggested that endosomes are involved (Albertson et 
al., 2005). Also, it is considered that perhaps the endosomal pathway may 
deliver lipids and proteins required for cytokinesis progression to the furrow; 
studies have shown that the lipid and protein composition of the membrane at 
furrow is distinct (Ng et al., 2005). Additionally, the recycling endosome is 
microtubule associated and localises to the microtubule-organising centre 
(MTOC), which is key to positioning of the contractile ring (Albertson et al., 
2005). 
A variety of evidence supports the model for the involvement of endosomal-
derived membranes in cytokinesis. Research has shown that furrow-specific 
endocytosis is crucial for the completion of cytokinesis. Endocytosis has been 
observed to occur specifically at the furrow during terminal cytokinesis in 
zebrafish embryos (Feng et al., 2002). Previously it was thought that endocytosis 
stopped during mitosis and only resumed after cell division, but two recent 
studies have shed new light on the changes which occur in endocytic recycing 
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during mitosis. Studies in cultured mammalian cells have shown that at the start 
of mitosis, as the cell rounds up, endocytic recycling of internalised membranes 
back to the cell surface slows significantly. Yet, clathrin-based endocytosis 
carries on as normal throughout cell division (Boucrot and Kirchhausen, 2007). 
Thus, there is a decrease in plasma membrane surface area and an accumulation 
of cell surface-derived membrane in the endosomal system at the beginning of 
mitosis. Following this, the contractile ring forms and furrow ingresses. As 
anaphase begins, endocytic recycling resumes and a massive fusion of endosomes 
with the plasma membrane has been observed. Consequently, the cell surface 
area recovers before abscission. These changes in endocytic recycling rates and 
cell surface area appear to be required for cytokinesis (Boucrot and Kirchhausen, 
2007). Another study using cultured HeLa cells shows that during furrow 
ingression, membrane is endocytosed from the plasma membrane at the polar 
regions of dividing HeLa cells, during furrow ingression in anaphase, and from 
the midbody during late telophase. Vesicles endocytosed from the polar region 
during ingression are trafficked to the midbody during late cytokinesis, perhaps 
delivering cargo required for abscission (Schweitzer et al., 2005). 
A variety of endocytic proteins have been shown to be important for the final 
events of animal cytokinesis. Inhibition of the GTPase dynamin, a protein 
involved in clathrin-dependent endocytosis, inhibits cleavage furrow ingression 
in C. elegans embryos (Thompson et al., 2002). Inhibition of cytokinesis is 
observed when clathrin-dependent endocytosis is blocked via expression of a 
dominant negative form of Eps15, an accessory protein of clathrin-mediated 
endocytosis (Schweitzer et al., 2005). An endocytic SNARE, VAMP8, has been 
shown to localise to the cleavage furrow and is required for cytokinesis (Low et 
al., 2003). 
The Rab GTPase family of proteins is essential for cytokinesis. As discussed in 
section 1.3.2, Rab proteins cycle between the GTP-active and GDP-inactive 
bound forms, recruiting different effector proteins which control targeting and 
fusion events (Zerial and McBride, 2001). Rab11 is localised to the recycling 
endosomes and is required for organisation and vesicular budding from this 
compartment to the plasma membrane (Ullrich et al., 1996;Chen et al., 
1999;Dollar et al., 2002). Several studies have uncovered a role for Rab11 in 
furrow ingression and cytokinesis. RNAi-induced depletion of Rab11 in C.elegans 
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embryos caused furrow regression during late cytokinesis (Skop et al., 2001). 
Rab11 is essential for furrow ingression during D. melanogaster cellularisation 
(Pelissier et al., 2003;Riggs et al., 2003). In HeLa cells, Rab11 plays a role in the 
delivery of recycling endosome derived membrane to the cleavage furrow during 
late telophase, and this is essential for cytokinesis completion (Wilson et al., 
2005;Fielding et al., 2005). Using a systematic RNAi approach, each of the 29 
Rab genes were downregulated in D. melanogaster S2-cultured cells (Kouranti et 
al., 2006) and downregulation of Rab35 resulted in cytokinesis defects which 
were attributed to de-stabilisation of the intracellular bridge. Rab35 was found 
to localise to the plasma membrane and the recycling endosomal pathway 
(Kouranti et al., 2006). 
The ARF family of small GTPases, discussed in section 1.3.3, is involved in 
regulating membrane trafficking by recruiting coat proteins, influencing 
phospholipid metabolism and regulating actin dynamics (D'Souza-Schorey and 
Chavrier, 2006). ARF6 regulates membrane trafficking in the endosomal pathway 
(D'Souza-Schorey et al., 1995). ARF6-GTP is upregulated during cytokinesis in 
animal cells and has been observed to accumulate at the cleavage furrow and 
midbody (Schweitzer and D'Souza-Schorey, 2002). Depletion of ARF6 with RNAi 
inhibited the final stages of cytokinesis in HeLa cells, resulting in an increased 
number of binuclear cells (Schweitzer and D'Souza-Schorey, 2005). Contrastingly, 
Yu et al. demonstrated that ARF6 depletion using RNAi did not result in a 
significant level of cytokinesis failure. However, simultaneous knockdown of 
Rab11 and ARF6 resulted in a binuclear count greater than the sum of the counts 
from knockdown of Rab11 or ARF6 alone, suggesting that these proteins act 
synergistically as the cell moves from furrowing into abscission (Yu et al., 2007). 
Recent data has shown that ARF6 is required for cytokinesis in the D. 
melanogaster male germ line (Dyer et al., 2007). ARF6 localises to recycling 
endosomes associated with the central spindle, but does not target them to this 
location. However, ARF6 is required for the rapid membrane addition during 
furrowing (Dyer et al., 2007). 
Another recycling endosomal protein family shown to play a role in cytokinesis is 
the Rab11-family interacting proteins (Rab11-FIPs or FIPs) (Horgan and 
McCaffrey, 2009). One member of this family is Rab11-FIP3 (more commonly 
referred to as FIP3), which forms a ternary complex with Rab11 and ARF6 
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(Fielding et al., 2005). Knockdown of FIP3 with RNAi results in an inhibition of 
abscission (Wilson et al., 2005). FIP3 in complex with Rab11 has been proposed 
to regulate the delivery and targeting of recycling endosomes to the cleavage 
furrow and midbody; this is essential for abscission (Hickson et al., 2003;Wilson 
et al., 2005;Fielding et al., 2005). FIP3 is discussed in section 1.5, along with a 
current working model for the role in membrane traffic in cytokinesis. 
1.5 Rab11-FIP3 
1.5.1 Rab11-family interacting proteins (Rab11-FIPs)  
Rab11-family interacting proteins (Rab11-FIPs or FIPs) are an evolutionary 
conserved protein family which are effector molecules for the Rab and ARF 
GTPases (Horgan and McCaffrey, 2009). FIP proteins are encoded by five genes, 
and, based on primary structure, they can be placed into two categories: class I 
FIPs include Rip11 (Rab11-FIP5), Rab11-FIP2 and RCP (Rab-coupling protein or 
Rab11-FIP1); class II FIPs include Rab11-FIP3 and Rab11-FIP4. A schematic 
representation of the FIP protein family is provided in figure 1.3 (Simon and 
Prekeris, 2008).  
Rab11-FIP3 (FIP3) was identified by several groups and thus has several aliases 
(Shin et al., 1999;Prekeris et al., 2001;Hales et al., 2001). Rab11-FIP3 was 
initially characterised by one group as an ARF5-binding protein and was called 
arfophilin (Shin et al., 1999;Shin et al., 2001). Other groups identified Rab11-
FIP3 as a Rab11-binding protein and referred to it as Eferin (Prekeris et al., 
2001). Rab11-FIP3 will be referred to as FIP3 in this thesis. Between them, FIPs 
display low sequence homology (14 to 34% amino acid identity) (Wallace et al., 
2002). However, FIPs share one distinguishing feature with which they were 
characterised. FIPs bind Rab11 via a conserved C-terminal twenty amino acid 
motif, called the Rab11-binding domain (RBD) (Prekeris et al., 2001;Meyers and 
Prekeris, 2002). In addition to the RBD, class I FIPs have a phospholipid-binding 
C2-domain, whereas Class II FIPs have calcium binding EF-hand domains. Further 
research has shown that Class II FIPs also possess binding domains for ARF 
proteins and CYK-4, as discussed in sections 1.5.6.2 and 1.5.6.3, respectively 
(Horgan and McCaffrey, 2009). FIPs are key proteins in the regulation of multiple 
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distinct membrane trafficking processes including recycling of cargo to the cell 
surface, delivery of membrane to the cleavage furrow and midbody, and linker 
proteins between Rab11 and motor proteins (Horgan and McCaffrey, 2009).  
 
 
Figure 1-3 Schematic representation of predicted domains and classification of the FIPs 
(modified from Simon and Prekeris, 2008) 
 
1.5.2 Nuf protein is a D. melanogaster homologue of FIP3 
As discussed in section 1.2.1.5, D. melanogaster cellularisation is a specialised 
form of cytokinesis. In D. melanogaster, nuclear fallout (nuf) is an essential 
maternal-effect gene, the product of which is required for cellularisation 
(Rothwell et al., 1998). Nuf is concentrated at the centrosomes during 
cellularisation and is essential for furrow formation by remodelling and 
recruiting actin to the cleavage furrow (Rothwell et al., 1998). Nuf has also been 
implicated in membrane recruitment to the furrow (Rothwell et al., 1999). Nuf 
and Rab11 colocalise at the centrosome during cellularisation (Riggs et al., 
2003), and since Rab11 is associated with the recycling endosome (Ullrich et al., 
1996), this suggests that Nuf is localised to the recycling endosomes during 
cellularisation. GST pull-downs show that Rab11 and Nuf interact and are 
mutually dependent upon each other for localisation to the recycling endosome, 
since disruption of either causes the other to mis-localise (Riggs et al., 2003). 
The association of Nuf and Rab11 is essential for cellularisation as both Rab11- 
and nuf-derived embryos display similar defects in actin and membrane 
recruitment to the furrow site, resulting in defects in furrowing (Riggs et al., 
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2003). Recent work has suggested that Rab11 and Nuf are involved in the 
delivery of F-actin-associated endosomal vesicles to the cellularisation furrow, 
via the microtubules (Albertson et al., 2008) and that Nuf promotes local actin 
polymerisation at the furrow (Cao et al., 2008).  
Bioinformatic analysis of protein sequences reveals that Nuf exhibits a degree of 
homology to the mammalian proteins FIP3 and FIP4. In particular their C-
terminal 300 amino acids share homology with Nuf in regions predicted to form 
coiled-coils (Riggs et al., 2003;Hickson et al., 2003). This region encompasses 
the RBD (Prekeris et al., 2001;Meyers and Prekeris, 2002). The N-termini are 
more divergent. In HeLa cells, FIP3 and FIP4 both localise to centrosomes in 
interphase cells (Hickson et al., 2003;Wilson et al., 2005;Fielding et al., 2005). 
In interphase HeLa cells, over-expressed GFP-Nuf and GFP-FIP4 alters the 
morphology of the recycling endosomes by confining them to a pericentrosomal 
region, suggesting that Nuf and FIP4 are functionally related (Hickson et al., 
2003). Thus Nuf and FIP3 are considered functional homologues in D. 
melanogaster and mammalian cells. 
1.5.3 Cellular functions of FIP3  
FIP3 was shown to regulate the late stage of cytokinesis. HeLa cells transfected 
with FIP3 RNAi for 48 and 72 hours produced in the order of 20 to 30% binuclear 
cells, indicating a failure of cytokinesis (Wilson et al., 2005). Phase-contrast 
time-lapse imaging of FIP3 RNAi treated HeLa cells revealed that FIP3 is required 
for a late stage of cytokinesis (Wilson et al., 2005). Cleavage furrows formed, 
but were not resolved; daughter cells remained connected by a long cytoplasmic 
bridge for an extended period of time. Frequently, daughter cells did not 
undergo cytokinesis, but appeared to detach and apoptose. The intracellular 
bridges of some cells appeared to break under the strain of pulling from the two 
daughter cells, which does not count as cytokinesis. Thus FIP3 is required for 
abscission, at the very end of telophase. FIP3 functions downstream of Rab11, 
and it has been proposed that the FIP3-Rab11 complex plays a key role in 
cytokinesis by delivering membrane derived from the recycling endosomes to the 
cleavage furrow and midbody (Wilson et al., 2005;Fielding et al., 2005), which is 
essential for abscission. A current working model for membrane traffic to the 
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furrow during cytokinesis was created by A.R. Skop and is reproduced in this 
thesis, in section 1.5.7, figure 1.5. As mentioned in section 1.5.2, the D. 
melanogaster homologue of FIP3, Nuf, regulates actin polymerisation at, and 
delivery of recycling endosomal material to, the cleavage furrow of D. 
melanogaster embryos (Rothwell et al., 1998). Recently FIP3 was also found to 
modulate the actin cytoskeleton (Jing et al., 2009). Knockdown of FIP3 by RNAi 
inhibits the motility of MDA-MB-231 breast carcinoma cells. Data suggests that 
FIP3 regulates polarised Rac1 activation by mediating the targeting of ARF6 to 
the leading edge of motile cells. Thus, FIP3 is at the centre of two processes: 
membrane traffic from the recycling endosome, via a Rab11 interaction, and 
plasma membrane and actin remodelling via an ARF6 interaction. 
1.5.4 Subcellular localisation of FIP3 
Time-lapse microscopy of HeLa cells expressing GFP-FIP3 has shown that FIP3 
undergoes spatial and temporal dynamics during mitosis (Wilson et al., 2005).  
During metaphase and early anaphase FIP3 is diffuse and localised to endosomal 
membrane structures in the cytosol. During early anaphase, following furrow 
initiation, FIP3 localises to membranes at the centrosome. At late cytokinesis, 
FIP3 rapidly relocates to the cleavage furrow and midbody. On separation of the 
daughter cells, FIP3 relocates to the centrosome. This is shown in figure 1.4. 
Immunofluorescence studies have shown that a proportion of FIP3 associates 
with the centrosome throughout the cell cycle (Wilson et al., 2005). 
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Figure 1-4 Temporal and spatial dynamics of GFP-FIP3 during mitosis (Wilson et al., 2005). 
HeLa cells stably expressing GFP-FIP3 were imaged using time-lapse microscopy. (A) A cell 
in metaphase with an asterisk labelling the midbody. (B) A cell in the late phase of 
cytokinesis. 
 
1.5.5 Structure of FIP3 
FIPs display low sequence homology with the exception being a conserved C-
terminal twenty amino acid motif, called the Rab11-binding domain (RBD) 
(Prekeris et al., 2001), the minimal area of which encompasses residues 733 to 
756 of FIP3 (Shiba et al., 2006). Analysis of the amino acid sequence reveals that 
FIP3 also contains two putative EF-hand domains (Prekeris et al., 2001) at 
approximately 202 to 237 and 234 to 269 amino acids (The UniProt Consortium, 
2009). EF-hand domains are involved in calcium binding (Grabarek, 2006). Only 
the class II FIPs possess EF-hand domains; Class I FIPs possess phospholipid 
binding C2 domains. Also important to note is the proline rich region found at 
the N-terminus of FIP3 (Prekeris et al., 2001), encompassing amino acids 5 to 
197 (The UniProt Consortium, 2009). This type of region is known to mediate a 
large number of protein to protein interactions (Kay et al., 2000). Prediction 
software has shown that FIP3 has an extensive α-helical coiled-coil region 
between residues 463 and 692 (Wallace et al., 2002;Horgan et al., 2007). 
Interestingly, the C-termini of FIPs mediate homodimerisation in vitro and 
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interact with two Rab11 proteins to form heterotetrameric complexes (Wallace 
et al., 2002;Junutula et al., 2004). A schematic representation of the domains of 
the FIP family is provided in figure 1.3 (Simon and Prekeris, 2008). 
The 3D crystal structure of FIP3 in its entirety is not yet known. The crystal 
structure of the FIP3-RBD (695 to 756 amino acids) in complex with Rab11 
reveals that the RBD of FIP3 mediates homodimerisation of the FIP molecules. 
Amphiphillic helices from two FIP3-RBDs form a parallel coiled-coil homodimer. 
This creates two symmetrical interfaces for binding the switch regions of two 
Rab11 molecules, thus forming a heterotetrameric complex between two FIPs 
and two Rab11s, with the FIPs forming the central α-helical coiled-coil (Eathiraj 
et al., 2006;Shiba et al., 2006). Resolution of the crystal structure of Rab11 in 
complex with the Class I FIP, FIP2, is similar, suggesting that this mode of 
binding is a feature of the FIP family (Jagoe et al., 2006). However, it is 
important to note that points of contact between the two FIP3 proteins may 
exist out with the RBD, since prediction software has shown that FIP3 has an 
extensive α-helical coiled-coil region between residues 463 and 692 (Wallace et 
al., 2002;Horgan et al., 2007). 
1.5.6 Interacting partners of FIP3 
1.5.6.1 FIP3 interacts with members of the Rab GTPase family 
FIP3 has been shown to directly interact with Rab11. The family of FIP proteins 
is characterised by a highly conserved RBD of 20 amino acids, located at the C-
terminus of the protein (Prekeris et al., 2001). A schematic representation of 
the protein binding domains of FIP3 is provided in figure 1.3 (Simon and Prekeris, 
2008). The crystal structure of the FIP3-RBD in complex with Rab11 shows a 
heterotetrameric complex between two FIPs and two Rab11s (Eathiraj et al., 
2006;Shiba et al., 2006). Work from our lab has shown that FIP3 has the binding 
preference of Rab11>ARF6>>ARF5 (Fielding et al., 2005). Significantly, FIP3 
binds to Rab11 and ARF6 at distinct and non-overlapping sites in its C-terminal 
domain, suggesting the FIP3 may interact with the two GTPases simultaneously, 
forming a ternary complex (Fielding et al., 2005). 
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During interphase, Rab11 is predominantly associated with recycling endosomes 
in the pericentrosomal region (Ullrich et al., 1996). Rab11-containing recycling 
endosomes become highly concentrated around the cleavage furrow and in the 
midbody in telophase (Wilson et al., 2005). FIP3 displays a similar cell-cycle 
distribution (Wilson et al., 2005). Rab11 knock-down with RNAi results in 
translocation of FIP3 from the membranes to the cytosol, suggesting that Rab11 
mediates the association of FIP3 with endosomes (Wilson et al., 2005). A Rab11-
binding deficient mutant of FIP3 (FIP3-I737E) is predominantly cytosolic. 
Interestingly, FIP3 association with the midbody is Rab11-independent, since 
expression of a Rab11-binding deficient mutant (FIP3-I737E) does still appear to 
localise to the midbody in cytokinesis (Wilson et al., 2005). However, Rab11 and 
FIP3 complex formation is required for abscission, since GFP-FIP3-I737E 
expression in HeLa cells resulted in cytokinesis defects and produced a binuclear 
count in the order of 35% (Wilson et al., 2005). It has been proposed that the 
FIP3-Rab11 complex plays a key role in cytokinesis, by delivering and targeting 
recycling endosomes to the cleavage furrow and midbody (Wilson et al., 
2005;Fielding et al., 2005). 
1.5.6.2 FIP3 interacts with members of the ARF GTPase family 
As discussed in section 1.3.3, the ADP-ribosylation factor (ARF) family of proteins 
belong to the Ras superfamily of small GTPases. They cycle between and active 
GTP-bound and inactive GDP-bound conformations and are involved in regulating 
membrane trafficking by recruiting coat proteins, influencing phospholipid 
metabolism and actin dynamics (D'Souza-Schorey and Chavrier, 2006).  
FIP3 has been found to interact with members of the ARF GTPase family through 
its C-terminal domain. FIP3 was initially identified by one group as an ARF5-
binding protein (Shin et al., 1999). ARF5 is a class II ARF GTPase. Subsequently, 
FIP3 was also found to interact with the sole member of the class III ARF 
GTPases, ARF6 (Shin et al., 2001). Later, work from our group showed that FIP3 
preferentially binds to Rab11>ARF6>>ARF5 (Fielding et al., 2005). Significantly, 
FIP3 binds to Rab11 and ARF6 at distinct and non-overlapping sites in its C-
terminal domain, suggesting that FIP3 may interact with the two GTPases 
simultaneously, forming a ternary complex (Fielding et al., 2005). Directly N-
terminal to the RBD is the ARF binding domain (ABD), which involves amino acids 
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650 to 695 (Fielding et al., 2005;Shiba et al., 2006;Schonteich et al., 2007). This 
is illustrated in figure 1.3 (Simon and Prekeris, 2008). 
ARF6 regulates membrane trafficking in the endosomal pathway (D'Souza-
Schorey et al., 1995). ARF6-GTP accumulates at the central spindle and midbody 
(Schweitzer and D'Souza-Schorey, 2002), and depletion of ARF6 with RNAi 
inhibits the final stages of cytokinesis in HeLa cells (Schweitzer and D'Souza-
Schorey, 2005). FIP3 association with the midbody is Rab11-independent, since 
expression of Rab11-binding deficient mutant (FIP3-I737E) did still appear to 
localise to the midbody in cytokinesis (Wilson et al., 2005). However, ARF6 
appears to mediate recruitment of FIP3 to the cleavage furrow, since FIP3 
association with the furrow and midbody is blocked on expression of GDP-
restricted ARF6-T27N (Fielding et al., 2005). ARF6 has been shown to bind to 
FIP3 prior to their arrival at midbody; thus ARF6 is not considered to be an 
endosome tethering factor (Schonteich et al., 2007). Recent work in D. 
melanogaster spermatocyte cytokinesis may shed light on this (Dyer et al., 
2007). ARF6 localises to recycling endosomes associated with the central 
spindle, but does not target them to this location. However, ARF6 is required for 
the rapid membrane addition during furrowing (Dyer et al., 2007). Recently FIP3 
was also found to modulate the actin cytoskeleton (Jing et al., 2009). 
Knockdown of FIP3 by RNAi inhibits the motility of MDA-MB-231 breast carcinoma 
cells, suggesting that FIP3 regulates polarised Rac1 activation by mediating the 
targeting of ARF6 to the leading edge of motile cells.  
1.5.6.3 FIP3 interacts with CYK-4 
As discussed in section 1.2.2.2, the role of RhoA is central to cytokinesis, by 
regulating actin dynamics at the furrow (Piekny et al., 2005). Centralspindlin is a 
protein assembly comprised of MKLP1 and CYK-4 (RhoA GAP). MKLP1 restricts 
this complex to the central spindle. CYK-4 recruits ECT2 (RhoA GEF) to the 
central spindle, where ECT2 activates RhoA, resulting in contractile ring function 
(Werner and Glotzer, 2008).  
The combined approach of immunopurification of FIP3 from HeLa cells and 
proteomics revealed that FIP3 interacts with CYK-4 (Simon et al., 2008). CYK-4 
binds to FIP3, N-terminal to the ARF binding domain (ABD), encompassing amino 
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acids 441 to 610 (Simon et al., 2008). This is illustrated in figure 1.3 (Simon and 
Prekeris, 2008). During anaphase, centralspindlin is located in the mid-zone, and 
by late telophase CYK-4 is highly concentrated at the midbody. CYK-4 co-
localises with FIP3 in the midbody at late telophase; the two proteins only 
interact at this stage (Simon et al., 2008). The binding regions for ECT2 and FIP3 
on CYK-4 overlap, thus they form mutually exclusive complexes with CYK-4. At 
late telophase, ECT2 dissociation from centralspindlin allows CYK-4 to recruit 
FIP3 and recycling endosomes to the midbody (Simon and Prekeris, 2008). 
1.5.6.4 FIP3 interacts with ASAP1 
ASAP1 is an ARF GTPase Activating Protein (GAP). The function of this protein 
family is discussed in section 1.3.3. A two-hybrid screen revealed that FIP3 
interacts with ASAP1 within the coiled-coil domain of the C-terminus of FIP3, 
including amino acids 565 to 650 (Inoue et al., 2008). ASAP1 forms a ternary 
complex with Rab11, via FIP3. It was shown that FIP3 binding activated ASAP1 
activity to ARF1, but not ARF6. Interestingly, ASAP1 and FIP3 co-localise in the 
pericentrosomal endocytic recycling compartment, where they function in 
endocytic recycling, since knockdown of ASAP1 or FIP3 disrupted localisation of 
the transferrin receptor to this compartment (Inoue et al., 2008). 
1.5.6.5 FIP3 interacts with molecular motor proteins 
Recent research has uncovered the ability of FIPs to couple to the molecular 
motor protein machinery of the cell. An RNAi screen of kinesin molecular motors 
identified kinesin I as the microtubule motor which directs transport of recycling 
endosomes during mitosis (Simon and Prekeris, 2008). Kinesin also co-
immunoprecipitated with the Rab11-FIP3 complex and depletion of kinesin I 
inhibits delivery of FIP3 to the furrow and inhibits cytokinesis (Simon and 
Prekeris, 2008). However, it has not been shown if this is a direct interaction 
between FIP3 and kinesin I. FIP3 has been suggested to interact with cytoplasmic 
dynein 1, a protein which is necessary for FIP3-dependent pericentrosomal 
accumulation of the ERC (Horgan and McCaffrey, 2009). However, this work is 
unpublished. Interestingly, Rip11 (Rab11-FIP5) has been shown to bind directly 
to kinesin II, a microtubule motor complex (Schonteich et al., 2008). Thus there 
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is scope for the role of microtubule motor proteins in directing FIP3-Rab11 
recycling endosomes to the furrow for cytokinesis. 
1.5.7 Model for membrane traffic during cytokinesis 
The exact mechanism of abscission is still to be resolved. Various studies 
implicate the accumulation and simultaneous fusion of multiple vesicles on one, 
or either side, of the midbody in the resolution the intracellular bridge (Gromley 
et al., 2005;Goss and Toomre, 2008). One model for the origin of the membrane 
delivered to the plasma membrane during cytokinesis suggests involvement of 
the endocytic pathway (Prekeris and Gould, 2008;Montagnac et al., 
2008;Fürthauer and González-Gaitán, 2009;Ai and Skop, 2009). It is thought that 
vesicles derived from the recycling endosome are tethered to microtubules at 
the centrosomes. Subsequently, they traffic to the furrow and midbody where 
they deliver the membrane and cargo essential for abscission (Gould and 
Lippincott-Schwartz, 2009). It has been proposed that FIP3 in complex with 
Rab11 plays a key role in the delivery and targeting of recycling endosomes to 
the furrow; this is essential for completion of cytokinesis (Wilson et al., 
2005;Fielding et al., 2005). 
A current working model for membrane traffic to the furrow during cytokinesis 
was created by A.R. Skop and is reproduced in figure 1.5. During prophase and 
metaphase, while clathrin-based endocytosis carries on as normal, endocytic 
recycling of internalised membranes back to the cell surface slows significantly. 
However, during early telophase endosomal recycling resumes and recycling 
endosomes are trafficked to the furrow. Rab11 recruits FIP3 onto recycling 
endosome-derived vesicles at the centrosome. In telophase, FIP3-Rab11 vesicles 
traffic to the furrow and at later stages the midbody. These vesicles are 
directed along the microtubules of the mitotic spindle, possibly via the motor 
protein kinesin I. A ternary complex is formed between ARF6-FIP3-Rab11. FIP3 
delivers ARF6 to the furrow and midbody where it may regulate actin dynamics 
or co-ordinate membrane insertion with furrow ingression. Additionally ARF6 and 
Rab11 may tether FIP3-containing vesicles to the Exocyst machinery, thus 
anchoring FIP3-containing vesicles to the midbody prior to abscission. FIP3 also 
interacts with CYK-4 of the centralspindlin complex at the late stages of 
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telophase, serving to tether FIP3-vesicles to the midbody. These vesicles may 
serve as an organisation platform for the assembly of the abscission machinery 
or they may deliver the cargo required for abscission. FIP3-Rab11 vesicles may 
also be involved in a compound fusion event which seals the intracellular bridge, 
thus resolving the two daughter cells. 
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Figure 1-5 Model for membrane traffic during cytokinesis 
 
A. Electron micrograph of an intracellular bridge in the late stages in telophase. Lateral 
constriction zones (NS) containing bundled microtubules are found either side of the central 
electron-dense midbody composed of overlapping ends of microtubules and a vast array of 
proteins (modified from Steigemann and Gerlich, 2009). 
B. Model of recycling endosome (RE) trafficking during cytokinesis (modified from Ai and 
Skop, 2009). An arrow points to FIP3 (RAB11FIP3) in the key. (1) REs are concentrated at the 
MTOC. RE vesicles traffic along the microtubules under the influence of dynein/dynactin 
motors. RACK1 is thought to interact with dynactin, thus targeting REs to the centrosomes. 
(2) Rab11 recruits FIP3 onto recycling endosome-derived vesicles at the centrosome which 
then traffic along both spindle and midzone microtubules, under the influence of kinesin 
motors, to the furrow and at later stages the midbody. At the furrow they interact with ARF6 
and members of the Exocyst family. A ternary complex is formed between ARF6-FIP3-
Rab11. The centralspindlin complex also mediates the accumulation of RE vesicles at the 
midbody, via the interaction CYK-4 with FIP3. RE vesicles may serve as an organisation 
platform for the assembly of the abscission machinery or they may deliver the cargo 
required for abscission or they may be involved in a compound fusion event which seals 
the intracellular bridge, thus resolving the two daughter cells. (3) RE vesicles are thought to 
traffic from the site of cleavage via dynein/dynactin motors. The interaction between ARF6 
and the scaffolding protein c-Jun-N-terminal-kinase interacting protein 4 (JIP4) is thought to 
control the bidirectional movement of endosomes, via association with kinesin or 
dynein/dynactin motors. 
 
1.5.8 Regulation of FIP3 
Time-lapse microscopy of HeLa cells expressing GFP-FIP3 has shown that FIP3 
undergoes spatial and temporal dynamics during mitosis (Wilson et al., 2005). A 
potential candidate for the spatial and temporal regulation of FIP3 is 
phosphorylation, since reversible phosphorylation is a commonly used control 
mechanism in mitotic regulation (Morgan, 2007) and can regulate the activity, 
localisation and half-life of a protein, as well as its interaction with other 
proteins (Cohen, 2000). 
Several lines of evidence suggest that FIP3 is a potential phospho-protein. As 
discussed in section 1.5.2, Nuf is a D. melanogaster homologue of FIP3 (Riggs et 
al., 2003;Hickson et al., 2003). Nuf is a highly phosphorlyated protein (Rothwell 
et al., 1998). Interestingly, Nuf localisation alters during the cell-cycle (Rothwell 
et al., 1998). During early Drosophila development, the embryo undergoes 
thirteen rapid nuclear divisions, which occur without cytokinesis. During this 
development, Nuf is concentrated at the centrosomes during prophase, but is 
predominantly cytoplasmic through the rest of the nuclear cycle and remains so 
in interphase. During nuclear cycle 14 the embryo undergoes cellularisation (the 
equivalent of mammalian cytokinesis). Nuf is centrosomal throughout 
Louise L. Collins, 2010  Chapter 1, 49 
cellularisation (Rothwell et al., 1998). Since Nuf is highly phosphorylated, it has 
been suggested that localisation may be regulated by cell-cycle-dependent 
kinases (Riggs et al., 2003). The activity of Class I FIPs is known to be regulated 
by phosphorylation. Prekeris et al., showed that phosphorylation of Rip11 results 
in its dissociation from apical recycling endosomes to the cytosol (Prekeris et 
al., 2000). The cell-cycle is rigorously regulated by a network of kinases. Thus, 
phosphorylation of FIP3 by cell-cycle-dependent kinases may play a key role in 
role in cytokinesis. 
1.6 Cell-cycle kinases 
1.6.1 Cell-cycle overview 
As discussed in section 1.2.2, cytokinesis involves co-ordination of a number of 
stages and a multitude of proteins (Eggert et al., 2006). These proteins undergo 
spatial and temporal regulation to ensure progression through the cell-cycle is 
error free. The two main regulators of the cell-cycle are protein phosphorylation 
and degradation. The cell-cycle is governed by a network of protein kinases 
which control the activity, localisation and interactions of proteins involved in 
cell-cycle progression (Nigg, 2001). The major mitotic regulators are CDK1, Plk1, 
Aurora A and Aurora B. Although the role of mitotic kinases in cytokinesis 
remains to be clearly defined, recent research points to these kinases playing a 
critical role in the regulation of events which control cytokinesis. A summary of 
some of the processes involved in cytokinesis and their regulation by cell-cycle 
kinases is provided in figure 1.6 (Barr and Gruneberg, 2007). 
Louise L. Collins, 2010  Chapter 1, 50 
 
Figure 1-6 Cell-cycle regulation of the central spindle (modified from Barr and Gruneberg, 
2007) 
In the early stages of mitosis, CDK1 activity peaks and the kinase inhibits PRC1, MKLP1 and 
ECT2. CDK1 is inactivated at the onset of anaphase and its substrates become 
dephosphorylated. PRC1 bundles the microtubules of the central spindle and recruits 
MKLP1 (of the centralspindlin complex) and MKLP2. PRC1 also recruits PLK1 to the spindle 
for its role in cytokinesis. MKLP2 is involved in Aurora B localisation to the central spindle. 
Aurora B then phosphorylates centralspindlin, promoting its assembly with ECT2 and 
therefore influencing furrow formation via RhoA.  
 
1.6.2 Cyclin-dependent kinase 1 (CDK1) 
Pioneering cell-cycle studies in fission yeast defined cell division control protein 
2 (cdc2) as the master regulator of cell-cycle progression (Nurse, 2000). Cdc2 
drives entry into mitosis and is conserved from yeast to mammalian cells, where 
it is known as cyclin-dependent kinase 1 (CDK1). CDK1 is a serine/threonine 
protein kinase which controls mitosis by phosphorylating a network of proteins 
involved in controlling the various mitotic stages (Morgan, 2007). It is a member 
of a large family of CDKs (CDK1 - CDK13), but only CDK1 drives mitosis 
(Malumbres and Barbacid, 2009). CDK substrates are serine or threonine residues 
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in a specific sequence context ([S/T*]PX[K/R]) which is recognised by the active 
site of the kinase. The target residue (S/T*) is usually followed by a proline 
residue (P) and often has a basic amino acid (K/R) two positions C-terminal to 
the target (Shetty et al., 1993;Brown et al., 1999;Ubersax and Ferrell Jr, 2007).  
CDKs are activated by binding to their regulatory subunits, known as cyclins, 
which induces a conformational change, thus activating the kinase (Morgan, 
2007). There are ten cyclins, in four different classes (the A-, B-, D- and E-type 
cyclins) involved in different stages of the cell-cycle, but only the A- and B-type 
cyclins are involved in mitosis (Malumbres and Barbacid, 2009). Cyclins are 
synthesised and destroyed at specific times during the cell cycle, thus 
controlling the temporal activation of their bound kinases (Fung and Poon, 
2005). Cyclins also direct their bound CDKs to the appropriate subcellular 
location, thus controlling the spatial activation of their bound kinases (Fung and 
Poon, 2005).  
The cyclin B1-CDK1 complex drives mitosis. In vertebrate cells, the 
concentration of cyclin B increases as the cell approaches mitosis and peaks in 
prophase/metaphase and associated CDK activity increases dramatically in 
prophase (Morgan, 2007). Cyclin B is destroyed in metaphase, which switches off 
CDK1 activity (Pines, 2006). There are two main types of cyclin B: B1 and B2 
(Fung and Poon, 2005). Cyclin B1-CDK1 co-localises with microtubules; cyclin B2-
CDK1 associates with the Golgi apparatus and stimulates phosphorylation of 
proteins which cause Golgi fragmentation during mitosis (Jackman et al., 1995). 
Mice lacking the cyclin B2 gene develop normally and are fertile, but mice 
lacking the cyclin B1 gene are not viable (Brandeis et al., 1998). Thus CDK1, in 
complex with cyclin B1, is chiefly responsible for the orchestration of mitosis 
(Nigg, 2001). 
Following cyclin binding, CDK1 must be phosphorylated at threonine 161 (T161) 
in the T loop, by a CDK-activating kinase (CAK), for full kinase activity. CDKs are 
also negatively regulated by phosphorylation. Phosphorylation of threonine 14 
(T14) and tyrosine 15 (Y15) in the ATP-binding site of CDK1 inhibits kinase 
activity. Wee1 is a kinase which is soluble and predominantly nuclear, although 
it also localises to the centrosomes; it inhibits CDK1 by phosphorylating Y15. In 
vertebrates, Myt1 is associated with Golgi and endoplasmic reticulum 
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membranes and is related to Wee1; it phosphorylates T14 and Y15 of CDK1, thus 
inhibiting the kinase. The dual-specificity phosphatase Cdc25C activates CDK1 by 
de-phosphorylating T14 and Y15. This regulation is referred to as the inner 
feedback loop of CDK1 activation (reviewed in Lindqvist et al., 2009). 
CDK1 activity undergoes a rapid ‘switch-like’ activation via a positive feedback 
loop (Morgan, 2007). CDK1 concentration is high during the cell-cycle, but its 
activity is low due to high Wee1 activity and low Cdc25C activity (Lindqvist et 
al., 2009). CDK1 affinity for cyclins is high, ensuring that as soon as cyclin B 
expression increases, CDK1 immediately binds to cyclin B. This causes the cell to 
accumulate a stockpile of cyclin B1-CDK1 complexes, which are inactive due to 
Wee1 phosphorylation. A positive feedback loop results from CDK1 itself. At the 
beginning of mitosis, CDK1 phosphorylates and inhibits its own inhibitor (Wee1) 
and activates its own activator (Cdc25C), thus removing the inhibitory phosphate 
groups of CDK1. This results in the rapid ‘switch-like’ activation of the cyclin B1-
CDK1 complex stockpile (Lindqvist et al., 2009). 
On activation of cyclin B1-CDK1, the cell enters mitosis (Nigg, 2001). CDK1 
phosphorylates a host of substrates. One of the principal targets of cyclin B1-
CDK1 is nuclear lamins, the cytoskeletal network that lies underneath the 
nuclear envelope. Before mitosis, cyclin B1-CDK1 is cytoplasmic, preventing its 
access to targets in the nucleus. In early prophase, when cyclin B1-CDK1 is first 
activated, the complex is found on duplicated centrosomes as they begin to 
separate. At late prophase it is rapidly translocated into the nucleus (Clute and 
Pines, 1999) where CDK1 phosphorylates nuclear lamin, thus stimulating nuclear 
envelope breakdown. Following nuclear envelope breakdown, the complex is 
once again located throughout the cell. CDK1 also functions in centrosome 
separation, disassembly of the Golgi apparatus, spindle assembly, chromosome 
condensation, Golgi fragmentation and anaphase promoting complex/cyclosome 
(APC/C) regulation (Nigg, 2001). Interestingly, phosphorylation by CDK1 can 
affect the membrane and cytosol distribution of proteins involved in mitosis: 
cyclin B1-CDK1 phosphorylation of the microtubule motor cytoplasmic dynein 
releases the protein from membranes, in vitro (Addinall et al., 2001). 
All B type cyclins have a short sequence (destruction box or D-box) which is a 
target of the APC/C, triggering their destruction and thereby inactivating CDK1 
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(Fung and Poon, 2005). APC/C is an E3 ubiquitin protein ligase which poly-
ubiquitinates proteins, thus marking them for degradation by the proteasome 
(Morgan, 2007). Degradation of cyclin B by the APC/C begins as the last 
chromosome lines up on the metaphase plate, just after inactivation of the 
spindle-assembly checkpoint (Clute and Pines, 1999). On destruction of cyclin B, 
CDK1 becomes inactivated allowing mitotic exit and cytokinesis (Pines, 
2006;Sullivan and Morgan, 2007).  
Cyclin B1-CDK1 negatively regulates many of the protein complexes required for 
cytokinesis, until anaphase onset, when the sister chromatids have successfully 
separated and CDK1 is inactivated (Barr and Gruneberg, 2007). Indeed, inhibition 
of CDK1 with BMI-1026 results in initiation of cytokinesis before chromosome 
segregation (Niiya et al., 2005). CDK1 regulation of events involved in 
cytokinesis is summarised in figure 1.6.  
Cyclin B1-CDK1 has been implicated in the regulation of centralspindlin assembly 
(Niiya et al., 2005;Glotzer, 2009). Cyclin B1-CDK1 phosphorylates the motor 
domain of MKLP1, reducing its affinity for, and ability to move along, the 
microtubules (Mishima et al., 2004). In metaphase, cyclin B1-CDK1 
phosphorylates ECT2, which adopts an autoinhibited conformation, preventing 
its interaction with CYK-4 (Yüce et al., 2005). Reports also suggest that CDK1 
phosphorylates CYK-4, in vitro (Touré et al., 2008). Regulation of the 
centralspindlin complex by CDK1 ensures that RhoA localisation to the equatorial 
cortex by ECT2 and subsequent furrow formation does not occur until the 
chromosomes have segregated (Barr and Gruneberg, 2007). Cyclin B1-CDK1 has 
been implicated in the regulation of the chromosomal passenger complex (CPC), 
which is composed of Aurora B kinase, inner centromere protein INCENP, survivin 
and borealin (Glotzer, 2009). This complex will be discussed in more detail in 
section 1.6.5. The mitotic kinesin MKLP2 recruits the CPC to the spindle 
midzone; the association between these two proteins is negatively regulated by 
CDK1, suggesting that, following CDK1 inactivation at the metaphase/anaphase 
transition, the CPC and MKLP2 interact, targeting this complex to the spindle 
midzone (Hümmer and Mayer, 2009). Microtubule-associated proteins (MAPs) are 
involved in central spindle assembly and MAP protein regulator of cytokinesis 1 
(PRC1) is involved in microtubule bundling (Glotzer, 2009). CDK1 phosphorylation 
of PRC1 in early mitosis keeps PRC1 in an inactive monomeric state, but on 
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dephosphorylation at anaphase onset, PRC1 is dephosphorylated, promoting 
PRC1 oligomerisation. This allows PRC1 to bundle microtubules, forming the 
spindle midzone which is necessary for cytokinesis (Mollinari et al., 2002;Zhu et 
al., 2006). Thus, on inactivation of CDK1 at anaphase onset various inhibitory 
phosphorylations are removed and the central spindle can assemble, driving 
cytokinesis (Barr and Gruneberg, 2007). 
1.6.3 Polo-like kinase 1 (Plk1) 
Polo-like kinase 1 (Plk1) is another key regulator of mitosis and has been 
implicated in the regulation of cytokinesis (Barr et al., 2004;Petronczki et al., 
2008). Plk1 is activated in early mitosis and is degraded in anaphase, via APC/C 
mediated proteolysis; this is necessary for mitotic exit (Lindon and Pines, 2004). 
The N-terminal region of Plk1 contains the serine/threonine kinase domain, 
followed by a central destruction motif (D-box) (Lindon and Pines, 2004). 
Towards the C-terminus is a conserved regulatory domain containing two motifs, 
classed as the polo-box domain (PBD) (Elia et al., 2003a;Elia et al., 2003b). The 
PBD is a phospho-peptide binding domain, which has a higher affinity for 
proteins which are phosphorylated at serine/threonine residues, within a certain 
sequence context, S-pS/pT-P/X. The PBD is thought to target Plk1 to specific 
substrates and subcellular localisations, thus conferring spatial regulation on 
Plk1 activity. The interaction of Plk1 with its substrates via the PBD requires 
prior phosphorylation (priming); this confers temporal regulation on Plk1 
activity. It is thought that priming by cyclin B1-CDK1 may promote interaction 
between Plk1 and certain substrates, since the consensus for PBD binding fulfils 
the requirements of the proline directed CDK1 (Ubersax and Ferrell Jr, 
2007;Lindqvist et al., 2009).  
Plk1 may be negatively regulated by its C-terminal domain (Barr et al., 2004). In 
the absence of a phosphorylated substrate, the PBD is thought to interact with 
the kinase domain, thus preventing Plk1 function. The catalytic domain is only 
released on interaction of the PBD with a phosphorylated substrate. The 
catalytic domain can then be phosphorylated on the T-loop (Thr210), which is 
necessary for Plk1 activation (Barr et al., 2004). 
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Plk1 displays dynamic cell-cycle dependent localisation (Petronczki et al., 2008). 
Plk1 localises to the centrosomes in prophase and becomes concentrated at the 
centrosomes and kinetochores in prometaphase and metaphase. At late 
anaphase Plk1 redistributes to the midzone of the mitotic spindle and midbody 
during telophase (Barr et al., 2004;Petronczki et al., 2008).  
Plk1 has been found to influence processes at its various cellular locations. In 
early mitosis Plk1 is localised at the centrosomes and is involved in centrosome 
separation and bipolar spindle formation (Petronczki et al., 2008). In the 
absence of functional Polo in animal cells, assembly of bipolar spindles fails and 
instead the mitotic chromosomes arrange in a circular array around the 
monopolar spindle (Sunkel and Glover, 1988). Plk1 may be involved in the 
attachment of microtubules to kinetochores in prometaphase, thus regulating 
chromosome congression (Petronczki et al., 2008). At the spindle poles, where 
cyclin B1-CDK1 is initially activated, Plk1 is thought to be involved in mitotic 
entry. Plk1 has been found to interact, via its PBD, with CDK1-primed Cdc25C at 
the centrosomes, thus activating it (Elia et al., 2003a). In addition, Plk1 can 
bind, phosphorylate and inhibit CDK1-primed Wee1 and Myt1 and this creates an 
outer feed back loop of cyclin B1-CDK1 activation (Lindqvist et al., 2009). Plk1 is 
also involved in mitotic exit since Plk1 phosphorylates subunits of the APC/C and 
is therefore involved in protein destruction in late mitosis (Barr et al., 2004). 
Plk1 relocates to the spindle midzone and then to the midbody in anaphase and 
telophase (Petronczki et al., 2008). PRC1 and MKLP2 have both been implicated 
in the targeting of Plk1 to the spindle midzone. In anaphase PRC1 binds to Plk1, 
targeting it to the central spindle (Neef et al., 2007). In metaphase, CDK1 
phosphorylates PRC1, thus preventing binding of Plk1. At anaphase onset, on 
inactivation of CDK1, the inhibitory phosphorylation is removed and Plk1 creates 
its own docking site (self-primes) on PRC1. This recruits Plk1 to the spindle, 
which is required for cytokinesis (Neef et al., 2007). Plk1 also interacts with and 
phosphorylates the mitotic kinesin MKLP2, which is necessary for MKLP2 function 
and the localisation of Plk1 to the central spindle in late anaphase/telophase 
(Neef et al., 2003). This is necessary for cytokinesis. 
The function of Plk1 in the regulation of the early stages of the cell cycle has 
meant that only relatively recently its role in the later stages of mitosis has been 
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revealed, owing to the development of inhibitors which can be used to block 
Plk1 activity at anaphase onset. Research has revealed that Plk1 controls 
initiation of cytokinesis via the ECT2-RhoA pathway (Petronczki et al., 2008). 
Use of the Plk1 inhibitor ZK-Thiazolidinone (TAL), in anaphase HeLa cells, 
showed that cleavage furrow formation and ingression failed on inhibition of 
Plk1, resulting in an increased population of multinucleate cells (Santamaria et 
al., 2007). TAL prevented RhoA accumulation at the equatorial cell cortex and 
ECT2 recruitment to the central spindle (Santamaria et al., 2007). Similarly, the 
Plk1 inhibitor Bl 2536 resulted in failure of furrow formation in anaphase HeLa 
cells due to a lack of RhoA localisation at the equatorial cortex (Petronczki et 
al., 2007). Via ECT2 immunoprecipitation of synchronized HeLa lysates, Bl 2536 
was found to abolish the anaphase interaction between ECT2 and CYK-4, thus 
preventing ECT2 localisation to the central spindle (Petronczki et al., 2007). 
Using tandem mass spectrometry and phosphospecific antibodies, Burkard et al., 
revealed that Plk1 binds and directly phosphorylates the CYK-4 at the midzone, 
creating a docking site for ECT2 (Burkard et al., 2009), which is essential for 
cleavage furrow formation. Thus, through data from these groups and others, it 
has been suggested that late mitotic activity of Plk1 is an upstream regulator of 
ECT2-RhoA cascade by promoting recruitment of ECT2 to the central spindle by 
CYK-4; this is essential for the initiation of cytokinesis. 
1.6.4 Aurora A kinase 
The mitotic kinase Aurora A is a member of the Aurora family serine/threonine 
protein kinases (Morgan, 2007). Aurora A is active in the early stages of mitosis, 
but is degraded via the APC/C when the spindle microtubules have elongated to 
their maximum in anaphase B (Lindon and Pines, 2004). Interestingly, 
degradation of Aurora A is only complete by G1 phase (Lindon and Pines, 2004). 
Aurora A is concentrated at the centrosomes and also localises to the spindle 
microtubules during mitosis (Marumoto et al., 2003;Lindon and Pines, 2004;Barr 
and Gergely, 2007). The consensus phosphorylation site for Aurora A was defined 
in budding yeast as [KR]X[TS][ILV] (Cheeseman et al., 2002) and later confirmed 
in higher eukaryotes in proteins such as Cdc25B (Dutertre et al., 2004). Aurora A 
is activated via autophosphorylation of Thr288 in its T loop and for full activity, 
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Aurora A also requires co-factors, including Bora, Ajuba, PAK1 and Tpx2 
(reviewed in Barr and Gergely, 2007). 
Aurora A regulates mitotic centrosomes and bipolar spindle assembly (Barr and 
Gergely, 2007). Aurora A has been identified as a key regulator of centrosome 
separation and maturation, spindle pole organisation, microtubule stability and 
accurate completion of chromosome segregation (reviewed in Barr and Gergely, 
2007). Depletion of Aurora A or addition of inactive kinase results in the 
formation of monopolar spindles (Liu and Ruderman, 2006). Aurora A has been 
implicated in regulation of the G2/M transition via the outer feed back loop of 
cyclin B-CDK1 activation (Lindqvist et al., 2009). In Xenopus egg extracts, 
depletion of Aurora A or addition of inactive kinase resulted in a delay of mitotic 
entry, but not a block (Liu and Ruderman, 2006). This could be explained by the 
fact that Aurora A directly phosphorylates and activates Cdc25B, thus 
stimulating cyclin B-CDK1 activity at the centrosomes further and promoting 
mitotic entry (Dutertre et al., 2004). 
Interestingly, Aurora A activity may impinge on cytokinesis. Microinjection of 
anti-Aurora A antibodies into metaphase HeLa cells prevented cells from 
completing cytokinesis, resulting in the formation of binucleate cells (Marumoto 
et al., 2003). This perhaps suggests that Aurora A functions in late mitosis, 
which is supported by the fact that Aurora A becomes localised on the spindle 
midzone towards the end of mitosis (Marumoto et al., 2003;Lindon and Pines, 
2004;Barr and Gergely, 2007) and while degradation of Aurora A commences in 
anaphase B, it is only complete by G1 phase (Lindon and Pines, 2004).  
1.6.5 Aurora B kinase 
The mitotic kinase Aurora B is a member of the Aurora family serine/threonine 
protein kinases (Morgan, 2007). Aurora B forms the chromosomal passenger 
complex (CPC) with inner centromere protein INCENP, survivin and borealin 
(Vagnarelli and Earnshaw, 2004;Vader et al., 2006;Ruchaud et al., 2007). These 
proteins are necessary for Aurora B activity and are required for its targeting to 
the correct compartments of the cell (Sessa et al., 2005;Jeyaprakash et al., 
2007).  
Louise L. Collins, 2010  Chapter 1, 58 
Aurora B displays dynamic cell-cycle localisation, where it functions to control 
different aspects of mitosis (Vader et al., 2006). In early mitosis the CPC 
localises to the arms of condensing chromosomes and concentrates at the 
centromeres and kinetochores during prometaphase and metaphase (Vagnarelli 
and Earnshaw, 2004;Vader et al., 2006). At this point Aurora B regulates 
processes including chromosome condensation and orientation, spindle 
assembly, microtubule-kinetochore interactions and the spindle assembly 
checkpoint (Vagnarelli and Earnshaw, 2004;Vader et al., 2006;Ruchaud et al., 
2007).  
Following separation of the sister chromatids in anaphase, Aurora B localises to 
the spindle midzone microtubules and later in telophase, Aurora B relocates to 
the intracellular bridge, either side of the midbody (Vagnarelli and Earnshaw, 
2004;Vader et al., 2006). Using RNAi to MKLP2 it was shown that at anaphase 
onset, the CPC is transferred from centromeres to the spindle midzone via the 
mitotic kinesin MKLP2 (Gruneberg et al., 2004). Aurora B has been found to 
regulate cytokinesis (Barr and Gruneberg, 2007). RNAi knockdown of Aurora B in 
C. elegans embryos causes furrow regression, resulting in multinucleate cells 
(Kaitna et al., 2000). Anaphase substrates of Aurora B include components of the 
centralspindlin complex, MKLP1 and CYK-4 (Minoshima et al., 2003;Guse et al., 
2005;Neef et al., 2006) and phosphorylation of these proteins by Aurora B is 
necessary for cytokinesis completion. Interestingly, Aurora B depletion 
prevented accumulation of FIP3 at the midbody of HeLa cells (Simon et al., 
2008). 
A study has recently shown that Aurora B phosphorylates tumour supressor 
RASSF1A on serine 203 during late mitosis (Song et al., 2009). During late mitosis 
RASSF1A recruits syntaxin 16 to the midzone and midbody; Aurora B activity is a 
requirement for this interaction and completion of cytokinesis. As discussed in 
section 1.5.7, membrane traffic is at the heart of cytokinesis and Song et al., 
have revealed that this key process is regulated by another important facet of 
the cell-cycle, namely regulation by the cell-cycle dependent kinases. 
 
 
Louise L. Collins, 2010  Chapter 1, 59 
1.7 Aims 
Time-lapse microscopy of HeLa cells expressing GFP-FIP3 has shown that FIP3 
undergoes spatial and temporal dynamics during mitosis (Wilson et al., 2005). It 
has been proposed that FIP3 in complex with Rab11 plays a key role in the 
delivery and targeting of recycling endosomes to the furrow; this is essential for 
completion of cytokinesis (Wilson et al., 2005;Fielding et al., 2005).  
The regulatory mechanisms underlying the spatial and temporal dynamics of FIP3 
during mitosis are unknown. The cell-cycle is governed by a network of protein 
kinases which control the activity, localisation and interactions of proteins 
involved in cell-cycle progression (Nigg, 2001). This work aims to determine if 
FIP3 can be phosphorylated by the mitotic kinases and whether this has an 
impact on its spatial and temporal dynamics. 
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2 Materials and Methods 
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2.1 Materials 
2.1.1 General reagents  
Avanti polar lipids, Alabaster, USA 
1,2-dioleoyl phosphatidylserine (DOPS) 
1-palmitoyl-2-oleoyl phosphatidylcholine (POPC) 
 
Applied Biosystems, Warrington, UK 
Nuclease-free water (not DEPC-treated) 
 
Bio-Rad Laboratories Ltd., Hemel Hempstead, Hertfordshire, UK 
Biobeads  
Quick Start Bradford 1x Dye Reagent 
 
Carl Zeiss Ltd., Welwyn Garden City, Hertfordshire, UK 
Immersol™ 518F 
 
Clontech, St-Germain-en-Laye, France  
Advantage® GC Genomic LA Polymerase  
 
Dundee Cell Products, Dundee, UK 
HeLa cytoplasmic extract (S100 fraction) 
 
Dutscher Scientific UK, Essex, UK 
Ethidium Bromide Dropper Bottle (0.5µg/ml) 
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Fisher Scientific UK Ltd., Loughborough, Leicestershire, UK 
Calcium chloride 
Pierce Immunopure Affinity-Purified Polyclonal Rabbit Anti-Sheep IgG (H + 
L) HRP-linked 
Dimethyl sulphoxide (DMSO) 
Ethanol 
Glycine 
N-(2-Hydroxyethyl)piperazine-N'-2-ethanesulphonic acid (HEPES)  
Shandon Immu-Mount™ 
Sucrose  
Trichloroacetic acid (TCA) 
Tris base  
 
Formedium Ltd., Hunstanton, Norfolk, United Kingdom 
Agar 
Tryptone enzymatic digest of casein 
Yeast Extract, Powder 
 
GE Healthcare Global Headquarters, Chalfont, St Giles, Buckinghamshire 
Amersham ECL Mouse IgG, HRP-Linked Whole Ab (from sheep) 
Amersham ECL Rabbit IgG, HRP-Linked Whole Ab (from donkey) 
Amersham ECL Rat IgG, HRP-Linked Whole Antibody (from goat) 
Protein G Sepharose 4 Fast Flow 
Protein A Sepharose Fast Flow 
 
Invitrogen Ltd., Paisley, UK 
Albumin from bovine serum (BSA) 
Alexa Fluor® 568 goat anti-rat IgG (H + L) 
Alexa Fluor® 488 donkey anti-rat IgG (H + L) 
Alexa Fluor® 647 goat anti-rat IgG (H + L) 
10mM dNTP Mix 
Lipofectamine™ 2000 Transfection Reagent 
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Myelin Basic Protein (MBP) from bovine brain 
NuPAGE® Sample Reducing Agent (10x) 
NuPAGE® Antioxidant 
NuPAGE® SDS Sample Buffer 
NuPAGE® MOPS SDS Running Buffer (20x) 
NuPAGE® NOVEX 10% Bis-Tris Gel 1.0mm, 10 well 
One Shot® TOP10 Chemically competent E.coli 
Plk1 kinase (PV3501) 
SOC medium 
 
New England Biolabs (UK) Ltd., Hitchin, Hertfordshre 
1 kb DNA Ladder 
Prestained Protein Marker, Broad Range (7-175 kDa) 
T4 DNA Ligase 
 
Kodak, Hemel Hempstead, Hertfordshire, UK 
X-ray film 
 
Melford Laboratories Ltd., Chelsworth, Ipswich, Suffolk, UK 
Dithiothreitol (DTT) 
 
Millipore (UK) Ltd., Watford, Hertfordshire, UK 
Aurora A kinase, active (14-511) 
Aurora B kinase, active (14-489) 
Cyclin B-CDK1, active (14-450) 
 
Premier Foods, Long Sutton, Spalding, Linconshire, UK 
Marvel 
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Promega, Southampton, UK 
Alkaline Phosphatase (Shrimp)  
DpnI 
EcoRI 
KpnI 
Wizard® Plus SV Minipreps DNA Purification System 
XhoI 
 
QIAGEN Ltd., Crawley, West Sussex, UK 
Nickel-NTA Agarose (Ni-NTA Agarose) 
QIAfilter™ Plasmid Maxi Kit  
QIAquick Gel Extraction Kit 
 
Roche Diagnostics Ltd., Burgess Hill, UK 
Agarose MP 
Complete™ Protease Inhibitor Cocktail Tablets 
Complete™, EDTA-free Protease Inhibitor Cocktail Tablets 
 
Severn Biotech Ltd., Kidderminster, Worcestershire, UK 
30% (w/v) Acrylamide [Acrylamide to Bis-Acrylamide 
ratio 37.5:1] 
 
Sigma-Aldrich Ltd., Gillingham, Dorset, UK 
Adenosine 5′-triphosphate magnesium salt (ATP.Mg2+) 
Ammonium persulphate (APS) 
Brilliant Blue R  
Brilliant Blue G-Colloidal Concentrate 
p-Coumaric acid  
4′,6-Diamidino-2-phenyindole, dilactate (DAPI, dilactate) 
Ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA) 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) 
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Ficoll® PM 400  
Gelatin from cold water fish skin  
Glycerol  
Goat serum 
Hygromycin B solution from Streptomyces hygroscopicus 
Kanamycin sulfate from Streptomyces kanamyceticus 
Luminol  
2-(N-Morpholino)ethanesulphonic acid (MES) 
MG132 (Z-Leu-Leu-Leu-al) 
3-(N-Morpholino)propanesulphonic acid (MOPS)  
Methanol  
Nocodazole  
Nonidet™ P 40 Substitute 
5-(N-2,3-Dihydroxypropylacetamido)-2,4,6-triiodo-N,N′-bis(2,3-
dihydroxypropyl)isophthalamide (Nycodenz®) 
OptiPrep
®
 Density Gradient Medium 
Paraformaldehyde  
Sodium dodecyl sulphate (SDS) 
Sodium fluoride  
Sodium orthovanadate (Na3VO4) 
Sodium phosphate monobasic dihydrate (NaH2PO4 · 2H2O) 
Thymidine 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) 
Triton® X-100  
TWEEN® 20  
Urea 
 
Spectrum laboratories 
 Float-a-lyzer, 3 ml 10000 kDa MWCO  
 
VWR International Ltd., Lutterworth, Leicestershire, UK 
Acetic acid (glacial) 100% 
Hydrogen peroxide  
Magnesium Chloride-6-Hydrate (MgCl2.6H2O) 
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Di-Potassium hydrogen phosphate (K2HPO4) 
Propan-2-ol 
Sodium chloride 
di-Sodium hydrogen orthophosphate anhydrous (Na2HPO4) 
tetra-Sodium pyrophosphate (Na4P2O7.10H20) 
 
2.1.2 Cell culture reagents 
All cell culture reagents were purchased from Invitrogen Ltd., Paisley, UK. 
Dulbecco's Modified Eagle Medium (D-MEM) (1x) liquid (High Glucose). (With 
L-Glutamine, with 4500mg/L, D-Glucose, without Sodium Pyruvate) 
Opti-MEM® I Reduced Serum Media 
Foetal Bovine Serum (Heat Inactivated), EU Approved 
L-Glutamine 200mM (100x) liquid 
Penicillin - Streptomycin 
Trypsin, 0.05% (1x) with EDTA 4Na, liquid 
 
Nutrient Mixture F-12 Ham, with L-glutamine and sodium bicarbonate (liquid, 
sterile-filtered, cell culture tested) was purchased from Sigma-Aldrich Ltd., UK. 
2.1.3 Primary antibodies  
Anti-FIP3 (sheep) was produced by The Scottish Blood Transfusion Service using 
baculovirus Sf9 insect cell expressed human His-tagged FIP3 as an antigen. 
Whole serum was purified using a FIP3 column. 
Phospho-specific antibodies were raised against the phospho-peptides detailed in 
section 2.1.7. This was carried out by The Scottish Blood Transfusion Service. 
Whole serum was obtained and purified against a Protein A Sepharose column. 
All other antibodies were purchased from the following suppliers: 
Abcam plc., Cambridge, UK 
Mouse monoclonal anti-GAPDH antibody 
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Rabbit polyclonal anti-GFP antibody 
 
BD Biosciences, San Jose, CA, USA 
Purified Mouse Anti-CDK1 (Monoclonal) 
Purified Mouse Anti-Syntaxin 6 (Monoclonal) 
 
Invitrogen Ltd., Paisley, UK 
Mouse anti-Transferrin Receptor (Monoclonal) 
 
Millipore (UK) Ltd., Watford, Hertfordshire, UK 
Anti-Tubulin, clone YL1/2 (Rat monoclonal) 
 
2.1.4 Escherichia coli (E. coli) strains  
Bacterial strains used are modifications of E. coli 
TOP10  F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 
∆lacX74 recA1 araD139 ∆(araleu) 7697 galU 
galK rpsL (StrR) endA1 nupG 
2.1.5 Plasmids 
GFP-FIP3 plasmid was constructed from human FIP3 cDNA cloned into pEGFPN1 
vector (Clonetech, PT3027-5) via XhoI and EcoR1. This plasmid carries a 
kanamycin resistance gene. This was provided by Dr. Rytis Prekeris, University of 
Colorado. 
GFP-FIP3-S102D was made using GFP-FIP3 as the template by Dundee Cell 
Products Ltd., Dundee, UK. 
pCR3.1 vector was purchased from Invitrogen Ltd., UK. 
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2.1.6 Primers 
All primers were purchased from Yorkshire Bioscience Ltd., Heslington, York, 
UK. 
Site directed mutagenesis primers: 
The sites of mutagenesis have been underlined. 
FIP3 S102A Forward  GGGCAGCTTGCGGCCCCCGACGCCCC 
FIP3 S102A Reverse  GGGGCGTCGGGGGCCGCAAGCTGCCC 
FIP3 S102D Forward  GGGCAGCTTGCGGACCCCGACGCCCC 
FIP3 S102D Reverse  GGGGCGTCGGGGTCCGCAAGCTGCCC 
FIP3 S281A Forward CTACGGTGGTGTCGCTGCTGCCCAAGATGAGGG 
FIP3 S281A Reverse CCCTCATCTTGGGCAGCAGCGACACCACCGTAG 
FIP3 S281D Forward GCTACGGTGGTGTCGCTGATGCCCAAGATGAGGAGC 
FIP3 S281D Reverse  GCTCCTCATCTTGGGCATCAGCGACACCACCGTAGC 
FIP3 S348A Forward  GACAGTGCCGGCGGCGCGGCCGTGCCCTCTGAG 
FIP3 S348A Reverse  CTCAGAGGGCACGGCCGCGCCGCCGGCACTGTC 
FIP3 S348D Forward  CAGTGCCGGCGGCGACGCCGTGCCCTCTGAG 
FIP3 S348D Reverse  CTCAGAGGGCACGGCGTCGCCGCCGGCACTG 
FIP3 S451A Forward  GAGGCCCTGGAGGACCCTGCCCCCGAGCTCATGGAGGGC 
FIP3 S451A Reverse  GCCCTCCATGAGCTCGGGGGCAGGGTCCTCCAGGGCCTC 
FIP3 S451D Forward  GAGGCCCTGGAGGACCCTGACCCCGAGCTCATGGAGGGC 
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FIP3 S451D Reverse  GCCCTCCATGAGCTCGGGGTCAGGGTCCTCCAGGGCCTC 
Sequencing primers: 
The pEGFP-N1 forward and reverse primers were designed to bind to sequences 
approximately 100bp upstream and downstream of the multiple cloning site of 
pEGFP-N1, respectively. The numbers in each FIP3 primer detail the base pair 
from which the primer starts within the human FIP3 sequence. 
pEGFP-N1 Forward  CCAAAATGTCGTAACAACTCCGCC 
pEGFP-N1 Reverse  GTGGTGCAGATGAACTTCAGGGTCAG 
FIP3 432 Reverse GCGGAAAGGCGCGCTCTCCGGGC 
FIP3 691 Forward GCTACGGTCTACGGGGCAGAGCAG 
FIP3 1161 Reverse CTCGCCCCCGATCACCGTGATGAC 
FIP3 1225 Forward GGGCAGCTGGGCTGCAGTGAC 
FIP3 1509 Reverse GGCGTTTGCTCTGTGCACCAGCTG 
2.1.7 Rab11-FIP3 phospho-peptides 
Phosphorylated and non-phosphorylated peptides to Rab11-FIP3 serines 102, 281, 
348 and 451, were purchased from Quality Controlled Biochemicals, Hopkinton, 
Mass, USA. The sequences of the peptides were as follows: 
Rab11-FIP3 Serine 102  GQLA(p)SPDAP 
Rab11-FIP3 Serine 281  GGVA(p)SAQDE 
Rab11-FIP3 Serine 348  SAGG(p)SAVPS 
Rab11-FIP3 Serine 451  LEDP(p)SPLEM 
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2.1.8 Radiochemicals 
Adenosine 5’ triphosphate, ATP, [γ-32P]-3000Ci/mmol (10mCi/ml) was purchased 
from PerkinElmer Life and Analytical Sciences, Monza (Milano), Italy 
2.1.9 Kinase Inhibitors 
BMI-1026 (CDK1 inhibitor) was a kind gift from Dr K.S. Lee, Laboratory of 
Metabolism, Centre for Cancer Research, National Cancer Institute, NIH. 
Bethesda, Maryland 20892, USA. 
Plk1 inhibitors U19479/72/1 (Plk1a) and U20723/56/1 (Plk1b) were gifted by 
Timothy J. Lansing, GlaxoSmithKline R&D 
All other kinase inhibitors were purchased from the following suppliers: 
 
MERCK CHEMICALS LTD., Beeston, Nottingham, UK 
PD 98059 (2′-Amino-3′-methoxyflavone) (Inhibitor of MAP kinase kinase, 
MEK) 
SB 203580 (4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-
imidazole) (inhibitor of p38 MAP kinase) 
 
Sigma-Aldrich Ltd., Gillingham, Dorset, UK 
Y-27632 dihydrochloride monohydrate [(R)-(+)-trans-4-(1-Aminoethyl)-N-(4-
Pyridyl)cyclohexanecarboxamide dihydrochloride monohydrate] (ROCK 
inhibitor) 
 
Tocris Bioscience, Avonmouth, Bristol, UK 
ZM 447439 (Aurora B Inhibitor) 
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2.1.10 General solutions 
Buffer A200 25mM Hepes pH 7.4, 200mM KCl, 10% (w/v) 
glycerol, 2mM β-mercaptoethanol 
Coomassie blue stain solution 0.25% Coomassie Brilliant Blue R in 90ml 
methanol:water at a ratio of 1:1 and 10ml 
glacial acetic acid. This was thoroughly mixed 
and filtered through Whatman No. 2 filter 
paper. 
Coomassie blue destain solution 10% (v/v) methanol and 10% (v/v) acetic acid 
DNA loading buffer (6x) 0.25% (w/v) Bromophenol Blue, 15% (w/v) 
Ficoll® PM 400  
ECL Solution A  100mM Tris-HCl, pH 8.5, 2.25mM Luminol, 
0.4mM p-coumaric acid, 1.44% (v/v) DMSO. 
ECL Solution B  100mM Tris-HCl, pH 8.5, 0.018% (v/v) H2O2 
4% ρ-formaldehyde 4% ρ-formaldehyde, 1mM CaCl2, 1mM MgCl2 in 
PBS. ρ-formaldehyde was dissolved in PBS using 
a microwave. The remaining components were 
added and then the solution filtered through a 
0.2µm Nalgene vacuum filter. 
HES buffer 20mM Hepes, pH 7.4, 1mM EDTA, 225mM 
sucrose, protease inhibitor tablet 
His-tag buffer 50mM sodium phosphate, 150mM NaCl, pH 7.4, 
0.02% (v/v) Triton X-100 
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HPFEV buffer 50mM Hepes pH 7.4, 10mM sodium 
pyrophosphate, 100mM sodium fluoride, 2mM 
EDTA, 2mM activated sodium orthovanadate, 
protease inhibitor tablet  
Immunofluorescence (IF) buffer PBS containing 0.2% (w/v) fish skin gelatin and 
0.1% (v/v) goat serum (different species to the 
one in which the secondary antibodies were 
raised). This was made on the day and filtered 
through a Nalgene 0.2µm vacuum filter. 
Kinase assay buffer  50mM Hepes pH 7.5, 10mM MgCl2, 2mM MnCl2, 
0.2mM DTT, 50µM ATP.Mg2+ 
Cell lysis buffer 50mM Hepes pH 7.2, 100mM KCl, 5mM NaCl, 
1mM MgCl2, 0.5mM EGTA, 1mM EDTA, 1X 
protease inhibitor tablet (added immediately 
before use), 0.1% (v/v) Triton X100, 1mM DTT 
(added immediately before use) 
Phosphate buffered saline (PBS)  136mM NaCl, 2.5mM KCl, 10mM Na2HPO4, 
1.8mM KH2PO4, pH 7.4 
PBS-T PBS, 0.01% (v/v) Tween-20 
SDS-PAGE electrode buffer  25mM Tris base, 190mM glycine, 0.1% (w/v) SDS 
SDS-PAGE sample buffer (4x)  200mM Tris-HCl pH 6.8, 400mM DTT (added 
immediately before use), 8% (w/v) SDS, 0.4% 
(w/v) bromophenol blue, 40% (w/v) glycerol  
TAE  40mM Tris-acetate, 1mM EDTA, pH 7.8 
Transfer buffer 25mM Tris base, 192mM glycine, 20% (v/v) 
ethanol 
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2 YT medium  1.6% (w/v) tryptone, 1% (w/v) yeast extract, 
0.5% (w/v) NaCl 
2 YT agar  1.6% (w/v) tryptone, 1% (w/v) yeast extract, 
0.5% (w/v) NaCl, 2% (w/v) agar 
2.2 General laboratory procedures  
2.2.1 Protein assays 
The protein concentration of purified protein fractions was measured using Bio-
Rad Bradford protein assay reagent. Bovine serum albumin (1-20µg) was used as 
the standard. The amount of sample assayed was selected in order to ensure the 
absorbance fell within the linear range of the standard. Assays were set up in 
triplicate in a 96 well plate, according to the manufacturer’s instructions. 
Absorbance was measured at 595nm using a FLUOstar Optima plate reader. 
Protein concentrations were calculated using a curve derived from the BSA 
standard values. 
2.2.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)  
SDS-PAGE was used to separate proteins on the basis of size. SDS-PAGE was 
performed using Bio-Rad Mini-PROTEAN 3 apparatus. Proteins were separated 
using tris-HCl gels. The percentage of acrylamide in the resolving gel ranged 
from 8 to 15% depending on the molecular weight of the protein of interest. 
Samples were solubilised in SDS-PAGE sample buffer and incubated in a heat 
block at 95°C for 5 minutes. Electrophoresis was carried out using SDS-PAGE 
electrode buffer. Gels were run at a constant voltage of 80 volts, until the 
protein sample had passed through the stacking gel; this was increased to 120 
volts through the resolving gel. Electrophoresis continued until the pre-stained 
broad range markers had separated adequately and the dye front had reached 
the bottom of the gel. 
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2.2.3 Western blotting 
Following SDS-PAGE, proteins were transferred onto a nitrocellulose membrane 
for immunodetection. Gels were removed from the glass plates and the stacking 
gel removed. Transfer components were pre-soaked in transfer buffer. The 
transfer system was assembled as follows, from cathode to anode: sponge pad, 
Whatman 3mm chromatography paper, nitrocellulose membrane (0.45µm pore 
size), polyacryamide gel (containing electrophoresed proteins, as outlined in 
section 2.2.2), Whatman 3mm chromatography paper and a sponge pad. This 
sandwich was assembled in a cassette and inserted into a Bio-Rad mini Trans-
Blot cell, filled with transfer buffer. Proteins were transferred onto 
nitrocellulose at room temperature for two hours at a constant current of 200mA 
or overnight at 40mA.  
2.2.4 Immunodetection of proteins 
Following Western Blotting, as detailed in section 2.2.3, proteins were visualised 
by Enhanced Chemical Luminescence (ECL). Nitrocellulose membranes were 
removed from the transfer cassette and washed with PBS-T.  To block non-
specific binding sites, membranes were incubated in 5% (w/v) dried non-fat milk 
made up in PBS-T, for 30 minutes at room temperature. Primary antibodies were 
diluted in 1% (w/v) dried non-fat milk/PBS-T at an appropriate dilution. 
Membranes were incubated, with shaking, in primary antibody for a minimum of 
1 hour at room temperature or overnight at 4°C, if required. Membranes were 
washed three times with PBS-T over a 30 minute period. Secondary IgG 
horseradish peroxidase-conjugated antibodies (HRP-linked IgG) were diluted in 
5% (w/v) dried non-fat milk/PBS-T to an appropriate dilution. Membranes were 
exposed to HRP-linked IgG for one hour at room temperature, with shaking. 
Membranes were washed three times with PBS-T over a 30 minute period.  
HRP-Immunolabelled proteins were visualised using the ECL system. ECL 
reagents 1 and 2 were mixed in a 1:1 ratio. The nitrocelluose membrane was 
immersed in ECL reagent for 1 minute then removed immediately. The 
membrane was exposed to Kodak X-ray film in a light-proof cassette and 
developed using an X-Omat Processor. 
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2.2.5 Stripping of nitrocellulose membranes 
To strip nitrocellulose membranes of bound antibodies, membranes were 
incubated in stripping buffer (50mM glycine, pH 2.5) for 20 minutes at room 
temperature under agitation. Blots were then washed with PBS-T and then 
blocked with 5% (w/v) dried non-fat milk/PBS-T for 1 hour. Blots were checked 
for effectiveness of stripping via ECL and then further incubated in primary 
antibody, as required. 
2.2.6 Coomassie blue staining of SDS polyacrylamide gels 
To detect protein in a SDS-PAGE gel, gels were immersed in Coomassie blue stain 
solution for one hour (minimum), with agitation. Coomassie blue stain was then 
removed and gels were destained overnight, under agitation in Coomassie blue 
destain solution. 
2.2.7 Brilliant Blue G-Colloidal Coomassie 
Brilliant Blue G-Colloidal Coomassie staining is used to stain for proteins destined 
for proteomic analysis, owing to the reversible binding of the Coomassie. Gels 
were stained according to the manufacturer’s instructions. All solutions, except 
the Brilliant Blue G-Colloidal Coomassie itself, were filtered prior to use. 
Manipulation of the gel was carried out in the fume hood to minimise 
contamination by keratin. Briefly, following eletrophoresis, proteins were fixed 
for one hour in a solution of 7% (v/v) glacial acetic acid in 40% (v/v) methanol. 
800 ml of deionised water was added to the bottle of Brilliant Blue G-Colloidal 
Concentrate, and this was mixed by inversion. This formed the 1x working 
solution, which was not filtered. Immediately before staining, 4 parts of the 1x 
working solution were combined with 1 part methanol. This was mixed well by 
vortexing for 30 seconds. The gel was placed in staining suspension for 1 to 2 
hours. Gels were destained with 10% (v/v) acetic acid in 25% (v/v) methanol for 
60 seconds with shaking. Gels were rinsed with 25% (v/v) methanol. This was 
discarded and then gels were destained in 25% (v/v) methanol for up to 24 
hours.  
Louise L. Collins, 2010  Chapter 2, 76 
2.3 General molecular biology 
2.3.1 Site directed mutagenesis 
Site-directed mutagenesis was carried out according to the QuickChange® 
method (Stratagene). Owing to the high GC content of Rab11-FIP3, Advantage® 
GC Genomic LA Polymerase Mix was purchased from Clontech. The exchange of 
one amino acid to another was performed using synthetic oligonucleotides which 
were designed with the desired mutation in the middle of the primer (refer to 
section 2.1.6 for primer details). The template was purified using QIAfilter™ 
Plasmid Maxi Kit. 
The reaction mixture used for site directed mutagenesis was as follows.  
2X Advantage GC-Melt LA Buffer   12.5µl   
dNTPs (10mM each dCTP, dGTP, dATP, dTTP)  1µl 
Forward primer      0.1 - 0.5µM    
Reverse primer      0.1 - 0.5µM    
Template DNA      10-100ng  
Polymerase mix     0.25µl    
Nuclease free water     to 25µl 
    
Tubes were flick mixed and briefly spun in a microcentrifuge.  
The thermocycling conditions used for site directed mutagenesis were as 
follows. 
94°C 1 min 
94°C 30 sec 
60°C 30 sec  16 to 30 cycles 
72°C 2min/kb 
72°C 5 min 
4°C Hold 
 
To remove the parental plasmid DNA, mixtures were incubated for 1 hour at 
37°C in the presence of 1µl DpnI. 5µl of the mixture was used to transform 
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TOP10 chemical competent cells, as detailed in section 2.3.2. Plasmids were 
isolated from single colonies as outlined in 2.3.3. Mutations were confirmed by 
DNA sequencing, as detailed in section 2.3.10. 
2.3.2 Transformation of Escherichia coli 
Chemically competent TOP10 cells were transformed according to the 
manufacturer’s instructions. Briefly, cells were thawed on ice for 15 minutes. 
5µl of SDM reaction/miniprep or 1µl maxiprep was added to the cells. These 
were incubated on ice for 30 minutes. The cells were then subject to heat shock 
at 42°C for 45 seconds, then chilled on ice for 1 minute. 250µl SOC medium was 
added to each vial of cells, which was then incubated at 37°C, with shaking, for 
1 hour. Cells were plated on warmed 2 YT selection plates, containing the 
required antibiotic. For pEGFP-N1 plasmid, containing human FIP3, Kanamycin at 
a concentration of 50µg/ml was used. For the pCR3.1 vector, Ampicillin at a 
concentration of 100µg/ml was used. Plates were inverted and grown at 37°C 
overnight.  
2.3.3 Small scale DNA preparations (miniprep) 
Small scale DNA preparations were carried out using Promega Wizard® Plus SV 
Minipreps DNA Purification System, following the manufacturer’s instructions. 
Briefly, individual bacterial colonies from 2 YT selective plates were picked and 
transferred to 5ml 2 YT media containing the appropriate antibiotic. For pEGFP-
N1 plasmid, containing human FIP3, Kanamycin at a concentration of 50µg/ml 
was used. For the pCR3.1 vector, Ampicillin at a concentration of 100µg/ml was 
used. These were grown overnight at 37°C with shaking. Cells were collected via 
centrifugation at 3273 g in a refrigerated bench top centrifuge and resuspended 
in 250µl cell resuspension buffer. Cells were transferred to 1.5ml eppendorf 
tubes. 250µl cell lysis buffer was added and the tubes were mixed by inverting 
four times. 5µl alkaline protease solution was added and the tubes were mixed 
by inverting four times. These were incubated at room temperature for 5 
minutes. 350µl neutralisation solution was added and the tubes were mixed by 
inverting four times. Microcentrifuge tubes were centrifuged for 10 minutes at 
full speed in a microcentrifuge and supernatants were decanted into spin 
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columns. These were then spun at full speed for 1 minute in a microcentrifuge. 
The flow through was discarded and 750µl column wash buffer (containing 
ethanol) was applied. This was spun at full speed for 1 minute in a 
microcentrifuge and the flow-through discarded. This was repeated using 250µl 
column wash buffer. Flow through was discarded and the tubes were spun for a 
further minute to remove any residual column wash solution. Columns were 
placed in fresh sterile 1.5ml microcentrifuge tubes tubes. 100µl nuclease free 
water was pipetted into the centre of the column. DNA was collected by 
centrifugation for 1 minute. 
2.3.4 Large-scale DNA preparation (maxiprep) 
Large-scale DNA preparations were performed using QIAfilter™ Plasmid Maxi Kit, 
according to the manufacturer’s instructions. Briefly, individual bacterial 
colonies from 2 YT selection plates were picked and transferred to 5ml 2 YT 
media containing the appropriate antibiotic. For pEGFP-N1 plasmid, containing 
human FIP3, Kanamycin at a concentration of 50µg/ml was used. For the pCR3.1 
vector, Ampicillin at a concentration of 100µg/ml was used. Several hours later 
the 5ml culture was added to 50ml 2 YT (including antibiotic) in a sterile 250ml 
conical flask. This was incubated at 37°C overnight, with shaking. Cells were 
harvested in 50ml centrifuge tubes at 3273 g in a refrigerated benchtop 
centrifuge for 30 minutes at 4°C. Bacterial pellets were resuspended in 10ml 
Buffer P1 (containing RNnase A). 10ml Buffer P2 was then added and mixed 
thoroughly by vigorously inverting the sealed tube 4-6 times. This was left to 
incubate at room temperature for 5 minutes. The reaction was neutralised on 
addition of 10ml pre-chilled Buffer P3. This was mixed immediately by vigorously 
inverting 4-6 times. The cap onto the outlet nozzle of the QIAfilter Maxi 
Cartridge was attached and placed in a 50ml centrifuge tube. The lysate was 
poured into the barrel of the QIAfilter Maxi Cartridge and incubated at room 
temperature for 10 minutes. The QIAGEN-tip 500 was equilibrated by applying 10 
ml QBT Buffer and allowed to empty by gravity flow. The cell lysate was filtered 
into the equilibrated tip and the cleared lysate entered the resin by gravity. The 
tip was then washed twice with 30ml Buffer QC (containing ethanol). DNA was 
eluted into a 50ml centrifuge tube with 15ml Buffer QF. DNA was precipitated by 
adding 10.5ml room temperature isopropanol. This was mixed and centrifuged 
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immediately at 3273 g for 1 hour in a refrigerated benchtop centrifuge. The 
supernatant was decanted and the pellet washed with 5ml room temperature 
70% (v/v) ethanol. This was centrifuged at 3273 g for 30 minutes. The 
supernatant was removed and the pellet air-dried for 5 to 10 minutes. The pellet 
was resuspended in 150 to 250µl nuclease-free water. 
2.3.5 DNA restriction digests 
Restriction digests were carried out according to manufacturer’s instructions. 
For digests using two restriction enzymes, the digest buffer used was selected on 
the basis that both enzymes retained 75-100% activity in the buffer. A general 
outline for a restriction digest using Promega enzymes is provided below.  
Restriction digests were set up as follows: 
DNA (1µg/µl)     1µl  
RE 10X Buffer    2µl 
Acetylated BSA (10µg/µl)   0.2µl 
Restriction enzyme 1 (10u/µl) 1µl 
Restriction enzyme 2 (10u/µl) 1µl 
Sterile nuclease-free water  to 20µl 
  
The tubes were flick mixed and briefly centrifuged in a microcentrifuge, prior to 
incubation at 37oC for 2 hours. The digestion products were prepared for agarose 
gel electrophoresis with the addition of 4µl 6x DNA loading buffer and 
electrophoresis was performed as outlined in section 2.3.7.  
2.3.6 Ligation 
Restriction digests of the destination vector and the vector containing insert 
were prepared separately using the same buffer and appropriate enzymes. The 
digests were then separated using agarose gel electrophoresis, as outlined in 
section 2.3.7, and the digested bands of the appropriate size were excised using 
a clean scalpel. The gel slices were purified, as outlined in section 2.3.8. The 
vector and insert were mixed at a ratio of 1:1 and 1:5. The final reaction volume 
was 10µl and this included 1µl of 10X T4 DNA ligase buffer and 1µl of T4 DNA 
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ligase. Controls were set up with vector only, insert only and vector with insert 
(minus T4 DNA ligase). Ligations were incubated at 16oC overnight to allow the 
complimentary ends to anneal. The following morning, the entire ligation 
mixture was used to transform Top10 cells, as outlined in section 2.3.2. 
2.3.7 Agarose gel electrophoresis 
1% (w/v) agarose gels were prepared in TAE buffer, using a microwave oven. 
Once cooled slightly, ethidium bromide from a dropper bottle (0.5µg/ml) was 
added. One drop was sufficient for 50ml of agarose solution. This was mixed and 
poured into a horizontal electrophoresis gel tray, within a casting tray, using the 
appropriate comb. Once set at room temperature, the gel was transferred to a 
submerged horizontal electrophoresis tank containing TAE buffer. All 
electrophoresis equipment was purchased from BioRad. DNA samples, prepared 
in 6x DNA loading buffer, were applied to the wells. 0.5µg of 1kb DNA ladder 
(500µg/ml) was applied to an adjacent lane. Electrophoresis was carried out at 
100 volts until the dye front had migrated far enough to have allowed the 
resolution of DNA fragments. Gels were visualized and recorded using a 
Molecular Imager ChemiDoc XRS+ System from BioRad. 
2.3.8 Gel extraction of DNA 
DNA products were separated via agarose gel electrophoresis as described in 
section 2.3.7 and the product of the correct size identified under UV light. Bands 
of interest were excised using a clean scalpel blade and placed in clean 1.5ml 
microcentrifuge tubes. The size of the gel slice was minimised by removing 
excess agarose. DNA of interest was then purified using the QIAquick Gel 
Extraction Kit following the manufacturer’s instructions.  Briefly, 600µl of 
solubilisation buffer QC was added to the gel slice. This was incubated at 50oC 
for 10 minutes or until the agarose had completely dissolved. The sample was 
vortexed at regular intervals to aid this process. Once dissolved, 200µl of 
isopropanol was added. This was transferred to a QIAspin column and 
centrifuged at full speed in a microcentrifuge for 1 minute. Eluate was 
discarded. The column was then washed with 750µl of Buffer PE and the eluate 
discarded. The column was then centrifuged for 1 minute, eluate discarded, and 
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any traces of ethanol removed by a final spin for 2 minutes.  The DNA was eluted 
in a final volume of 20µl of nuclease-free water, which was added to the centre 
of the column and incubated for 1 minute prior to centrifugation for 1 minute at 
full speed in a microcentrifuge. 
2.3.9 Alkaline phosphatase treatment of linearised plasmid DNA 
Shrimp Alkaline Phosphatase prevents the re-ligation of linearised plasmid DNA 
by catalyzing the dephosphorylation of phosphate groups from both 5´ termini. 
SAP (1 unit/µg DNA) was incubated with gel purified restriction-digested vector 
at 37ºC for 30 minutes in 1x SAP reaction buffer in a final volume of 20µl. SAP 
was inactivated by heating at 65°C for 15 minutes. The reaction mix was 
centrifuged in a microcentrifuge and used in subsequent ligation reactions, as 
detailed in section 2.3.6. 
2.3.10 DNA sequencing 
The University of Dundee Sequencing Service performed all DNA sequencing. For 
each sequencing run, 600ng DNA was provided in 30µl; primers were provided at 
a concentration of 3.2µM in 10µl. FIP3 sequencing primers are detailed in section 
2.1.6. Sequencing was analysed using Vector NTi version 11 from Invitrogen. 
2.4 Mammalian cell culture 
2.4.1 Cell culture conditions 
Human cervical carcinoma HeLa cells were cultured in Dulbecco's Modified Eagle 
Medium (D-MEM), supplemented with 10% (v/v) Foetal Calf Serum EU, 2mM 
Glutamine, 100Units/ml Penicillin and 100µg/ml Streptomycin. This is referred 
to as HeLa complete growth media.  
HeLa cells stably expressing GFP-FIP3 were obtained from Rytis Prekeris, 
University of Colorado. These were maintained in D-MEM supplemented with 10% 
(v/v) Foetal Calf Serum EU, 2mM Glutamine and 100µg/ml Hygromycin B. This is 
referred to as GFP-FIP3 selection media. 
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Chinese hamster ovary (CHO) cells were cultured in Nutrient Mixture F-12 Ham, 
supplemented with 10% (v/v) Foetal Calf Serum EU, 2mM Glutamine and 
100Units/ml Penicillin and 100µg/ml Streptomycin. This is referred to as CHO 
complete growth media.  
Cells were grown at 37ºC in 5% (v/v) CO2. Cells were cultured in 75cm
2 flasks. 
2.4.2 Passage of cells 
Cells were passaged at approximately 70% confluency. Media was aspirated and 
cells rinsed with 2ml of trypsin/EDTA, which had been warmed to 37°C. This was 
aspirated and replaced with 3ml of trypsin/EDTA, evenly distributed over the 
monolayer of cells. Cells were incubated for several minutes at 37°C and gently 
dislodged by tapping the flask. Media was added to the cells to give the 
appropriate dilution. Cells were transferred to fresh flasks or culture dishes, 
containing the desired volume of complete growth media. For confocal 
microscopy, cells were plated onto 13mm diameter glass coverslips that had 
been immersed in 100% ethanol, air dried in the cell culture hood and then 
exposed to UV for a minimum of one hour.  
2.4.3 Cryopreservation of cells 
Cells were cultured as normal to achieve a confluent 75cm2 flask 24 hours later. 
Cells trypsinised, as detailed in section 2.4.2, were added to 12ml of complete 
growth media. Cells were centrifuged at 1000 rpm for 5 minutes. Media was 
removed, the pellet dislodged, and the cells resuspended in 5ml complete 
growth media. Cells were centrifuged at 1000 rpm for 5 minutes and the media 
removed. Cells were resuspended in 1 ml freezing media per flask of cells. 
Freezing media contained Foetal Calf Serum EU supplemented with 10% (v/v) 
DMSO. These were transferred to 1 ml to 1.8ml polypropylene cryo-vials on ice. 
These were stored in 5100 Cryo 1°C Freezing Container from Nalgene, containing 
isoropanol for four hours at -80°C. Cells were then transferred to a liquid 
nitrogen storage vat. 
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2.4.4 Resurrecting cells 
To resurrect cells from liquid nitrogen storage, vials were rapidly thawed in a 
37°C water bath. Cells were then transferred to 15ml warmed complete growth 
media in 75cm2 flask. 24 hours later the media was changed to remove DMSO. 
2.4.5 HeLa cell synchronisation 
2.4.5.1 Thymidine, nocodazole block 
HeLa cells were synchronised using a thymidine, nocodazole block (Harper, 
2005). Cells were passaged into flasks to achieve approximately 50 to 60% 
confluency by the following day. In the evening of day two, thymidine was added 
to the cells at a concentration of 5mM. Cells were incubated for 16 hours at 
37°C in 5% (v/v) CO2. On the morning of day three, flasks were washed twice in 
cold sterile PBS and twice in warm media. Cells were incubated for 
approximately 8 hours. Cells were then incubated in 100ng/ml of nocodazole for 
16 hours at 37°C in 5% (v/v) CO2. On the morning of day four, metaphase 
arrested cells were harvested. Flasks were gently transported to the cell culture 
hood and media removed. Flasks were tapped gently on the cell culture hood 
bench and dislodged cells were washed off from the growth surface with sterile 
PBS. Cells were collected in 15ml centrifuge tubes, washed twice in sterile PBS, 
three times in warm media, then plated as required. In our hands, plated HeLa 
cells tend to divide at 45 (metaphase) and 90-110 minutes (telophase).  
2.4.5.2 Thymidine, nocodazole and MG132 block 
HeLa cells were synchronised using a thymidine, nocodazole and MG132 block 
(Petronczki et al., 2007). Cells were passaged into flasks to achieve 
approximately 50 to 60% confluency by the following day. Cells were incubated 
overnight at 37°C in 5% (v/v) CO2. Thymidine (prepared in water) was added to 
the cells at a concentration of 2mM for 24 hours. Cells were then washed twice 
in cold sterile PBS and twice in warm media. Cells were released for 
approximately six hours. Following this 50ng/ml nocodazole (prepared in DMSO) 
was added for four hours. Next, media was removed gently and replaced with 
media containing 10µM MG132 (prepared in DMSO) for two hours. Cells were 
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gently transported to the cell culture hood and media removed. Cells were 
tapped gently on the cell culture hood bench and dislodged cells were washed 
off the growth surface with sterile PBS. Cells were collected in 15ml centrifuge 
tubes and washed twice in warm media. Cells were plated as desired. This 
treatment arrested cells in metaphase and on release cells entered anaphase. At 
approximately 60 minutes cells entered telophase.  
2.4.6 Plasmid DNA transfection 
Cells were transfected with plasmid DNA, using Lipofectamine™ 2000, following 
the manufacturer’s instructions. The following instructions detail how to 
transfect DNA into mammalian cells in a 24-well format. For other formats, the 
volumes used were scaled up or down, as directed by the manufacturer. All 
amounts and volumes are on a per well basis. Briefly, cells were passaged in 
500µl antibiotic free growth media per well of a 24-well cell culture plate, to 
achieve 90-95% confluency for the following day. For cells destined for 
immunofluorescence, cells were passaged onto ethanol sterilised 13mm 
diameter glass coverslips and the confluency was lowered to 60-70%. The 
following day complexes were prepared as follows. Firstly, 0.8µg DNA was 
diluted in 50µl of Opti-MEM® I Reduced Serum Medium and mixed. Secondly, 
Lipofectamine™ 2000 was mixed gently before use and 2µl was diluted in 50 µl of 
Opti-MEM® I Medium. This was incubated for 5 minutes at room temperature. 
Next, the diluted DNA was combined with the diluted Lipofectamine™ 2000 
(total volume of 100µl). This was mixed gently and incubated for 20 minutes at 
room temperature. The DNA/Lipofectamine™ 2000 complex was added to the 
well containing cells and 500µl of fresh antibiotic-free growth media. This was 
mixed gently by rocking the plate back and forth. Cells were incubated at 37°C 
in 5% (v/v) CO2. The antibiotic-free growth media was changed after 4-6 hours. 
Cells were processed for transgene expression 24 to 72 hours post-transfection.  
2.4.7 Cell lysis 
For crude analysis of protein expression in cells, lysis buffer containing 0.1% 
(v/v) Triton X100 was used, as detailed in section 2.1.10. On day of harvest, 
cells were placed on ice, media was removed and cells washed three times in ice 
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cold PBS. All PBS was removed and 50µl (12 well plate), 100µl (6 well plate), 
500µl (10cm plate) of cell lysis buffer was added per well. Cells were scraped off 
and placed in microcentrifuge tubes. Cells were then subject to ten passes 
through a 26G needle and allowed to rest on ice for 20 minutes, before 
repeating the needle homogenisation. Cells were then spun at 23,880 g in a 
refrigerated benchtop centrifuge. The supernatant was retained and prepared 
for electrophoresis in 4x SDS-PAGE sample buffer. 
2.4.8 Membrane and cytosol fractionation 
Cells were collected in 15 ml centrifuge tubes via centrifugation at 3273 g for 5 
minutes in a refrigerated benchtop centrifuge. Cells were resuspended in 1.5 ml 
HPFEV buffer. Cells were passed ten times through a ball-bearing homogeniser, 
with a 14µm clearance, from Isobiotec, Germany. 75µl of the homogenate was 
retained and diluted in 4x SDS-PAGE sample buffer for analysis. Cell homogenate 
was then transferred to Beckman Thinwall Polyallomer 11x34mm tubes and 
centrifuged in a bench top ultracentrifuge at 35,000 g for 1 hour at 4ºC in a 
Beckman TLS.55 rotor. 
Cytosolic proteins in the supernatant fraction were precipitated by the addition 
of TCA to a final concentration of 10% (w/v). After incubation on ice for 15 
minutes, the sample was centrifuged at 23,880 g in a refrigerated benchtop 
centrifuge for 15 minutes at 4ºC. The pellet, containing cytosolic proteins, was 
resuspended in 80µl 2x SDS-PAGE sample buffer. 5µl saturated Tris solution was 
added.  
The cell pellet from the first spin, containing cell membranes, was washed by 
resuspending in 2 ml of HES buffer and centrifuged in a bench top 
ultracentrifuge at 35,000 g for 1 hour 4ºC. For the purposes of SDS-PAGE, 
membrane bound proteins were released from the membrane fraction. 
Membrane proteins within the pellet were resuspended in 1ml of HES buffer, 
containing 1% Triton X100, using a 26G needle. This was left on ice for 10 
minutes and centrifuged in a bench top ultracentrifuge at 214,200 g for 1 hour. 
The supernatant was removed and solubilised membrane proteins were 
precipitated using TCA, as before. The pellet, containing membrane proteins, 
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was resuspended in 80µl 2x SDS-PAGE sample buffer. 5µl saturated Tris solution 
was added. 
Cytosolic and membrane fractions were analysed for proteins of interest using 
immunoblotting. Syntaxin 6 and GAPDH were used as markers for membrane and 
cytosol fractions, respectively. 
2.4.9 Density gradient fractionation 
Recombinant baculovirus Sf9 cell expressed FIP3 was incubated with either HeLa 
membranes or protein-free liposomes. These membranes (or vesicles) were then 
floated up through an Optiprep gradient. Fractions were collected and the 
distribution of proteins within the gradients was assayed by immunoblotting.  
HeLa membranes were prepared by homogenising HeLa cells in HES buffer via 
ten passes through a ball-bearing homogeniser with a 14µm clearance, from 
Isobiotec, Germany. The homogenate was centrifuged in a refrigerated benchtop 
centrifuge at 3000 g to pellet nuclei and heavy debris. The supernatant was 
transferred to Beckman Ultra-Clear 13x51mm tubes in a Beckman TLA 100.3 
rotor. Membranes were collected by sedimentation using a benchtop 
ultracentrifuge at 100,000 g for 60 minutes.  Membrane pellets were re-
suspended in HES buffer to approximately 2mg/ml. 
Protein-free liposomes were first prepared (Brandie et al., 2008). In brief, lipid 
stocks were prepared in chloroform and stored at −80°C under nitrogen. A 15mM 
lipid stock was prepared in chloroform containing 85 mol% Palmitoyl oleoyl 
phosphatidyl choline (POPC) and 15 mol% dioleoylphosphatidylserine (DOPS). 
100µl of 15mM lipid stock was placed at the bottom of a 12×75 mm glass test 
tube. The chloroform was then evaporated using a stream of nitrogen for 15 
minutes in a fume hood. To ensure that the lipid films were completely dry the 
samples were then dried for 30 minutes under vacuum. The lipid film was then 
resuspended, in A200 buffer containing 1% (w/v) octyl glucoside, by vortexing 
for 15 minutes. After the lipid film was completely resuspended, the detergent 
was diluted below its critical micellar concentration via the addition of 1 ml of 
Buffer A200 containing 1mM DTT, drop-wise, while the sample was continuously 
vortexed. To remove any remaining detergent, the samples were placed into 
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pre-equilibrated 3ml Float-a-Lyzers with a molecular weight cut off of 10,000 
and dialysed against 4 L of Buffer A200, containing 1mM DTT and 4g of Bio-
Beads, with stirring at 4°C overnight. Samples were recovered the following day 
and placed at the bottom of an SW60 tube on ice for subsequent separation 
using gradient centrifugation. Liposomes were recovered by floatation on a 
Nycodenz (Histodenz™) gradient. An equal volume of 80% (v/v) Nycodenz in 
buffer A200 containing 1mM DTT was mixed with the recovered dialysate to 
produce a 40% (v/v) Nycodenz mixture. This was overlaid with 1.5ml of 30% (v/v) 
Nycodenz in buffer A200 containing 1mM DTT. This layer was then overlaid with 
250µl of glycerol-free A200 and centrifuged at 65,000 g for 4 hours at 4°C. 
Liposomes were recovered by removal of 400µl from the top of the gradient, 
snap frozen and stored at −80°C. 
30µl of HeLa membranes were mixed with or without 10µM recombinant FIP3 in 
HES buffer and incubated on ice for 90 minutes with occasional mixing. In 
parallel, 30µl of protein-free liposomes were also incubated with 10µM 
recombinant FIP3 in HES buffer on ice for 90 minutes. After this incubation, 
samples were mixed with OptiPrep
®
 Density Gradient Medium such that the final 
concentration was 40% (v/v), and overlaid with 1ml of 20% (v/v) and 1ml of 5% 
(v/v) OptiPrep
®
 Density Gradient Medium. These were prepared in Beckman 
Ultra-Clear 13x51mm tubes. These were centrifuged in a bench top 
ultracentrifuge, using a Beckman TLA 100.3 rotor at 85,000 g for 4 hours at 4°C. 
Under these conditions, membranes and liposomes float to the top of the 
gradient, whereas soluble proteins remain in the dense, lower layer. Samples 
were collected by tube puncture and subjected to TCA precipitation. TCA was 
added to a final concentration of 10% (w/v), the samples vortexed and incubated 
on ice for 20 min. After this, samples were centrifuged at 23,880 g in a 
refrigerated bench top centrifuge for ten minutes. The supernatant was 
discarded and the protein precipitate re-suspended in 4x SDS-PAGE sample 
buffer containing 20mM DTT and 1M Urea. Thereafter the distribution of proteins 
within the gradients was assayed by immunoblotting. 
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2.5 Immunofluorescence 
2.5.1 Immunofluorescence 
Cells were passaged in 12-well plates containing ethanol sterilised 13 mm 
diameter glass coverslips. Cells were grown on coverslips for 24 hours prior to 
processing. The exposure of coverslips to light was minimised throughout the 
procedure to help prevent photo-bleaching. Media was aspirated and cells 
washed gently three times in room temperature PBS. Cells were fixed with 1 ml 
4% (w/v) ρ-formaldehdye per well and incubated at room temperature for 20 
minutes. Coverslips were washed three times with PBS and then incubated in 1 
ml of 30mM NH4Cl for 10 minutes. Coverslips were washed three times with PBS.  
If all that was required was to verify the presence of a GFP-FIP3 plasmid, 
coverslips were mounted onto glass slides using a drop of Immunomount and 
stored overnight in the dark to dry. 
For immunofluorescence, following the PBS washes, 0.1% (v/v) Triton (in PBS) 
was added to permeabilise the cells for 4 minutes. Cells were washed three 
times in PBS. Cells were then left to block in immunofluorescence (IF) buffer, 
which was prepared freshly on the day and filtered through a Nalgene 0.2µm 
vacuum filter. Primary antibody was diluted to the appropriate concentration in 
IF buffer. 100µl of primary antibody was then applied to a sheet of nescofilm 
and the coverslip placed cell-side down onto the antibody. After 1 hour 
incubation at room temperature, the cells were washed again three times in IF 
buffer. Alexa Fluor® Dyes were used to fluorescently label the primary 
antibodies. Alexa Fluor® 568 goat anti-rat IgG (H + L) emits fluorescence in the 
red-orange part of the spectra. The secondary antibodies were diluted in IF 
buffer at 1:400. 100µl secondary antibody solution was applied to each coverslip 
as before and incubated for 1 hour in the dark. The coverslips were again 
washed three times in IF buffer. For nuclear staining, DAPI (4′,6-Diamidino-2-
phenyindole, dilactate) was diluted in IF buffer to a final concentration of 
1µg/ml. 1ml of the DAPI solution was added to each well and incubated for 5 
minutes in the dark, before a final three washes with IF buffer. Coverslips were 
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then mounted onto glass slides using a drop of Immunomount and stored 
overnight in the dark to dry.  
2.5.2 Confocal microscopy 
Mounted coverslips were analysed using a 63X Zeiss oil immersion objective, on a 
Zeiss confocal microscope (Carl Zeiss, Germany) equipped with a Zeiss LSM5 
Pascal instrument. An argon laser was used to excite 488nm Alexa Fluor® Dyes 
and GFP fusion proteins. Helium neon lasers were used to excite 568nm Alexa 
Fluor® Dyes. Zeiss Pascal software was used to collect images, which were saved 
as .mdb files. 
2.6 In vitro phosphorylation assays 
Recombinant Aurora A, Aurora B and cyclin B-CDK1 were purchased from 
Upstate; Plk1 was purchased from Invitrogen. FIP3 was expressed and purified by 
the University of York Biocentre using the baculovirus Sf9 insect cell system. The 
construct used to express this protein was made by a previous student of the 
Gould lab and has a tag of six histidine residues at the C-terminus.  
Reactions were set up in screw capped microcentrifuge tubes, as follows. Firstly, 
50ng kinase was added to appropriate tubes, followed by kinase assay buffer 
(containing 50µM ATP.Mg2+) to produce a final volume of 50µl. Then 2µg or 5µg 
recombinant FIP3 was added to appropriate tubes. 2µg myelin basic protein 
(MBP) was used as a positive control for kinase activity. To start the reaction, 
6µCi adenosine 5’-triphosphate [γ-32P] (ATP-γ-32P) was added to each tube and 
reactions were incubated in a water bath at 30ºC for 30 minutes. 20µl of 4x SDS-
PAGE sample buffer (with 80mM DTT) was added to each tube to stop the 
reaction. Samples were separated by SDS-PAGE, as detailed in section 2.2.2, 
using an 8% gel for FIP3 samples and a 15% gel for MBP samples. Gels were 
stained with Coomassie blue stain (as detailed in section 2.2.6). Gels were dried 
using cellophane and exposed to Kodak X-ray film in a cassette with no 
intensifying screen at room temperature for 24 to 96 hours. 
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2.7 Proteomics 
2.7.1 Phosphorylation site mapping of Rab11-FIP3 
Phosphorylation site mapping of kinase phosphorylated FIP3 was carried out 
commercially by the FingerPrints Proteomic Facility at the University of Dundee.  
A summary of the sample preparation process and techniques used to map the 
sites of phosphorylation are provided below. Importantly, measures were taken 
to minimise dust contamination (specifically, keratin). All gel manipulation was 
carried out in a laminar flow cabinet; buffers were filtered; ultrapure SDS-PAGE 
reagents were purchased from Invitrogen.  
In vitro phosphorylation assays were performed on recombinant FIP3 using the 
kinases Aurora A, cyclin B-CDK1 and Plk1. FIP3 which had not been kinase –
phosphorylated was included as a control. The ability of the recombinant FIP3 
sample to autophosphorylate was abolished by heat treatment of FIP3 at 60ºC 
for 30 minutes. For more details, refer to section 3.3.4 where this is discussed 
fully. In vitro phosphorylation assays were performed, as detailed in section 2.6, 
with some modifications to ensure a band corresponding to FIP3 was present at 
good intensity by colloidal Coomassie staining. Reactions were set up in screw 
capped microcentrifuge tubes, as follows. Firstly, 200ng recombinant kinase was 
added to appropriate tubes, followed by kinase assay buffer (supplemented with 
100µM ATP.Mg2+) to produce a final volume of 100µl. Next, 50µg recombinant 
heat treated FIP3 was added. This was incubated at 30°C for 60 minutes. Protein 
was TCA precipitated, on ice for 15 minutes. This was centrifuged at 23,880 g in 
a refrigerated benchtop centrifuge for 15 minutes at 4ºC. 
Samples were separated via SDS-PAGE using NuPAGE® reagents from Invitrogen, 
following the manufacturer’s instructions. TCA precipitated protein pellets were 
resuspended in 20µl NuPAGE® SDS Sample Buffer, with NuPAGE® Sample 
Reducing Agent (10x). 5µl saturated-Tris solution was added. Samples were 
separated using NuPAGE® NOVEX 10% Bis-Tris, with NuPAGE® MOPS SDS Running 
Buffer (20x) containing NuPAGE® Antioxidant. The gel was removed from the 
plastic casing and stained with colloidal Coomassie, as detailed in section 2.2.7, 
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following the manufacturer’s instructions. Following destaining, bands according 
to FIP3 were excised, placed in sterile microcentrifuge tubes and shipped on dry 
ice to the FingerPrints Proteomics Facility at the University of Dundee.  
This service uses a technique known as parent ion scanning (also known as 
Parents of -79) to detect phosphorylated peptides (Loyet et al., 2005;Paradela 
and Albar, 2008), in conjunction with the generation of tandem MS data to 
identify the protein(s) in the solution (www.matrixscience.com) (Perkins et al., 
1999). Together these are used to determine the sites of phosphorylation in the 
protein.  
2.7.2 Proteomic analysis of recombinant Rab11-FIP3 
The FIP3 sample used in this thesis was expressed and purified by the University 
of York Biocentre using the baculovirus Sf9 insect cell system and has a tag of six 
histidine residues at the C-terminus. Via an in vitro phosphorylation assay 
discussed in section 3.3.4, the FIP3 sample was shown to possess kinase activity. 
To identify any potential kinases contaminating the purified FIP3 sample, a 
proteomic approach was used. Two attempts were made at this. Firstly using the 
Sir Henry Wellcome Functional Genomics Facility (SHWFGF) at the University of 
Glasgow and secondly using Aberdeen Proteomics at the University of Aberdeen. 
Sample preparation for the two proteomic facilities are described below. 
Measures were taken to minimise dust contamination (specifically, keratin). All 
gel manipulation was carried out in a laminar flow cabinet; buffers were 
filtered; SDS-PAGE NuPAGE® reagents were purchased from Invitrogen. 
Two different sample preparations were analysed by the SHWFGF at the 
University of Glasgow. Firstly, 15µg of the recombinant FIP3 solution was 
analysed by the facility to identify proteins in the sample solution. This was 
achieved using nanoflow HPLC Electrospray Tandem Mass Spectrometry (nLC-ESI-
MS/MS), searching Mammalia and Drosophila databases (Bridges et al., 2008). 
Concern was raised over the overexpressed FIP3 protein masking the presence of 
less well expressed kinases. To that end the FIP3 sample was separated by SDS-
PAGE and gel slices were analysed individually, allowing proteins to be analysed 
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in the absence of FIP3. The FIP3 sample was separated using SDS-PAGE, using 
NuPAGE® reagents from Invitrogen, following the manufacturer’s instructions.  
In brief, 5µg FIP3 was made up in NuPAGE® SDS Sample Buffer, with NuPAGE® 
Sample Reducing Agent (10x). Samples were separated using NuPAGE® NOVEX 
10% Bis-Tris, with NuPAGE® MOPS SDS Running Buffer (20x) containing NuPAGE® 
Antioxidant. The gel was removed from the plastic casing and stained with 
colloidal Coomassie, as detailed in section 2.2.7. The FIP3 lane was cut into 5 
slices which were placed in sterile Eppendorfs and analysed using nLC-ESI-MS/MS 
searching Mammalia and Drosophila databases. Data was exported to the Mascot 
(Matrix Science) search engine for protein identification 
(www.matrixscience.com) (Perkins et al., 1999). Only proteins with a probability 
based MASCOT score greater than the cut off score that indicates homology or 
identity, were included in the list of proteins. 
In a further attempt to identify contaminating kinases, 5µg FIP3 was separated 
by SDS-PAGE, as described above, and cut into 16 gel slices which were analysed 
by Aberdeen Proteomics at the University of Aberdeen. Protein identification of 
gel bands was achieved by LC-MS/MS searching Human and Spodoptera 
Frugiperda databases. 
2.8 Phospho-specific antibody production 
2.8.1 Phospho-specific antibody generation 
We sought to produce a panel of antibodies generated against phosphorylated 
serines 102, 281, 348 and 451 of FIP3. Phospho-peptides, according to the four 
sites, were synthesised by Quality Controlled Biochemicals, Hopkinton, Mass, 
USA. Both phospho-specific and non-phosphorylated peptides were generated, 
the amino acid sequences of which are listed in section 2.1.7. The phospho-
specific peptides were immunised in rabbits by The Scottish Blood Transfusion 
Service. Whole serum was obtained.  
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2.8.2 Phospho-specific antibody purification 
The IgG fraction for each antibody was affinity purified from whole serum, 
against a protein A sepharose column. The purification of the antibodies was 
carried out by Mrs M.C. Millar. 
To prepare the column, 4ml of protein A sepharose slurry was re-suspended in 
PBS, applied to a 2ml column and washed three times with 10ml of PBS. Prior to 
use, the column was washed with 30ml PBS. A vial of serum was thawed and 10X 
PBS was added to bring the concentration to 1x. 5ml of the serum was applied to 
the column. The flow through was collected and re-applied. This was repeated 
so that the serum had passed through the column three times. Following this, 
the column was washed with 30-40ml PBS. 20ml 0.05M sodium acetate, pH 3.0 
was then applied to the column. 1ml fractions were collected and 25µl saturated 
Tris solution added to each. The column was stripped by applying 20ml 1M 
sodium acetate, pH 2.5. The column was then re-equilibrated in PBS with sodium 
azide and stored at 4°C for re-use. The protein concentration of each fraction 
was calculated by measuring the optical density at 280nm (OD280). Fractions 
spanning the peak protein concentration were pooled and dialysed against PBS. 
Following dialysis, the protein concentration was determined and the purified 
phospho-specific antibodies stored at -80°C. 
2.8.3 Peptide competition assay (PCA) 
To validate the specificity of a phospho-specific antibody, we performed a 
peptide competition assay (PCA). The protocol used was obtained from Rockland 
Immunochemicals, a brief outline of which is provided. This procedure describes 
a PCA using phosphorylated and non-phosphorylated peptides. 
We first separated various FIP3 samples by SDS-PAGE, as described in section 
2.2.2. These were 200ng baculovirus sf9 insect cell expressed FIP3; 1µg CDK1 
phosphorylated heat-treated FIP3 (prepared according to section 2.6); HeLa 
lysate stably expressing GFP-FIP3; mitotic HeLa lysate. FIP3 proteins were 
transferred onto nitrocellulose, as described in section 2.2.3, and blocked in 
PBS-T containing 5% (w/v) dried non-fat milk overnight. This was done in 
triplicate to produce three identical test samples for analysis by PCA.  
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Affinity purified phospho-specific primary antibodies, described in section 2.8.2, 
were diluted to 1:500 in PBS-T containing 1% (w/v) dried non-fat milk. For each 
blot a 3ml solution of primary antibody was prepared, thus 9ml was prepared in 
total. 
Lyophilised peptides (both the phosphorylated and non-phosphorylated forms of 
the immunising peptide) were reconstituted to a concentration of 100µM using 
nuclease-free water, at room temperature. The peptides were allowed to 
dissolve at room temperature, and then gently triturated several times using a 
pipette. The introduction of air bubbles was avoided. 
Three test samples were labelled as follows. Sample A: water only (no peptide 
control); sample B: phosphorylated peptide; sample C: non-phosphorylated 
peptide. Next, peptide stock solutions of 2.66µM and water control were 
prepared by pipetting the following. Sample A, the no peptide control, 
contained 973µl PBS-T containing 1% (w/v) dried non-fat milk plus 27µl water. 
Sample B, the phosphorylated peptide incubation, contained 973µl PBS-T 
containing 1% (w/v) dried non-fat milk plus 27µl reconstituted (100µM) 
phosphorylated peptide. Sample C, the non-phosphorylated peptide incubation, 
contained 973µl PBS-T containing 1% (w/v) dried non-fat milk plus 27µl 
reconstituted (100µM) non-phosphorylated peptide.  
3ml of the phospho-specific antibody was added into each of the samples 
marked A, B or C. The tubes were incubated for 2 hours at room temperature 
with gentle rocking. Samples were centrifuged at 3273 g in a refrigerated 
benchtop centrifuge for 15 minutes at 4°C to pellet any immune complexes. The 
supernatant was removed and the pellet discarded. The pre-incubated antibody 
was added to one of the three identical nitrocellulose membranes for 
immunoblotting. These were incubated overnight at 4°C. These were processed 
for immunodetection using an Amersham ECL Rabbit IgG, HRP-Linked Whole Ab, 
as described in section 2.2.4. The signals obtained with antibody incubated with 
sample A (water only, no peptide control) represent the maximum signal. Signals 
obtained with sample B (phosphorylated peptide) and sample C (non-
phosphorylated peptide) are compared to the signal from sample A to determine 
if the peptide(s) compete for FIP3 binding.  
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3.1 Introduction 
Rab11-FIP3 (FIP3) undergoes spatial and temporal regulation during mitosis 
(Wilson et al., 2005). During metaphase and early anaphase FIP3 is largely 
cytosolic with some localised to endosomal membrane structures. During late 
anaphase, following furrow initiation, FIP3 localises to the centrosome. At late 
cytokinesis, FIP3 relocates to the cleavage furrow and midbody. On separation of 
the daughter cells, FIP3 returns to the centrosome. This is shown in figure 1.4 
(section 1.5.4) of the introduction. 
A potential candidate for the spatial and temporal regulation of FIP3 is 
phosphorylation, since reversible phosphorylation is a commonly used control 
mechanism in mitotic regulation and can regulate the activity, localisation and 
half-life of a protein, as well as its and interaction with other proteins (Cohen, 
2000). 
Several lines of evidence suggest that FIP3 is a potential phospho-protein. 
Firstly, Nuclear fallout (Nuf), a D. melanogaster protein identified as a 
homologue of FIP3 (Riggs et al., 2003;Hickson et al., 2003), is a highly 
phosphorlyated protein (Rothwell et al., 1998). Interestingly, Nuf localisation 
alters during the cell-cycle (Rothwell et al., 1998;Riggs et al., 2003). During 
early D. melanogaster development, the embryo undergoes thirteen rapid 
nuclear divisions, which occur without cytokinesis. During this development, Nuf 
is concentrated at the centrosomes during prophase, but is predominantly 
cytoplasmic through the rest of the nuclear cycle. During nuclear cycle 14, the 
embryo undergoes cellularisation (the equivalent of mammalian cytokinesis). Nuf 
is centrosomal throughout cellularisation (Rothwell et al., 1998). Since Nuf is 
highly phosphorlyated, it has been suggested that its localisation may be 
regulated by cell-cycle dependent kinases (Riggs et al., 2003). 
In addition, work from a collaborating lab proposes that FIP3 phosphorylation 
and dephosphorylation may be a regulator of FIP3 localisation (R. Prekeris, 
personal communication). Figure 3.1 illustrates mass spectrometry data from 
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this lab. Briefly, lysates from synchronised cells at metaphase were separated by 
2D gel electrophoresis and probed for FIP3, as detailed in figure 3.1A. Four forms 
of FIP3 are observed (top panel); on phosphatase treatment three of these 
disappear (bottom panel). This suggests that FIP3 is a phospho-protein, which 
can exist in different, reversible phosphorylation states. FIP3 was 
immunoprecipitated from metaphase cells and subject to proteomic analysis to 
identify the phosphorylation sites. The experiment was repeated three times and 
the sites found in all three repeats are serines 102, 281, 348 and 451, as shown 
in figure 3.1B.  
3.2 Aims 
This work aims to understand the mechanism of controlling FIP3 localisation 
during cytokinesis. It is considered likely that phosphorylation or 
dephosphorylation of FIP3 may be involved in the regulation of FIP3 localisation 
to the centrosome and midbody during cytokinesis. In order to prevent aberrant 
cell division, the cell-cycle is tightly regulated via a network of kinases, which 
phosphorylate a vast number of protein substrates (Morgan, 2007). A variety of 
mitotic kinases are active during the cell-cycle, including Aurora A, Aurora B, 
Plk1 and CDK1. This work aims to determine whether candidate cell-cycle 
kinases can phosphorylate FIP3 in vitro. 
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Figure 3-1 Identification of FIP3 phosphosites from metaphase HeLa lysates (R. Prekeris, 
personal communication) 
HeLa cells were synchronised and arrested in metaphase using a thymidine-nocodazole 
block. (A) Lysates from synchronised cells at metaphase were separated by 2D gel 
electrophoresis and probed for FIP3. Four forms of FIP3 are observed (top panel); on 
phosphatase treatment, three of these disappear (bottom panel). This suggests that FIP3 
can exist in different, reversible phosphorylation states. (B) FIP3 was immunoprecipitated 
from metaphase cells and subject to proteomic analysis to identify the phosphorylation 
sites. The experiment was repeated three times and the sites found in all three repeats are 
shown. These results suggest that FIP3 can be phosphorylated at serines 102, 281, 348 and 
451. 
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3.3 Results 
3.3.1 Generic (non kinase specific) phosphorylation predictions 
Firstly, we sought to map potential phosphorylation sites in the sequence of 
human Rab11-FIP3. This was achieved using the NetPhos 2.0 server (Technical 
University of Denmark) which uses an artificial neural network (ANN) method to 
predict serine, threonine and tyrosine phosphorylation sites in eukaryotic protein 
sequences (Blom et al., 1999). The prediction server is available at 
http://www.cbs.dtu.dk/services/NetPhos/.  
For Rab11-FIP3, 42 serine residues, 7 threonine residues and 4 tyrosine residues 
were predicted to be potentially phosphorylated. Table 3.1 details the output 
from NetPhos for serine residues. The output score is provided as a value in the 
range 0.000 - 1.000, with a threshold of 0.500. Below this threshold the residue 
is predicted not to be phosphorylated; scores above the threshold of 0.500 are 
predicted to be potential phosphosites. In general, the higher the score, the 
higher the confidence of the prediction and the higher the similarity to one or 
more of the phosphorylation sites used in development of the NetPhos 2.0 
method. From the 42 serine residues predicted to be phosphorylated, three of 
these were mapped by the Prekeris lab. Serines 102, 281 and 451 have scores of 
0.522, 0.814 and 0.983, respectively. Serine 348 was not identified as a 
phosphosite, with a score just short of the threshold of 0.428. 
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Pos     Context          Score      Pred 
3         --MASAPPA      0.002      . 
8         APPASPPGS     0.982      *S* 
12       SPPGSEPPG      0.768     *S* 
52       PDPQSPGLD     0.908      *S* 
71       GARWSAGPA    0.750     *S* 
88       DPGPSAPPP      0.654     *S* 
94       PPPRSGPRG      0.593     *S* 
102     GQLASPDAP      0.522     *S* 
112     PGPRSEAPL       0.415     . 
124     DPLFSWTEE      0.967     *S* 
136     CGPASCPES      0.699     *S* 
140     SCPESAPFR       0.028     . 
148     RLQGSSSSH      0.823     *S* 
149     LQGSSSSHR      0.142     . 
150     QGSSSSHRA      0.961     *S* 
151     GSSSSHRAR      0.555     *S* 
162     VDVFSPFPA      0.798     *S* 
180     QGPGSPPQP     0.927     *S* 
185     PPQPSDLSQ      0.222     . 
188     PSDLSQTHP      0.279     . 
195     HPLPSEPVG      0.337     . 
200     EPVGSQEDG     0.997     *S* 
249     YLDPSGLGV     0.041     . 
255     LGVISFEDF      0.981     *S* 
281     GGVASAQDE    0.814     *S* 
308     EVTDSAYMG    0.506     *S* 
313     AYMGSESTY    0.005     . 
315     MGSESTYSE    0.824     *S* 
318     ESTYSECET     0.995     *S* 
329     DEDTSTLVH    0.940     *S* 
344     GDADSAGGS   0.740     *S* 
348     SAGGSAVPS    0.428     . 
 
 
Pos     Context         Score       Pred 
352     SAVPSECLD     0.117       . 
379     PHGQSVITV    0.004        . 
397     YGEGSEAEL    0.842       *S* 
402     EAELSPETL     0.987       *S* 
414     QLGCSDPAF    0.011       . 
422     FLTPSPTKR    0.073        . 
428     TKRLSSKKV    0.996        *S* 
429     KRLSSKKVA    0.998        *S* 
439     YLHQSGALT   0.018        . 
451     LEDPSPELM    0.983       *S* 
488     GEQHSRLRQ   0.987       *S* 
538     EREKSIEIE      0.979       *S* 
556     DEENSELRS    0.368        . 
560     SELRSCTPC    0.011        . 
585     DEIESLTLR    0.004        . 
591     TLRLSEEQE   0.976        *S* 
605     GDRLSHERH  0.997        *S* 
646     RRGRSSSMG  0.971        *S* 
647     RGRSSSMGL  0.985        *S* 
648     GRSSSMGLQ  0.990        *S* 
656     QEYHSRARE  0.834        *S* 
661     RARESELEQ   0.997       *S* 
692     IITLSIQGA     0.016        . 
698     QGAKSLFST   0.960       *S* 
701     KSLFSTAFS    0.729       *S* 
705     STAFSESLA    0.625       *S* 
707     AFSESLAAE    0.140       . 
713     AAEISSVSR    0.009        . 
714     AEISSVSRD    0.898        *S* 
716     ISSVSRDEL    0.972        *S* 
751     ETNPSILEV    0.639        *S* 
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Table 3.1 Generic (non kinase specific) phosphorylation predictions for serine residues of 
human Rab11-FIP3. 
Potential phosphorylation sites of human Rab11-FIP3 were mapped using the NetPhos 2.0 
server (Technical University of Denmark). Overall for Rab11-FIP3, 42 serine residues were 
predicted to be potentially phosphorylated. Column 1 details the position of the residue 
being analysed (pos); column 2 provides the sequence context shown as a 9-residue 
sequence centred on the residue being analysed (context); column 3 gives the output score  
as a value in the range 0.000-1.000 (score); column 4 details the assignment (pred). 
Prediction scores above the threshold of 0.500 are potential phosphosites and are assigned 
as '*S*'. If the residue is predicted not to be phosphorylated then the position is marked by a 
dot (.). Serine residues shown to be phosphorylated by Prekeris et al., are highlighted in red. 
 
3.3.2 Kinase specific phosphorylation predictions 
Next we sought to map the kinase specific phosphorylation sites of human 
Rab11-FIP3. A range of prediction programmes are available (Amanchy et al., 
2007). We chose to use the NetPhosK 1.0 server (Technical University of 
Denmark), available at http://www.cbs.dtu.dk/services/NetPhosK/. This server 
uses an ANN method to predict kinase specific protein phosphorylation sites in 
eukaryotic protein sequences, based on a data set of known phosphorylation 
sites (Blom et al., 2004). To date, NetPhosK covers the following kinases: 
protein kinase A (cyclic-AMP dependent protein kinase, PKA), protein kinase C 
(PKC), protein kinase G (cyclic-GMP dependent protein kinase, PKG), casein 
kinase-II (CK2), cdc2 (cell division cycle 2 kinase, CDK1), Ca2+/calmodulin-
dependent protein kinase-II (CaM-II), ataxia-telangiectasia mutated kinase 
(ATM), DNA-dependent protein kinase (DNA-PK), CDK5, p38 mitogen-activated 
protein kinase (p38 MAPK), glycogen synthase kinase 3 (GSK-3), casein kinase-I 
(CK-I), protein kinase B (PKB), p90 ribosomal S6 kinase (RSK), insulin receptor 
(INSR), epidermal growth factor receptor (EGFR) and Src. As for the generic 
phosphorylation predictions in section 3.3.1, scores are produced that range 
from 0.000-1.000. Above the threshold of 0.500, phosphorylation by the specific 
kinase is likely. 
Many potential kinase specific phosphorylation sites were identified, but the 
focus was directed to those sites mapped by the Prekeris lab. For serine 102, p38 
MAPK was found to be a potential kinase, with a score of 0.57. This site is also 
potentially phosphorylated by CDK5, with a score of 0.55. CDK5 is a member of 
the CDK family (Malumbres and Barbacid, 2009). Although CDK5 is ubiquitously 
expressed, neuronal cells demonstrate maximum expression and activity of this 
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kinase (Dhariwala and Rajadhyaksha, 2008), where it regulates pathways 
unrelated to the cell-cycle. CDK5 phosphorylates serine and threonine residues 
that have a proline residue at position +1 (Dhariwala and Rajadhyaksha, 2008). 
This consensus phosphorylation site is common to all CDKs as they are proline 
directed kinases (Shetty et al., 1993;Brown et al., 1999;Ubersax and Ferrell Jr, 
2007). Perhaps other CDK family members could phosphorylate this site, 
including CDK1. For serine 281, CKII was identified as a potential kinase, with a 
score of 0.51. There was no potential kinase for serine 348, as expected, since 
this residue was not predicted to be a phospho-site in section 3.3.1. For serine 
451, ATM produced a score of 0.55 and GSK3 a score of 0.50. The highest score 
produced was 0.89 for PKC at position 429. 
3.3.3 In vitro phosphorylation of FIP3 by mitotic kinases 
To address the question of whether FIP3 is a direct substrate of the mitotic 
kinases, in vitro phosphorylation assays were performed, using baculovirus Sf9 
insect cell expressed FIP3 and a selection of mitotic kinases. We hypothesise 
that dephosphorylation of FIP3 is occurring in the later stages of mitosis, so 
kinases which show activity in the earlier stages of mitosis were selected. Aurora 
A, Aurora B, CDK1 (in complex with cyclin B) and Plk1 were selected as a starting 
point.  
In vitro phosphorylation assays were performed, as detailed in section 2.6. 
Briefly, 50ng kinase was incubated with 2µg or 5µg recombinant FIP3 at 30ºC for 
30 minutes, in the presence of 6µCi ATP-γ-32P. 2µg myelin basic protein (MBP) 
was used as a positive control for kinase activity. Further kinase only or 
substrate only controls were included. Samples were separated by SDS-PAGE and 
autoradiography was performed.  
Figure 3.2 presents the autoradiographs for each kinase. As a control for kinase 
activity, myelin basic protein (MBP) was incubated with ATP-γ-32P, in the 
presence and absence of kinase. Figures 3.2E-H show that MBP was 
phosphorylated in the presence of Aurora A, Aurora B, cyclin B-CDK1 and Plk1, 
thus confirming that all kinases were active. Autoradiographs 3.2A-D show that 
in the absence of kinase, FIP3 becomes phosphorylated, suggesting the presence 
of a contaminating kinase in the baculovirus Sf9 insect cell expressed FIP3 
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sample. FIP3 phosphorylation increases on addition of kinases Aurora A (Figure 
3.2A), Aurora B (Figure 3.2B), cyclin B-CDK1 (Figure 3.2C) and Plk1 (Figure 3.2D). 
This work suggests that, in vitro, FIP3 is potentially phosphorylated by various 
mitotic kinases. 
 
 
Figure 3-2 In vitro phosphorylation of FIP3 by mitotic kinases 
In vitro phosphorylation assays were performed as detailed in section 2.6. Briefly, 50ng 
kinase was incubated with 2µg or 5µg recombinant FIP3 at 30ºC for 30 minutes, in the 
presence of 6µCi ATP-γ-32P (top panel). Figure legends are as follows: Lane 1, 2µg 
recombinant FIP3 incubated with kinase; Lane 2, 5µg recombinant FIP3 incubated with 
kinase; Lane 3, kinase only; Lane 4, 2µg recombinant FIP3 only; Lane 5, 5µg recombinant 
FIP3 only. The position of the Broad Range Prestained Protein Marker is illustrated. 2µg 
myelin basic protein (MBP) was used as a positive control for kinase activity (bottom panel). 
Figure legends are as follows: Lane 1, 2µg MBP incubated with kinase; Lane 2, 2µg MBP 
only. The position of the Broad Range Prestained Protein Marker is illustrated, with markers 
175, 83, 62, 47.5 and 32.5 omitted due to space constraints. Samples were separated by 
SDS-PAGE as detailed in section 2.2.2 and autoradiography was performed. The positions 
of FIP3 and MBP on the autoradiographs are marked by arrows. Autoradiographs show that 
in the absence of kinase, FIP3 becomes phosphorylated. FIP3 phosphorylation increases on 
addition of kinases Aurora A (A), Aurora B (B), cyclin B-CDK1 (C) and Plk1 (D). Figures 3.2E-
F show that all kinases are active since they phosphorylate MBP. Representative 
autoradiographs from an experiment performed in duplicate are presented.   
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3.3.4 Analysis of recombinant FIP3’s capacity to 
autophosphorylate 
Results from the in vitro phosphorylation assays performed in section 3.3.3 show 
that in the absence of kinase, FIP3 is phosphorylated in the presence of ATP-γ-
32P. This suggests that either FIP3 is capable of autophosphorylation or that 
there may be a contaminating kinase in the sample. Since FIP3 is not a kinase, 
the latter was investigated. 
An in vitro phosphorylation assay was performed, as detailed in section 2.6, 
using MBP as the substrate and FIP3 as the ‘kinase’. 2µg MBP was incubated for 
30 minutes at 30ºC in the presence of 2µg FIP3 and 6µCi ATP-γ-32P. Samples were 
separated by SDS-PAGE and autoradiography was performed. Interestingly, the 
Baculovirus Sf9 insect cell expressed human FIP3 sample is capable of 
phosphorylating MBP, as shown in figure 3.3A.  
To study whether FIP3 can be phosphorylated by mitotic kinases, the 
autophosphorylating capacity of the FIP3 sample must first be removed. This was 
achieved through the incubation of FIP3 for 30 minutes at 60 or 80ºC. Following 
this treatment, the FIP3 sample was tested in an in vitro phosphorylation assay. 
2µg FIP3 was incubated for 30 minutes at 60 or 80ºC and then subject to an in 
vitro phosphorylation assay for 30 minutes at 30ºC in the presence of 6µCi ATP-
γ-32P. Samples were separated by SDS-PAGE and autoradiography was performed. 
Figure 3.3B shows that the capacity of the FIP3 sample to autophosphorylate is 
lost on pre-incubation of FIP3 at 60 and 80ºC. 
Following this, the ability of FIP3 which had been incubated at 60ºC (referred to 
heat-treated FIP3 from now on) to phosphorylate MBP was tested. Figure 3.3A 
shows that heat-treated FIP3 cannot phosphorylate MBP. Thus recombinant FIP3 
was heat-treated in subsequent in vitro phosphorylation assays.  
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Figure 3-3 Analysis of recombinant FIP3’s capacity to autophosphorylate 
The capacity of the Baculovirus Sf9 insect cell expressed FIP3 sample to autophosphorylate 
was investigated via an in vitro phosphorylation assay, as detailed in section 2.6. (A) 2µg 
MBP was incubated for 30 minutes at 30ºC in the presence of 2µg FIP3 (with or without heat-
treatment at 60ºC for 30 minutes) and 6µCi ATP-γ-32P. Samples were separated by SDS-
PAGE (section 2.2.2) and autoradiography was performed. Figure legends are as follows: 
Lane 1, 2µg MBP incubated with 2µg recombinant FIP3; Lane 2, 2µg MBP incubated with 2µg 
heat-treated recombinant FIP3. The position of the Broad Range Prestained Protein Marker 
is illustrated.  Baculovirus expressed recombinant FIP3 is capable of phosphorylating MBP, 
but on heat-treatment this ability is lost. (B) 2µg recombinant FIP3 was incubated for 30 
minutes at 60ºC or 80°C and then subject to an in vitro phosphorylation assay for 30 
minutes at 30ºC in the presence of 6µCi ATP-γ-32P. Samples were separated by SDS-PAGE 
and autoradiography was performed. Figure legends are as follows: Lane 1, 2µg 
recombinant FIP3 only; Lane 2, 2µg recombinant FIP3 incubated at 60ºC; Lane 3, 2µg 
recombinant FIP3 incubated at 80ºC. The position of the Broad Range Prestained Protein 
Marker is illustrated. Baculovirus expressed recombinant FIP3 which has not been heat-
treated is capable of autophosphorylation, but when heat treated, this kinase activity is lost. 
Data from a single experiment is presented. 
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3.3.5 In vitro phosphorylation of heat-treated FIP3 by mitotic 
kinases 
To address the question of whether FIP3 is a direct substrate of the mitotic 
kinases, in vitro phosphorylation assays have been performed using Baculovirus 
Sf9 insect cell expressed human FIP3 (which had been subject to heat-
treatment) and a selection of mitotic kinases. Kinase assays were performed as 
detailed in section 2.6. Firstly, recombinant FIP3 was subject to heat-treatment 
at 60ºC for 30 minutes to abolish the autophosphorylating capacity of the 
sample. 50ng kinase was incubated with 2µg or 5µg recombinant FIP3 at 30ºC for 
30 minutes, in the presence of 6µCi ATP-γ-32P. 2µg myelin basic protein (MBP) 
was used as a positive control for kinase activity. Further kinase only or 
substrate only controls were included. Samples were separated by SDS-PAGE and 
autoradiography was performed.  
Figure 3.4 presents the autoradiographs for each kinase. It appears that FIP3 can 
be phosphorylated by cyclin B-CDK1 (Figure 3.4C), Plk1 (Figure 3.4D) and Aurora 
A (Figure 3.4A). Aurora B (Figure 3.4B) phosphorylates FIP3 to a lesser extent. 
Myelin basic protein (MBP) was phosphorylated only in the presence of kinase 
(Figures 3.4E-H). This work suggests that, in vitro, FIP3 is potentially 
phosphorylated by various mitotic kinases.  
To examine this further, the stoichiometry of ATP-γ-32P incorporation into 5µg 
FIP3 was calculated, for each kinase. Phosphorylation of 5µg FIP3 by Aurora A, 
Aurora B, CDK1 and Plk1 incorporated 0.0094 (0.94%), 0.0008 (0.08%), 0.072 
(7.2%) and 0.02 (2%) pmol ATP/pmol FIP3, respectively. Whilst FIP3 can be 
phosphorylated by all kinases tested, as shown in figure 3.4, CDK1 
phosphorylates FIP3 to the greatest extent. This may, however, reflect the fact 
that CDK1 appears to be the most active kinase against MBP, as shown in figure 
3.4G. 
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Figure 3-4 In vitro phosphorylation of heat-treated FIP3 by mitotic kinases 
In vitro phosphorylation assays were performed as detailed in section 2.6. Firstly, 
Baculovirus Sf9 insect cell expressed FIP3 was subject to heat treatment at 60ºC for 30 
minutes to abolish the autophosphorylating capacity of the sample. 50ng kinase was 
incubated with 2µg or 5µg recombinant FIP3 at 30ºC for 30 minutes, in the presence of 6µCi 
ATP-γ-32P (top panel). Figure legends are as follows: Lane 1, 2µg recombinant FIP3 
incubated with kinase; Lane 2, 5µg recombinant FIP3 incubated with kinase; Lane 3, kinase 
only; Lane 4, 2µg recombinant FIP3 only; Lane 5, 5µg recombinant FIP3 only. Samples were 
separated by SDS-PAGE as detailed in section 2.2.2 and autoradiography was performed. 
The position of the Broad Range Prestained Protein Marker is illustrated. The position of 
FIP3 on the autoradiograph is marked by an arrow. Autoradiographs show that FIP3 can be 
phosphorylated by cyclin B-CDK1 (C), Plk1 (D) and Aurora A (A). Aurora B (B) 
phosphorylates FIP3 to a lesser extent. 2µg myelin basic protein (MBP) was used as a 
positive control for kinase activity (bottom panel). Figure legends are as follows: Lane 1, 
2µg MBP incubated with kinase; Lane 2, 2µg MBP only. The position of the Broad Range 
Prestained Protein Marker is illustrated, with markers 175, 83, 62, 47.5 and 32.5 omitted due 
to space constraints. The position of MBP on the autoradiograph is marked by an arrow. 
Figure E-F show that all kinases are active since they phosphorylate MBP. Representative 
autoradiographs from an experiment performed in triplicate are presented.   
 
3.3.6 Phosphorylation site mapping of FIP3 
Next we sought to map the phosphorylation sites of Aurora A, cyclin B-CDK1 and 
Plk1 in FIP3. This was carried out commercially by the FingerPrints Proteomic 
Facility at the University of Dundee.  
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A summary of the sample preparation process and techniques used to map the 
sites of phosphorylation are provided in section 2.7.1. In brief, in vitro 
phosphorylation assays were performed on recombinant heat-treated FIP3 using 
the kinases Aurora A, cyclin B-CDK1 and Plk1. A control was included in which 
FIP3 was not treated with any kinases. 200ng kinase was incubated with 50µg 
Baculovirus Sf9 insect cell expressed FIP3 (heat-treated) in a volume of 100µl 
kinase assay buffer, supplemented with 100µM ATP.Mg2+. This was incubated at 
30ºC for 60 minutes and protein was TCA precipitated. Proteins were separated 
by SDS-PAGE and the bands corresponding to FIP3 were excised. These were 
shipped on dry ice to the FingerPrints Proteomic Facility where nano-liquid 
chromatography-tandem mass spectrometry (nLC-MS/MS) and a technique known 
as parent ion scanning (Parents of -79) were used to detect phosphorylated 
peptides (Loyet et al., 2005;Paradela and Albar, 2008). From this a mascot 
report was generated of the identified phosphorylation sites 
(www.matrixscience.com) (Perkins et al., 1999). 
Mascot reports of kinase phosphorylated FIP3 peptides are shown in figure 3.5. 
E-values of less than 1 denote significant FIP3 phosphorylation. No significant 
phosphorylation was detected in non-phosphorylated FIP3 (Figure 3.5A), or Plk1 
phosphorylated FIP3 (Figure 3.5D). Significant phosphorylation was identified in 
CDK1-phosphorylated FIP3 (Figure 3.5C) at Serine 102 (GQLASPDAPGPGPR), with 
an E-value of 0.19. Potentially CDK1 phosphorylates FIP3 at serine 52 
(LGAPVGGPDPQSPGLDEPAPGAAADGGAR), with an E-value of 0.69. Interestingly 
serine 102 was identified by collaborators as a potential phosphorylation site, 
from the proteomic analysis of FIP3 immunoprecipitated from metaphase HeLa 
cells (R. Prekeris, personal communication). Weak phosphorylation was detected 
at Serine 71 (WSAGPAPGLEGGPR) with and E-value of 0.31, in Aurora A 
phosphorylated FIP3 (Figure 3.5B). In conclusion, this work shows that cyclin B-
CDK1 phosphorylates FIP3 at serine 102, in vitro.
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Figure 3-5A Phosphorylation site mapping of non-phosphorylated FIP3 
Mascot report of non-phosphorylated FIP3 peptides, performed by the FingerPrints Proteomic Facility, University of Dundee. An in vitro phosphorylation 
assay was performed on 50µg recombinant heat-treated FIP3, in the presence of 100µM ATP.Mg2+, at 30ºC for 60 minutes. The sample was TCA precipitated 
and separated by SDS-PAGE (section 2.2.2). The band corresponding to FIP3 was excised and subjected to nLC-MS/MS and parent ion scanning. Sites of 
significant phosphorylation (with E-values (expect) less than 1) are marked with a star. No significant phosphorylation was detected in non-phosphorylated 
FIP3. 
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Figure 3-5B Phosphorylation site mapping of Aurora A phosphorylated FIP3 
Mascot report of Aurora A phosphorylated FIP3 peptides, performed by the FingerPrints Proteomic Facility, University of Dundee. An in vitro 
phosphorylation assay was performed on 50µg recombinant heat-treated FIP3 using 200ng Aurora A, in the presence of 100µM ATP.Mg2+, at 30ºC for 60 
minutes. The samples was TCA precipitated and separated by SDS-PAGE (section 2.2.2). The band corresponding to FIP3 was excised and subjected to 
nLC-MS/MS and parent ion scanning. Sites of significant phosphorylation (with E-values (expect) less than 1) are marked with a star. Weak phosphorylation 
was found in Aurora A phosphorylated FIP3 at Serine 71 (WSAGPAPGLEGGPR). 
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Figure 3-5C Phosphorylation site mapping of CDK1 phosphorylated FIP3 
Mascot report of CDK1 phosphorylated FIP3 peptides, performed by the FingerPrints Proteomic Facility, University of Dundee. An in vitro phosphorylation 
assay was performed on 50µg recombinant heat-treated FIP3 using 200ng CDK1/cyclin B, in the presence of 100µM ATP.Mg2+, at 30ºC for 60 minutes. The 
sample was TCA precipitated and separated by SDS-PAGE (section 2.2.2). The band corresponding to FIP3 was excised and subjected to nLC-MS/MS and 
parent ion scanning. Sites of significant phosphorylation (with E-values (expect) less than 1) are marked with a star. Significant phosphorylation was 
identified in CDK1 phosphorylated FIP3, at Serine 102 (GQLASPDAPGPGPR) and Serine 52 (LGAPVGGPDPQSPGLDEPAPGAAADGGAR).  
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Figure 3-5D Phosphorylation site mapping of Plk1 phosphorylated FIP3 
Mascot report of Plk1 phosphorylated FIP3 peptides performed by the FingerPrints Proteomic Facility, University of Dundee. An in vitro phosphorylation 
assay was performed on 50µg recombinant heat-treated FIP3 using 200ng Plk1, in the presence of 100µM ATP.Mg2+, at 30ºC for 60 minutes. The sample was 
TCA precipitated and separated by SDS-PAGE (section 2.2.2). The band corresponding to FIP3 was excised and subjected to nLC-MS/MS and parent ion 
scanning. Sites of significant phosphorylation (with E-values (expect) less than 1) are marked with a star. No significant phosphorylation was detected in 
Plk1 phosphorylated FIP3.
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3.3.7 In vitro phosphorylation of FIP3 by Aurora B (co-expressed 
with INCENP and survivin) 
For full activity of Aurora B, as tested via in vitro phosphorylation assays, the 
kinase must be co-expressed and purified with the chromosomal passenger 
proteins INCENP and survivin (AIS complex) (Sessa et al., 2005). Figure 3.4B 
shows that FIP3 is weakly phosphorylated by Aurora B, when tested in an in vitro 
phosphorylation assay. Aurora B used in the assay of section 3.3.5 was obtained 
from Upstate (now known as Millipore (UK) Ltd, as detailed in section 2.1.1), and 
the methods of expressing and purifying Aurora B were not described. Thus, to 
examine Aurora B phosphorylation further, Aurora B co-expressed and purified 
with INCENP and survivin was obtained from Dr. Sandrine Ruchaud at the 
University of Edinburgh.  
In vitro phosphorylation assays were repeated with Aurora B (purchased from 
Upstate) as used in section 3.3.5 and elution 1 and elution 2 of the AIS complex. 
These were the fractions provided by Dr. Ruchaud which demonstrated the 
highest level of kinase activity, as tested by in vitro phosphorylation assays. 5µg 
heat-treated recombinant FIP3 was phosphorylated with 50ng Aurora B 
(purchased from Upstate), or with elution 1 and elution 2 of the AIS complex. 
Incubations were carried out at 30ºC for 30 minutes, in the presence of 6µCi 
ATP-γ-32P. 2µg myelin basic protein (MBP) was used as a control for kinase 
activity. Samples were separated by SDS-PAGE and autoradiography was 
performed. 
Elution 1 and elution 2 of the AIS complex phosphorylates MBP control protein, 
but not FIP3 (data not shown). This suggests, in addition to the results presented 
in section 3.3.5, that Aurora B may not phosphorylate FIP3. 
3.3.8 In vitro phosphorylation of CDK1 and Aurora A primed FIP3 
For Plk1 to phosphorylate its substrate, the substrate first requires to be 
phosphorylated by another kinase, for example CDK1 (Petronczki et al., 2008). 
This is known as phosphate priming. Plk1 can then bind to the substrate via its 
phosphopeptide binding domain, known as the Polo-box domain (PBD) (Elia et 
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al., 2003a;Elia et al., 2003b). To that end, in vitro phosphorylation assays were 
performed on recombinant FIP3, primed with cyclin B-CDK1 and also Aurora A. 
Firstly, FIP3 was primed with either cyclin B-CDK1 or Aurora A via in vitro 
phosphorylation assays, as detailed in section 2.6 (without the addition of ATP-γ-
32P). 2µg heat-treated recombinant FIP3 was pre-incubated with 50ng of cyclin 
B-CDK1 (Figure 3.6A) or Aurora A (Figure 3.6C) for 90 minutes at 30ºC, in the 
presence of 50µM ATP.Mg2+. The control protein MBP was similarly pre-incubated 
with cyclin B-CDK1 and Aurora A (Figures 3.6B and 3.6D, respectively). In vitro 
phosphorylation assays were then performed on the phosphate primed FIP3 and 
MBP, in the presence of 6µCi ATP-γ-32P and 50ng of Aurora A, Aurora B, Plk1 or 
cyclin B-CDK1, as described in section 2.6. Incubations were carried out in a 
water bath at 30ºC for 60 minutes. Samples were separated by SDS-PAGE, as 
described in section 2.2.2, and autoradiography was performed.  
The phosphorylation increase in CDK1 primed samples on addition of Aurora A, 
Aurora B or Plk1 is due to residual CDK1 activity in the presence of ATP-γ-32P, as 
shown in lane 1 of figure 3.6A. This is also seen in CDK1 primed MBP samples, 
shown in figure 3.6B. A similar effect can be seen on pre-incubation of FIP3 or 
MBP with Aurora A, as shown in figure 3.6C and figure 3.6D. Owing to the lack of 
conclusive data, this experiment was only performed once for each priming 
kinase and was not investigated further.   
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Figure 3-6 In vitro phosphorylation of CDK1 and Aurora A primed FIP3 
 
(Top panel) 2µg heat-treated recombinant FIP3 was pre-incubated with 50ng of cyclin B-
CDK1 (A) or Aurora A (C) for 90 minutes at 30ºC, in the presence of 50µM ATP.Mg2+. Kinase 
assays were then performed on the phosphate primed FIP3, in the presence of 6µCi ATP-γ-
32P and 50ng of Aurora A, Aurora B, Plk1 or cyclin B-CDK1. Incubations were carried out in a 
water bath at 30ºC for 60 minutes. Samples were separated by SDS-PAGE and 
autoradiography was performed. Figure legends for figure 3.6A are as follows: Lane 1, 2µg 
recombinant FIP3 pre-incubated with CDK1; Lane 2, 2µg recombinant FIP3 pre-incubated 
with CDK1 and phosphorylated by Aurora A; Lane 3, 2µg recombinant FIP3 pre-incubated 
with CDK1 and phosphorylated by Aurora B;  Lane 4, 2µg recombinant FIP3 pre-incubated 
with CDK1 and phosphorylated by Plk1;  Lane 5, 2µg recombinant FIP3; Lane 6, 2µg 
recombinant FIP3 phosphorylated by Aurora A; Lane 7, 2µg recombinant FIP3 
phosphorylated by Aurora B; Lane 8, 2µg recombinant FIP3 phosphorylated by Plk1. The 
position of the Broad Range Prestained Protein Marker is illustrated. Data from a single 
experiment is presented. 
(Bottom panel) This was repeated for the control protein, MBP which was pre-incubated 
with CDK1 (B) and Aurora A (D). Figure legends for figure 3.6B are as follows: Lane 1, 2µg 
MBP pre-incubated with CDK1; Lane 2, 2µg MBP pre-incubated with CDK1 and 
phosphorylated by Aurora A; Lane 3, 2µg MBP pre-incubated with CDK1 and 
phosphorylated by Aurora B;  Lane 4, 2µg MBP pre-incubated with CDK1 and 
phosphorylated by Plk1;  Lane 5, 2µg MBP. The position of the Broad Range Prestained 
Protein Marker is illustrated, with markers 175, 83, 62, 47.5 and 32.5 omitted due to space 
constraints.  The positions of FIP3 and MBP on the autoradiograph are marked. Data from a 
single experiment is presented. 
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3.3.9 In vitro phosphorylation of Alkaline Phosphatase treated 
FIP3 by mitotic kinases 
An attempt was made to improve kinase phosphorylation of FIP3 by 
dephosphorylating the protein, prior to performing the in vitro phosphorylation 
assays. This was achieved by treating FIP3 with alkaline phosphatase. Prior to 
this treatment, FIP3 was coupled to Ni-NTA agarose, allowing the removal of the 
alkaline phosphatase before performing the in vitro phosphorylation assays.  
Firstly, recombinant FIP3 (2µg per reaction) was heat-treated. This FIP3 sample 
was then brought to a volume of 500µl with His-tag buffer. Next, 200µl of Ni-NTA 
agarose was washed three times with 1ml of His-tag buffer, before resuspending 
in 200µl of His-tag buffer. 160µl of the Ni-NTA agarose slurry was added to the 
FIP3 sample and this was incubated with end-over-end rotation at 4ºC overnight. 
This was washed twice with His-tag buffer and re-suspended in 100µl Alkaline 
Phosphatase buffer from Promega. To half of this suspension, 10µl Alkaline 
Phosphatase was added for 30 minutes at room temperature. Three washes in 
His-tag buffer followed, in an attempt to remove the alkaline phosphatase. Both 
samples of Ni-NTA agarose immobilised FIP3 were then re-suspended in 100µl 
kinase assay buffer, and were then subject to kinase assays, as detailed in 
section 2.6. 20µl Ni-NTA agarose immobilised FIP3 (with or without alkaline 
phosphatase treatment) were incubated with 50ng kinase, at 30ºC for 60 
minutes, in the presence of 6µCi ATP-γ-32P. A control was included where the 
kinase was omitted. Following this incubation, the reactions were washed twice 
in cold kinase assay buffer (without the ATP). Following the last wash, the Ni-
NTA agarose immobilised FIP3 was re-suspended in 20µl SDS-PAGE sample buffer, 
boiled for 5 minutes and the supernatants separated by SDS-page and 
autoradiography was performed.  
This experiment was carried out twice, with no significant results and the data is 
not presented. Interestingly, in one of the experimental repeats, Plk1 
phosphorylation of phosphatase treated FIP3 may have been reduced. This may 
correlate with Plk1’s requirement for substrate phosphate priming, however this 
result is preliminary and was not investigated further. 
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3.3.10 Proteomic analysis of recombinant FIP3 
In vitro phosphorylation assays in section 3.3.4 suggest that the baculovirus Sf9 
insect cell expressed FIP3 sample co-purified with a kinase. Indeed, when 2µg or 
5µg recombinant FIP3 was separated by SDS-PAGE (as detailed in section 2.2.2) 
and stained with Coomassie brilliant blue (as detailed in section 2.2.6), FIP3 
appears in addition to numerous other bands, as shown in figure 3.7. These were 
assumed to be FIP3 degradation products, however owing to the kinase activity 
of the FIP3 solution, it was thought that perhaps one of these bands could be an 
insect cell kinase. This could point to a mammalian kinase which could 
potentially phosphorylate FIP3.  
 
Figure 3-7 Recombinant FIP3 separated by SDS-PAGE and stained with Coomassie Blue 
Stain. 
2µg (Lane 1) and 5µg (Lane 2) recombinant FIP3 were diluted in 4X SDS-PAGE loading 
buffer. Samples were separated by SDS-PAGE as detailed in section 2.2.2 and Coomassie 
Blue stained as outlined in section 2.2.6. The position of the Broad Range Prestained 
Protein Marker is illustrated. FIP3 appears as expected at approximately 100 kDa. Additional 
proteins bands are present. These may show degradation of the FIP3 sample or perhaps 
suggest the purification procedure resulted in contamination with insect cell proteins. 
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To identify any potential insect cell kinases contaminating the recombinant FIP3 
sample, a proteomic approach was used. Two attempts were made at this. 
Firstly using the Sir Henry Wellcome Functional Genomics Facility (SHWFGF) at 
the University of Glasgow and secondly using Aberdeen Proteomics at the 
University of Aberdeen. Sample preparation and methods used by the two 
proteomic facilities are described in section 2.7.2. 
Firstly 15µg of the recombinant FIP3 sample was analysed for protein content 
using nLC-ESI-MS/MS by the SHWFGF at the University of Glasgow (Bridges et al., 
2008). Data was exported to the Mascot (Matrix Science) search engine for 
protein identification (www.matrixscience.com) (Perkins et al., 1999) and the 
results are presented in section 7.1.1 of the appendix. The scoring system 
measures the degree of similarity between the experimental MS/MS data and the 
theoretical spectra constructed for each database peptide (database parameters 
are set by the user). The significance threshold is set at 5% (p<0.05) and above 
the MASCOT cut-off score, the match has less that 5% probability of being a 
random event and indicates homology or extensive identity. Candidate peptides 
are ranked according to the score and the highest scoring peptide is the best 
match. Multiple matches to peptides from the same protein produce the highest 
scores. 
A search of the Mammalia (Table 7.1) or Drosophila (Table 7.2) databases did 
not reveal any kinases in the FIP3 sample. Both alpha and beta tubulin were 
detected. This could be a side effect of the purification procedure. However, 
the association of FIP3 and tubulin has been previously reported, as tubulin co-
immunoprecipitated with FIP3 (J. Matheson, unpublished data). Whether this is a 
direct or indirect interaction is still in question. Two protein hits of interest in 
the FIP3 solution, searching the Mammalia database, were for protein 
phosphatase 2A (PP2A). However, these hits had scores of 58 and 50, just above 
the cut off score of 49. Another protein hit of interest in the FIP3 solution, 
searching the Drosophila database, was for kinesin heavy chain, with a score of 
62 (the cut off score is 39). The kinesins are a superfamily of microtubule-based 
molecular motor proteins (Hirokawa et al., 2009), members of which are known 
to have mitotic functions (Sharp et al., 2000). As discussed in section 1.5.6.5, 
FIP3 may interact with members of the kinesin family. 
Louise L. Collins, 2010  Chapter 3, 119 
 
Concern was raised over the overexpressed FIP3 protein masking the presence of 
less well expressed insect cell kinases in the solution. Thus 5µg FIP3 was 
separated by SDS-PAGE, the gel lane cut into 5 slices and analysed for protein 
content using nLC-ESI-MS/MS. Gel slice 1 contained the major FIP3 band. Data 
was exported to the Mascot (Matrix Science) search engine for protein 
identification, searching the Mammalia and Drosophila databases. The results 
are presented in the Appendix, section 7.1.2. 
As expected, a search of the Mammalia databases shows that FIP3 is present in 
gel slice 1 (Table 7.3 of the appendix). Searches of the Mammalia databases for 
gel slices 2 (Table 7.5 of the appendix), 3 (Table 7.7 of the appendix), 4 (Table 
7.9 of the appendix) and 5 (Table 7.11 of the appendix), show that FIP3 is 
present in all gel slices. This perhaps suggests that the protein bands observed in 
figure 3.7 could be FIP3 degradation products. Searches of the Mammalia and 
Drosophila databases for all gel slices again show the presence of alpha and beta 
tubulin in the FIP3 solution. One protein hit from gel slice 3 was a peptide 
similar to casein kinase-II (known as CK2) alpha 1 subunit. A search of the 
Mammalia database detects CK2 alpha 1 subunit isoform a, with a score of 121 
and CK2 alpha 1 subunit isoform b, with a score of 98 (Table 7.7, cut off score of 
48); a search of the Drosophila database detects CK2 with a score of 78 (Table 
7.8, cut off score of 38). CK2 is a serine/threonine kinase thought to play a role 
in mitotic progression via maintenance of centrosome integrity, spindle 
formation, chromosomal segregation (St Denis et al., 2009) and entry into 
mitosis by regulating Wee1 stability (Yde et al., 2008). Interestingly, CK2 was 
predicted to potentially phosphorylate FIP3 at serine 281, as discussed in section 
3.3.2. The presence of CK2 in the FIP3 sample was investigated further (see 
section 3.3.11). 
Other potential kinase hits were for a peptide similar to ribosomal S6 kinase. 
This was detected in gel slice 3, searching the Mammalia database (Table 7.7 of 
the appendix). It produced a score of 54, which was marginally above the cut off 
score of 48. The 90kDa ribosomal S6 kinase (RSK) family of proteins are highly 
conserved serine/threonine kinases shown to regulate cell proliferation, 
survival, growth and motility (Anjum and Blenis, 2008). Other potential kinase 
hits were for a peptide similar to BMK1 alpha kinase. This was detected in gel 
slice 2, searching the Mammalia database (Table 7.5 of the appendix). It 
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produced a score of 68, which was marginally above the cut off score of 49. 
BMK1 is also known as extracellular-regulated protein kinase 5 (ERK5) and is a 
mitogen-activated protein kinase (MAPK) (Wang and Tournier, 2006). ERK5 is 
active during mitosis and has been implicated in the survival of dividing cells 
(Gírio et al., 2007). 
Next, 5µg FIP3 was separated by SDS-PAGE and the gel lane cut into 16 gel slices 
which were analysed by Aberdeen Proteomics at the University of Aberdeen. 
Protein identification of gel bands was achieved by LC-MS/MS searching Human 
and Spodoptera Frugiperda databases. The top of the gel was excised as gel slice 
1; the bottom gel was excised as gel slice 16; the major FIP3 was excised in gel 
slice 4.  
A summary of the results are presented in the Appendix, section 7.1.3, table 
7.13. Searches of the human database showed that FIP3 was present in gel slice 
4 as expected. FIP3 was also detected in slices 1, 3, 5, 6, 7, 9, 10 and 12. This 
suggests that the bands observed in figure 3.7 may be degradation products of 
FIP3. Also detected was beta-tubulin in gel slice 8 in both the human and 
Spodoptera Frugiperda databases. No kinases were detected in this analysis. 
In summary, proteomic analysis of the recombinant FIP3 sample was carried out 
in the hope that a contaminating insect kinase would be revealed. The results 
suggest that the protein bands observed in figure 3.7, which run at a molecular 
weight lower than expected for FIP3, may be FIP3 degradation products. 
However, proteomic data suggests that CK2 may be present in the FIP3 sample. 
On discussion with others in the kinase field, it was revealed that the 
baculovirus Sf9 insect cell expression system is notorious for producing purified 
protein samples with contaminating kinases. In future, perhaps different 
expression systems may be used to produce FIP3. 
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3.3.11 Immunoblot analysis of recombinant FIP3 
We next tested whether any contaminating kinase present in the FIP3 sample 
could be identified by immunoblotting. 2µg recombinant FIP3 sample was 
separated by SDS-PAGE as detailed in section 2.2.2. As a control, 10µg of a HeLa 
cytoplasmic extract (known as the S100 fraction) and a HeLa lysate (produced in 
our lab) were included on the gel. SDS-PAGE gels were then subject to Western 
Blotting, as detailed in section 2.2.3. Nitrocellulose membranes were then 
probed for a selection of mitotic kinases, as described in section 2.2.4. Kinases 
tested were CDK1, Aurora A, Aurora B, Plk1, ROCK, MLCK and CK2. The results 
for each kinase were similar, thus only the data for CDK1 is presented in figure 
3.8. Kinases were only detected in the S100 fraction and homemade HeLa lysate. 
No kinases were detected in the recombinant FIP3 sample, even upon prolonged 
exposure of the immunoblots.  
We then went on to perform immunoprecipitation experiments to determine if 
FIP3 immunoprecipitated from metaphase HeLa lysates interacted with any 
kinases from the HeLa lysate. Ten T150 flasks of HeLa cells were synchronised, 
as detailed in section 2.4.5.1. FIP3 was then immunoprecipitated from these 
cells. Samples were then separated by SDS-PAGE (section 2.2.2), western blotted 
(section 2.2.3) and subject to immunoblotting (section 2.2.4) with antibodies 
directed to FIP3 and the mitotic kinases mentioned previously. This was 
repeated several times, with attempts made to increase the starting volume of 
cells. FIP3 was successfully immunoprecipitated from metaphase lysates, but no 
kinases were detected, thus the data has not been presented. 
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Figure 3-8 Immunoblot analysis of recombinant FIP3 
2µg recombinant FIP3 sample was separated by SDS-PAGE, as detailed in section 2.2.2. As 
a control, 10µg of S100 fraction and a HeLa lysate were included on the gel. SDS-PAGE gels 
were then subject to western blotting, as detailed in section 2.2.3. Nitrocellulose membranes 
were then probed for a selection of mitotic kinases, as described in section 2.2.4. A 
representative blot is shown, depicting FIP3 (A) and CDK1 (B). Figure legends are as 
follows: Lane 1, 2µg FIP3; Lane 2, 10µg S100 fraction; Lane 3, homemade HeLa lysate. The 
position of the Broad Range Prestained Protein Marker is illustrated. Samples were run on 
the same SDS-PAGE gel, with the protein marker in a lane between 2µg FIP3 and the S100 
fraction, but for presentation purposes the protein marker was removed from the above 
figure. Kinases were detected in the S100 fraction and homemade HeLa lysate. No kinases 
were detected in the recombinant FIP3 sample, even upon prolonged exposure of the 
immunoblots. Data from a single experiment is presented. 
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3.3.12 FIP3 autophosphorylation in the presence of kinase   
inhibitors 
In another attempt to identify the kinase(s) potentially contaminating the 
recombinant FIP3 sample, we employed a range of kinase inhibitors in FIP3 
autophosphorylation reactions, to ascertain whether any decrease in FIP3 
phosphorylation could be observed. 
Recombinant FIP3 which had not been heat-treated was used in an in vitro 
phosphorylation assay, as described in section 2.6. 2µg autophosphorylating FIP3 
was incubated for 30 minutes at 30ºC in the presence of 6µCi ATP-γ-32P. 
Identical incubations were set up, but with kinase inhibitors which were added 
for the duration of the assay: 100µM ZM447439 (inhibitor of Aurora B and Aurora 
A); 100µM PD98059 (inhibitor of MEK1); 100µM SB203580 (inhibitor of p38-MAPK); 
100µM Plk1a (Plk1 inhibitor supplied by GSK); 100µM Plk1b (Plk1 inhibitor 
supplied by GSK); 100µM Y-27632 (inhibitor of ROCK-I and ROCK-II); 5µM BMI 1026 
(inhibitor of CDK1). Samples were separated by SDS-PAGE and autoradiography 
was performed. No significant change in FIP3 autophosphorylation was observed 
for any of the kinase inhibitors tested, as shown in figure 3.9A. To test the 
extent of CDK1 inhibition by BMI-1026, 2µg MBP and 50ng CDK1 were incubated 
for 30 minutes at 30ºC with 6µCi ATP-γ-32P. This was carried out in duplicate, 
with 5µM BMI-1026 added to one for the duration of the assay. 5µM BMI-1026 
quantitatively inhibits CDK1 phosphorylation of MBP, as seen in figure 3.9B. 
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Figure 3-9 FIP3 autophosphorylation in the presence of kinase inhibitors 
(A) 2µg autophosphorylating FIP3 was incubated for 30 minutes at 30ºC in the presence of 
6µCi ATP-γ-32P (Lane 1). Identical incubations were set up, but with kinase inhibitors which 
were added for the duration of the assay: 100µM ZM447439 (Lane 2), 100µM PD98059 (Lane 
3), 100µM SB203580 (Lane 4), 100µM Plk1a (Lane 5), 100µM Plk1b (Lane 6), 100µM Y-27632 
(Lane 7) and 5µM BMI-1026 (Lane 8). Samples were separated by SDS-PAGE (section 2.2.2) 
and autoradiography was performed. The position of the Broad Range Prestained Protein 
Marker is illustrated. No significant change in FIP3 autophosphorylation was observed for 
any of the kinase inhibitors tested. (B) To test the extent of CDK1 inhibition by BMI-1026, 
2µg MBP and 50ng CDK1 were incubated for 30 minutes at 30ºC with 6µCi ATP-γ-32P (Lane 
1). This was carried out in duplicate, with 5µM BMI-1026 added to one for the duration of the 
assay (Lane 2). 5µM BMI-1026 inhibits CDK1 phosphorylation of MBP. The positions of FIP3 
and MBP on the autoradiographs are marked. Representative autoradiographs from an 
experiment performed in duplicate are presented.   
 
3.3.13 HeLa cytoplasmic S100 fraction phosphorylation of 
FIP3 
Next we tested whether kinases within a HeLa cytoplasmic extract could 
phosphorylate FIP3, as tested in an in vitro phosphorylation assay. HeLa 
cytoplasmic fraction S100 was purchased from Dundee Cell Products at the 
University of Dundee. An in vitro phosphorylation assay was carried out, as 
detailed in section 2.6, with several modifications. 
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Firstly, baculovirus Sf9 insect cell expressed FIP3 was subject to heat-treatment 
at 60ºC for 30 minutes to abolish the autophosphorylating capacity of the 
sample. 50µg of S100 fraction was added to screw topped microcentrifuge tubes. 
Kinase assay buffer was added to a final volume of 50 µl and 20µg recombinant 
heat-treated FIP3 was added. The reaction was started on addition of 6µCi ATP-
γ-32P and carried out in a 30ºC water bath. At 0, 30, 60 and 120 minutes, 12.5 µl 
of the reaction mixture was removed and added to screw topped 
microcentrifuge tubes containing 3µl 4x SDS-PAGE loading buffer. FIP3 only and 
S100 fraction only controls were set up, and, at 120 minutes, 20µl 4x SDS-PAGE 
loading buffer was added to each tube. Samples were separated by SDS-PAGE, as 
detailed in section 2.2.2, and autoradiography was performed. The resulting 
autorad is presented in figure 3.10. 
A phospho-protein(s) band can be seen at the expected molecular weight for 
FIP3, suggesting that FIP3 may be phosphorylated by a kinase(s) contained within 
the HeLa cytoplasmic S100 fraction. However, a band is present in the S100 
fraction only lane at the same molecular weight as FIP3. Thus, by using this 
method, proteins from the S100 fraction cannot be distinguished from FIP3. 
Various attempts were made to refine this experiment. Recombinant FIP3 
protein (which contains an N-terminal hexa-His-tag) was bound to Ni-NTA 
agarose before incubating with S100 fraction in an in vitro phosphorylation 
assay. Following the assay, it was hoped that FIP3 could be separated from S100 
proteins by washing the Ni-NTA agarose with buffer. The intention was to use 
kinase inhibitors to block potential phosphorylation of FIP3 in an attempt to 
identify any kinase(s) which might phosphorylate FIP3. However, FIP3 could not 
be separated from proteins in the HeLa cytoplasmic S100 fraction, or the 
contaminant proteins from the original baculovirus system (see figure 3.7). Thus 
it was decided not to pursue this further. 
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Figure 3-10 HeLa cytoplasmic S100 fraction phosphorylation of FIP3 
Baculovirus Sf9 insect cell expressed FIP3 was subject to heat-treatment at 60ºC for 30 
minutes. 50µg of S100 fraction was added to screw topped eppendorfs. Kinase assay buffer 
was added to a final volume of 50µl followed by 20µg recombinant heat-treated FIP3. The 
reaction was started on addition of 6µCi ATP-γ-32P and carried out in a 30ºC water bath. At 0 
(lane 3), 30 (lane 4), 60 (lane 5) and 120 (lane 6) minutes, 12.5µl of the reaction mixture was 
removed and added to screw topped eppendorfs containing 3µl 4x SDS-PAGE loading 
buffer. FIP3 only (lane 1) and S100 fraction only (lane 2) controls were set up, and, at 120 
minutes, 20µl 4x SDS-PAGE loading buffer was added to each tube. Samples were 
separated by SDS-PAGE, as detailed in section 2.2.2, and autoradiography was performed. 
The position of the Broad Range Prestained Protein Marker is illustrated. The positions of 
FIP3 on the autoradiograph are marked. Data from a single experiment is presented. 
 
3.4 Conclusions  
The regulatory controls governing the spatial and temporal regulation of FIP3 
during mitosis are unknown. A potential candidate is phosphorylation, since 
phosphorylation is a commonly used control mechanism in mitotic regulation 
(Cohen, 2000). FIP3 has been identified as a phospho-protein (R. Prekeris, 
personal communication) and four potential phosphosites have been mapped 
(serines 102, 281, 348 and 451). In order to prevent aberrant cell division, the 
cell-cycle is tightly regulated via a network of kinases, which phosphorylate a 
vast number of protein substrates (Morgan, 2007). A variety of mitotic kinases 
are active during the cell-cycle, including Aurora A, Aurora B, Plk1 and CDK1. 
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This work aimed to determine whether candidate cell-cycle kinases 
phosphorylate FIP3 in vitro. 
First we sought to map the kinase specific phosphorylation sites of human FIP3 
using a prediction programme, focusing on the sites identified by the Prekeris 
lab. FIP3 was not identified as a potential substrate of Aurora A, Aurora B or 
Plk1. Serine 102 (in the sequence context GQLAS*PDAPGPGPR) was identified as 
a potential target of the CDKs, owing to the presence of a proline residue 
immediately following the phospho-serine (Shetty et al., 1993;Brown et al., 
1999;Ubersax and Ferrell Jr, 2007). CDK1 substrates typically have a basic 
residue at the +2 or +3 positions, which serine 102 lacks. However, other CDK1 
sites are known to lack this basic residue (Yüce et al., 2005). 
We examined whether recombinant FIP3 is a substrate for mitotic kinases in 
vitro and found that FIP3 was phosphorylated by cyclin B-CDK1, Plk1, Aurora A 
and weakly by Aurora B. Cyclin B-CDK1 produced the most robust 
phosphorylation of FIP3, but this may be a result of the higher activity of this 
enzyme when compared to the other kinases, via in vitro phosphorylation of 
control protein MBP. Using a proteomic approach, the phosphorylation sites of 
Aurora A, cyclin B-CDK1 and Plk1 in FIP3 were mapped. Cyclin B-CDK1 
phosphorylation of FIP3 was the only substrate/kinase pair to produce significant 
phosphorylation. This approach characterised serine 102 as a phosphorylation 
site of cyclin B-CDK1. Weak phosphorylation was detected at serine 71 in Aurora 
A-phosphorylated FIP3. Plk1 was found not to phosphorylate FIP3.  
Serine 102 was predicted to be a potential CDK1 phospho-site and this was 
validated via in vitro phosphorylation assays, but the other kinases tested 
yielded no significant results. However, these kinases should not be discounted. 
Modification of the in vitro phosphorylation assay, such as buffer composition, 
amounts of protein used and incubation time may have yielded better results. As 
previously mentioned, cyclin B-CDK1 produced the most robust phosphorylation 
of FIP3, possibly due to the higher activity of this enzyme when compared to the 
other kinases via in vitro phosphorylation of control protein MBP. Perhaps Aurora 
A, Aurora B and Plk1 were not fully active. For full activity of Aurora B, as tested 
via in vitro phosphorylation assays, the kinase must be co-expressed and purified 
with the chromosomal passenger proteins INCENP and Survivin (AIS complex) 
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(Sessa et al., 2005). We obtained AIS complex and tested its phosphorylation of 
FIP3 and MBP via in vitro phosphorylation assays, however FIP3 phosphorylation 
was not observed. Indeed, even phosphorylation of MBP was weak, leading us to 
question the activity of Aurora B in the purification. Perhaps a fresh purification 
of Aurora B would produce a higher level of phosphorylation. In addition, a 
kinase must recognise its substrate in a huge pool of potentially 
phosphorylatable residues. Specificity of phosphorylation results, among other 
factors, from the structure of the catalytic site and interactions between the 
substrate and kinase, local and distal to the phosphorylation site (Ubersax and 
Ferrell Jr, 2007). FIP3 used in the phospho-site mapping of kinase 
phosphorylated FIP3 was heat-treated at 60ºC for 30 minutes to abolish the 
contaminating kinase activity in the FIP3 preparation. Perhaps this heat-
treatment affected the structure of FIP3, thus inhibiting kinase recognition of 
the substrate. For Plk1 to phosphorylate its substrate, the substrate first 
requires to be phosphorylated by another kinase, for example CDK1 (Petronczki 
et al., 2008). This was investigated via in vitro phosphorylation assays and an 
increase in phosphorylation by Plk1 of CDK1-primed FIP3 was observed. But it is 
likely that this was due to residual CDK1 activity in the assay. Perhaps CDK1 
phosphorylated FIP3 could be heat-treated to denature CDK1, prior to in vitro 
phosphorylation with Plk1. It was questioned whether a lack of phosphorylation 
by Aurora A, Aurora B and Plk1 was due to FIP3 being already phosphorylated at 
the key phospho-sites. We carried out a study using alkaline phosphatase to 
remove phosphate groups from FIP3, but no significant improvement in 
phosphorylation was observed. Plk1 phosphorylation of phosphatase treated FIP3 
may have been reduced, correlating with Plk1’s requirement for substrate 
phosphate priming, but this was not a reproducible result and was not pursued 
further. 
Surprisingly, the Baculovirus Sf9 insect cell expressed FIP3 sample had intrinsic 
kinase activity and work was carried out to identify the contaminating kinase(s). 
The hope was that any identified kinase may relate to a human kinase which 
phosphorylates FIP3 during the cell-cycle. Various different approaches were 
used. Firstly, various proteomic approaches were carried out to analyse the FIP3 
solution and potentially CK2 may contaminate the solution. CK2 is a 
serine/threonine kinase thought to play a role in mitotic progression via 
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maintenance of centrosome integrity, spindle formation, chromosomal 
segregation (St Denis et al., 2009) and entry into mitosis by regulating Wee1 
stability (Yde et al., 2008). Using a kinase specific phosphorylation prediction 
programme, CK2 was predicted to phosphorylate FIP3 as serine 281. However, 
the presence of CK2 in the FIP3 solution was not verified, nor was CDK1, Aurora 
A, Aurora B, Plk1, ROCK and MLCK, in the various immunoblot analyses of the 
recombinant FIP3 solution. FIP3 immunoprecipitated from metaphase HeLa 
lysates did not co-precipitate with the kinases mentioned above. In another 
attempt to identify the kinase(s) potentially contaminating the recombinant FIP3 
sample, we performed in vitro phosphorylation assays on ‘autophosphorylating’ 
FIP3, using a range of kinase inhibitors, to ascertain whether any decrease in 
FIP3 phosphorylation could be observed. No significant change in FIP3 
autophosphorylation was observed for any of the kinase inhibitors tested. On 
discussion with others in the kinase field, we learned that the baculovirus Sf9 
insect cell expression system is notorious for producing purified protein samples 
with contaminating kinases. In future, perhaps different expression systems may 
be used to produce FIP3. 
In summary, this work has shown that FIP3 can be phosphorylated at serine 102 
by cyclin B-CDK1, in vitro. CDK1 in complex with its regulatory subunit, cyclin 
B1, is chiefly responsible for the orchestration of mitosis (Nigg, 2001). The 
activity of the cyclin B1-CDK1 complex peaks in prophase and prometaphase. 
Degradation of cyclin B1 by the APC/C begins as the last chromosome lines up on 
the metaphase plate, just after inactivation of the spindle-assembly checkpoint 
(Clute and Pines, 1999). On destruction of cyclin B, CDK1 becomes inactivated 
allowing mitotic exit and cytokinesis. FIP3 was found to be phosphorylated at 
serine 102 in metaphase HeLa lysates (R. Prekeris, personal communication), 
when the activity of CDK1 is at its peak and we have shown that CDK1 
phosphorylates FIP3 at serine 102. Thus, a candidate for FIP3 regulation is CDK1. 
This will be investigated further in the following chapters. 
   130 
 
4 Consequences of Rab11-FIP3 phosphorylation 
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4.1 Introduction 
Rab11-FIP3 (FIP3) undergoes spatial and temporal regulation during mitosis 
(Wilson et al., 2005). During metaphase and early anaphase, FIP3 is largely 
cytosolic with some localised to endosomal membrane structures. During late 
anaphase, following furrow initiation, FIP3 localises to the centrosome. At late 
cytokinesis, FIP3 relocates to the cleavage furrow and midbody. On separation of 
the daughter cells, FIP3 relocates to the centrosome. This is shown in figure 1.4 
(section 1.5.4) of the introduction. 
A potential candidate for the spatial and temporal regulation of FIP3 is 
phosphorylation, since reversible phosphorylation is a commonly used control 
mechanism in mitotic regulation and can regulate the activity, localisation and 
half-life of a protein, as well as its interaction with other proteins (Cohen, 
2000). 
Work from a collaborating lab proposes that FIP3 phosphorylation and 
dephosphorylation may be a regulator of FIP3 localisation (R. Prekeris, personal 
communication). FIP3 has been identified as a phospho-protein and four 
potential phospho-sites have been mapped (Serines 102, 281, 348 and 451), as 
described in chapter 3. Analysis of the role of phosphorylation in the membrane 
and cytosol distribution of FIP3 throughout the cell-cycle has shown that 
phosphorylation and dephosphorylation of FIP3 during mitosis may regulate FIP3 
association with membranes. Synchronised HeLa cells fractionated at metaphase 
and telophase show that during prometaphase and metaphase, FIP3 is 
predominantly cytosolic. FIP3 is membrane associated in telophase cells, as 
detailed in figures 4.1A and B. This association is dependent upon 
dephosphorylation of FIP3, as phosphatase treatment of cell extracts from 
metaphase results in FIP3 associating with membranes; this is shown in figure 
4.1D. Interestingly, FIP3 phosphorylation appears to decrease at telophase, as 
shown in figure 4.1C. Such data offer the hypothesis that FIP3 is phosphorylated 
during early stages of the cell-cycle, and that dephosphorylation of FIP3 is the 
trigger for the association of FIP3 with membranes. 
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Figure 4-1 Analysis of the role of phosphorylation in the membrane and cytosol distribution 
of FIP3 throughout the cell-cycle (R. Prekeris, personal communication). 
HeLa cells were synchronised using a thymidine and nocodazole block. Cells were released 
into metaphase and fractionated at metaphase and telophase. A. Fractionation at various 
time points after release from nocodazole. Fractions were blotted for FIP3 and the ratio of 
FIP3 in the membrane and cytosol was determined. During prometaphase and metaphase, 
FIP3 is predominantly cytosolic; FIP3 is membrane associated in telophase cells. B. 
Examples of gels from experiment shown in A. Fractions were blotted for FIP3, transferrin 
receptor (TfR) and RCP (class I FIP). C. Qiagen phospho-binding column was used to isolate 
phosphorylated proteins from metaphase or telophase cells. FIP3 phosphorylation appears 
to decrease at telophase; there is no effect on RCP phosphorylation. D. Analysis of the 
effect of phosphorylation on FIP3 binding to membranes. Fractions from metaphase cells 
were isolated and treated with phosphatase, resulting in increased FIP3 association with 
membranes. There is no effect on RCP phosphorylation. In summary, phosphorylation and 
dephosphorylation of FIP3 during mitosis may regulate FIP3 association with membranes. 
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4.2 Aims 
This work aimed to expand on the findings of Prekeris et al., and further analyse 
the role of phosphorylation on the spatial and temporal regulation of FIP3. We 
aimed to recreate the fractionation of synchronised HeLa cells and analyse the 
membrane and cytosol distribution of FIP3 during the cell-cycle. We then aimed 
to make phospho-specific antibodies to FIP3 serines 102, 281, 348 and 451. 
Following their validation via peptide competition assays, we then screened a 
crude homogenate from synchronised HeLa cells in order to study the cell-cycle 
dependent distribution of the four phosphorylated forms of FIP3. We also aimed 
to perform initial studies of the effect of kinase inhibitors on the localisation of 
GFP-FIP3. This work aimed to expand our current understanding of the role of 
phosphorylation on the spatial and temporal regulation of FIP3. 
4.3 Results  
4.3.1 Membrane and cytosol fractionation of synchronised GFP-
FIP3 expressing HeLa cells 
Unpublished data from Prekeris et al., has shown that the membrane and cytosol 
ratio of FIP3 alters during mitosis. During prometaphase and metaphase FIP3 is 
cytosolic, but in telophase FIP3 becomes membrane associated. We sought to 
replicate this work, with the intention of expanding the scope of the initial 
studies. 
This work was initially performed in HeLa cells. However, detecting endogenous 
FIP3 with the available antibodies is a commonly encountered problem in the 
field. A stable HeLa cell line expressing FIP3 with a GFP tag at the C-terminus 
was obtained from Rytis Prekeris. These cells were grown in normal HeLa growth 
media, under the selection of Hygromycin, as described in section 2.4.1. These 
cells were first synchronised in either metaphase or telophase, then processed 
into membrane or cytosol fractions. These were then probed for FIP3 to analyse 
its membrane and cytosol distribution during the cell-cycle. Briefly, GFP-FIP3 
expressing HeLa cells were synchronised at the G2/M transition using a 
thymidine/nocodazole block, as detailed in section 2.4.5.1. This blocked the 
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cells in the G2/M transition and on release, the cells entered metaphase as a 
synchronous population. In our hands, plated HeLa cells tend to divide at 45 
(metaphase) and 90-110 minutes (telophase), as assessed by microscopy. Cells 
were fractionated, as described in section 2.4.8, using HPFEV buffer and a ball-
bearing homogeniser at 45, 60, 90 and 110 minutes. Proteins were separated by 
SDS-PAGE, as detailed in section 2.2.2; transferred to nitrocellulose via western 
blotting, as detailed in section 2.2.3; detection of proteins was performed by 
immunodetection, as detailed in section 2.2.4. Antibodies to both FIP3 and GFP 
were used to detect the GFP-FIP3. Syntaxin 6 and GAPDH were used as markers 
for membrane and cytosol fractions, respectively. Immunoblot data is presented 
in figure 4.2.  
Syntaxin 6 (Figure 4.2C) and GAPDH (Figure 4.2D) show consistent levels of 
protein in the input (crude homogenate), membrane and cytosol fractions. FIP3 
levels are constant throughout the cell-cycle in the input (Figure 4.2A). 
However, in metaphase membrane extracts, FIP3 is present at low levels; these 
levels increase as the cell progresses through the cell-cycle and peak as the cell 
enters telophase. In contrast, levels of FIP3 peak in metaphase cytosol extracts, 
but decrease as the cell goes through the cell-cycle. This is replicated by GFP 
(Figure 4.2B). Figure 4.3 shows the quantification of GFP levels in the membrane 
and cytosol fractions of synchronised GFP-FIP3 expressing HeLa cells, from an 
experiment performed in duplicate. Thus in correlation with unpublished data 
from Prekeris et al., during prometaphase and metaphase FIP3 is predominantly 
cytosolic, but in telophase FIP3 becomes membrane associated. 
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Figure 4-2 Membrane and cytosol fractionation of synchronised GFP-FIP3 expressing HeLa 
cells 
HeLa cells stably expressing GFP-FIP3 were synchronised using a thymidine and 
nocodazole block, as detailed in section 2.4.5.1. Cells were fractionated using HPFEV buffer 
and a ball-bearing homogeniser at metaphase (45 minutes) and telophase (90 and 110 
minutes), as detailed in section 2.4.8. Proteins were separated by SDS-PAGE, as detailed in 
section 2.2.2; transferred to nitrocellulose via western blotting, as detailed in section 2.2.3; 
detection of proteins was performed by immunodetection, as detailed in section 2.2.4. 
Crude homogenate (input), membrane and cytosol fraction were probed for FIP3, GFP, 
syntaxin 6 (membrane control) and GAPDH (cytosol control). The position of the Broad 
Range Prestained Protein Marker is illustrated. Samples were run on the same gel, with 
protein markers separating the input, membrane and cytosol fractions; these have been 
removed for the purpose of presentation. Data from a typical experiment is presented. 
Syntaxin 6 (Figure 4.2C) and GAPDH (Figure 4.2D) show consistent levels of protein in the 
input, membrane and cytosol fractions. FIP3 levels are constant throughout the cell-cycle in 
the input (Figure 4.2A). In metaphase FIP3 is predominantly cytosolic; in telophase FIP3 is 
predominantly membrane associated. Representative immunoblots from an experiment 
performed in duplicate are presented.   
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Figure 4-3 Quantification of GFP levels in the membrane and cytosol fractions of 
synchronised GFP-FIP3 expressing HeLa cells. Data from an experiment performed in 
duplicate are presented.   
 
4.3.2 Phospho-specific antibody validation via peptide 
competition assays (PCAs) 
In metaphase, we hypothesise that FIP3 is phosphorylated and cytosolic, but in 
telophase FIP3 is dephosphorylated and membrane bound (R. Prekeris, personal 
communication). FIP3 isolated from metaphase lysates has shown to be 
phosphorylated at serines 102, 281, 348 and 451. Next we sought to analyse 
these phospho-sites in more detail. Four phospho-specific antibodies to serines 
102, 281, 348 and 451 were generated by The Scottish Blood Transfusion Service. 
Details are provided in section 2.8.1. In brief, phospho-specific peptides were 
generated, the amino acid sequences of which are listed in section 2.1.7. The 
phospho-specific peptides were immunised in rabbits and whole serum was 
obtained. IgG fractions were affinity purified from whole serum, against a 
protein A sepharose column, as detailed in section 2.8.2. The purification of the 
antibodies was carried out by Mrs M.C. Millar. 
To validate the specificity of the phospho-specific antibodies, we performed 
peptide competition assays (PCAs). The protocol used is detailed in section 
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2.8.3. This procedure describes a PCA using phosphorylated and non-
phosphorylated peptides. 
In brief, various FIP3 samples were separated by SDS-PAGE, as described in 
section 2.2.2. These were 200ng baculovirus Sf9 insect cell expressed FIP3, 1µg 
CDK1 phosphorylated heat-treated FIP3 (prepared according to section 2.6), 
HeLa lysate stably expressing GFP-FIP3 and a wild type HeLa lysate. FIP3 
proteins were transferred onto nitrocellulose, as described in section 2.2.3, and 
blocked in PBS-T containing 5% (w/v) non fat milk overnight. This was done in 
triplicate and identical membranes were incubated with either a no peptide 
control, phosphorylated peptide or non-phosphorylated peptide. These were 
processed for immunodetection using an Amersham ECL Rabbit IgG, HRP-Linked 
Whole Ab, as described in section 2.2.4. 
The resulting immunoblots are presented in figures 4.4-4.7. The phospho-specific 
antibody to pS102 (from rabbit 2294) produced the most significant results to 
date, as shown in figure 4.4. pS102 (2294) antibody detects recombinant FIP3 
and CDK1 phosphorylated FIP3. On incubation of the antibody with the phospho-
specific peptide this avidity is all but lost. On incubation of the antibody with 
the non-phosphorylated peptide pS102 once again detects recombinant FIP3 and 
CDK1 phosphorylated FIP3. pS102 does not detect GFP-FIP3, which runs just 
below the 175 kDa marker. It is unclear whether pS102 detects FIP3 in the wild 
type HeLa lysate. Thus pS102 antibody from rabbit 2294 appears to be specific 
for pS102 and detects CDK1 phosphorylated FIP3.   
The phospho-specific antibody to pS281 (from rabbit 2295) produced less striking 
results, as shown in figure 4.5. The pS281 antibody detects recombinant FIP3, 
but not CDK1 phosphorylated FIP3. On incubation of the antibody with the 
phospho-specific peptide there is a small decrease in signal. On incubation of 
the antibody with the non-phosphorylated peptide, pS281 again detects 
recombinant FIP3. However, the specificity of this interaction is not as 
convincing as for the pS102 antibody. pS281 does not detect GFP-FIP3, which 
runs just below the 175 kDa marker. It is unclear whether pS281 detects FIP3 in 
the wild type HeLa lysate. Thus pS281 antibody from rabbit 2295 does not 
appear to be specific for pS281.  
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The PCA for phospho-specific antibody to pS348 (from rabbit 2297) is shown in 
figure 4.6. The pS348 antibody detects recombinant FIP3, but not CDK1 
phosphorylated FIP3. On incubation of the antibody with the phospho-specific 
peptide this is lost. On incubation of the antibody with the non-phosphorylated 
peptide, p348 again detects recombinant FIP3. pS348 does not appear to detect 
FIP3 in the GFP-FIP3 HeLa lysate or the wild type HeLa lysate. Thus pS348 
antibody from rabbit 2297 could be specific for pS348.  
The PCA for phospho-specific antibody to pS451 (from rabbit 2299) is shown in 
figure 4.7. The pS451 antibody detects recombinant FIP3, but not CDK1 
phosphorylated FIP3. On incubation of the antibody with the phospho-specific 
peptide this reduced. On incubation of the antibody with the non-
phosphorylated peptide, p451 again detects recombinant FIP3. pS451 does not 
appear to detect FIP3 in the GFP-FIP3 HeLa lysate or the wild type HeLa lysate. 
Thus pS451 antibody from rabbit 2299 could be specific for pS451.  
In summary, pS102, pS348 and p451 detect baculovirus Sf9 insect cell expressed 
human FIP3, and are competed for by the peptides from which the antibodies 
were generated. pS281 detects FIP3, but the signal is not competed for with the 
phospho-peptide. These antibodies do not appear to detect phospho-FIP3 in 
endogenous HeLa lysates. However, it is important to note that our lab, and 
others, cannot readily detect FIP3 in endogenous HeLa lysates with various 
antibodies against FIP3. These experiments introduce an interesting result in 
that pS102 (2294) detects CDK1 phosphorylated FIP3, but pS281, p348 and pS451 
do not. This may reflect on our previous findings (presented in section 3.3.6) 
that cyclin B-CDK1 phosphorylates baculovirus Sf9 insect cell expressed human 
FIP3 at serine 102, as tested in vitro. 
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Figure 4-4 FIP3 pS102 peptide competition assay 
To validate the specificity of the phospho-specific antibodies, we performed peptide 
competition assays (PCAs). The protocol used is detailed in section 2.8.3. In brief, various 
FIP3 samples were separated by SDS-PAGE, as described in section 2.2.2. These were 
200ng baculovirus sf9 insect cell expressed FIP3 (Lane 1); 1µg CDK1 phosphorylated heat-
treated FIP3 (Lane 2); HeLa lysate stably expressing GFP-FIP3 (Lane 3); HeLa lysate (Lane 
4). FIP3 proteins were transferred onto nitrocellulose, as described in section 2.2.3, and 
blocked in PBS-T containing 5% (w/v) non fat milk overnight. This was done in triplicate to 
produce three identical test samples for analysis by PCA. Three test samples were prepared 
as follows. Sample A: water only (no peptide control) in a total volume of 1ml PBS-T 
containing 1% Marvel; sample B: 2.66µM phosphorylated peptide to serine 102 in a total 
volume of 1ml PBS-T containing 1% Marvel; sample C: 2.66µM non-phosphorylated peptide 
to serine 102 in a total volume of 1ml PBS-T containing 1% Marvel. 3ml of a 1:500 dilution of 
the phospho-specific antibody was added into each of the samples. The tubes were 
incubated for 2 hours at room temperature with gentle rocking. Samples were centrifuged at 
3273 g in a refrigerated benchtop centrifuge for 15 minutes at 4°C to pellet any immune 
complexes. The pre-incubated antibody was added to one of the three identical 
nitrocellulose membranes for immunoblotting. These were incubated overnight at 4°C and 
processed for immunodetection using an Amersham ECL Rabbit IgG, HRP-Linked Whole 
Ab, as described in section 2.2.4. The position of the Broad Range Prestained Protein 
Marker is illustrated. Representative immunoblots from an experiment performed in 
duplicate are presented.   
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Figure 4-5 FIP3 pS281 peptide competition assay 
To validate the specificity of the phospho-specific antibodies, we performed peptide 
competition assays (PCAs), details of which can be found in the figure legend of Figure 4.4. 
Representative immunoblots from an experiment performed in duplicate are presented.   
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Figure 4-6 FIP3 pS348 peptide competition assay  
To validate the specificity of the phospho-specific antibodies, we performed peptide 
competition assays (PCAs), details of which can be found in the figure legend of Figure 4.4. 
Representative immunoblots from an experiment performed in duplicate are presented.    
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Figure 4-7 FIP3 pS451 peptide competition assay 
To validate the specificity of the phospho-specific antibodies, we performed peptide 
competition assays (PCAs), details of which can be found in the figure legend of Figure 4.4. 
Representative immunoblots from an experiment performed in duplicate are presented.   
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4.3.3 Phospho-specific antibody analysis of membrane and 
cytosol fractions from synchronised GFP-FIP3 expressing 
HeLa cells 
As shown in Figure 4.2, in prometaphase and metaphase FIP3 is cytosolic, but in 
telophase FIP3 becomes membrane associated. Work from Rytis Prekeris, shown 
in figure 4.1, has revealed that this association is dependent upon 
dephosphorylation of FIP3, as phosphatase treatment of cell extracts from 
metaphase results in FIP3 associating with membranes. Interestingly, FIP3 
phosphorylation appears to decrease at telophase.  
We have a panel of antibodies generated against phosphorylated serines 102, 
281, 348 and 451. We have performed competition assays to validate their 
specificity. The pS102 antibody has produced the most significant results to 
date. The immunoblot presented in figure 4.2 was stripped of antibody (section 
2.2.5) and reprobed for pS102. The data is presented in figure 4.8, along with 
the original FIP3 and GFP blots. Figure 4.9 shows the quantification of pS102 
expression in the membrane and cytosol fractions of synchronised GFP-FIP3 
expressing HeLa cells from figure 4.8. In addition, quantification of pS102 
expression in the input fractions of synchronised GFP-FIP3 expressing HeLa cells 
from figure 4.8 and 4.10D is presented in figure 4.9. In the input, FIP3 levels 
remain constant throughout the cell-cycle. However, pS102 peaks in metaphase, 
but decreases towards telophase. pS102 is all but absent in the membrane 
fraction. In the cytosol fraction pS102 peaks in metaphase, but decreases as the 
cell progresses through the cell cycle and is present at very low levels in 
telophase. This adds a new level to the original understanding that FIP3 is 
phosphorylated in metaphase and dephosphorylated in telophase; serine 102 is 
likely to be involved. 
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Figure 4-8 Analysis of phosphorylated serine 102 in membrane and cytosol fractionated 
synchronised GFP-FIP3 expressing HeLa cells 
HeLa cells stably expressing GFP-FIP3 were synchronised using a thymidine and 
nocodazole block, as detailed in section 2.4.5.1. Cells were fractionated using HPFEV buffer 
and a ball-bearing homogeniser at metaphase (45 minutes) and telophase (90 and 110 
minutes), as detailed in section 2.4.8. Proteins were separated by SDS-PAGE, as detailed in 
section 2.2.2; transferred to nitrocellulose via western blotting, as detailed in section 2.2.3; 
detection of proteins was performed by immunodetection, as detailed in section 2.2.4. 
Crude homogenate (input), membrane and cytosol fraction were probed for FIP3, GFP, 
syntaxin 6 (membrane control) and GAPDH (cytosol control). These immunoblots, 
previously presented in figure 4.2, were stripped of antibody (section 2.2.5) and reprobed for 
pS102 (Figure 4.8A). The position of the Broad Range Prestained Protein Marker is 
illustrated. Samples were run on the same gel, with protein markers separating the input, 
membrane and cytosol fractions; these have been removed for the purpose of presentation. 
In the input, FIP3 levels remain constant throughout the cell-cycle. However, pS102 peaks in 
metaphase, but decreases towards telophase. pS102 is all but absent in the membrane 
fraction. In the cytosol fraction pS102 peaks in metaphase, but decreases as the cell 
progresses through the cell-cycle and is present at very low levels in telophase. Data from a 
single experiment is presented. 
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Figure 4-9 Quantification of pS102 expression in the input, membrane and cytosol fractions 
of synchronised GFP-FIP3 expressing HeLa cells. 
Input fractions are quantified from pS102 expression from figures 4.8 and 4.10D (data from 
an experiment performed in duplicate). Membrane and cytosol fractions are quantified from 
pS102 expression from figure 4.8 (data from a single experiment).  
 
We performed a screen of all phospho-specific antibodies on just the crude 
homogenate from synchronised GFP-FIP3 expressing HeLa cells. This experiment 
was repeated in duplicate with consistently similar results; representative 
immunoblots are presented in figure 4.10. Immunoblots of GFP (Figure 4.10A) 
and GAPDH (Figure 4.10B) show equal loading of protein. Crude homogenate was 
also analysed for cyclin B1 expression (Figure 4.10C). Cyclin B1 is the regulatory 
subunit of CDK1; on activation of this complex the cell enters mitosis (Fung and 
Poon, 2005). Degradation of cyclin B1 by the APC begins as the last chromosome 
lines up on the metaphase plate, just after inactivation of the spindle-assembly 
checkpoint (Clute and Pines, 1999). On destruction of cyclin B1, CDK1 becomes 
inactivated allowing mitotic exit and cytokinesis. Thus levels of cyclin B1 should 
be observed to degrade at the metaphase/anaphase transition. Cyclin B1 
expression is constant in the 45 and 60 minute fractions, when the cells are in 
early mitosis. However, as cells enter telophase at approximately 90 to 110 
minutes, cyclin B1 expression decreases. As shown previously, pS102 detects 
GFP-FIP3, the levels of which decrease from 45 minutes to 110 minutes post 
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release (Figure 4.10D). It is unclear whether pS281 (Figure 4.10E), pS348 (Figure 
4.10F) and pS451 (Figure 4.10G) detect the GFP-FIP3 band expected at the 175 
kDa marker. However, they detect faint bands just below the 175 kDa marker, 
but it is unclear whether these relate to FIP3. The intensity of the bands 
detected by pS281, pS348 and pS451 do not alter during the cell-cycle. Thus, the 
pS102 antibody, which is specific for phosphorlyated serine 102 (validated in 
section 4.3.2) detects phosphorylated GFP-FIP3, the levels of which are highest 
in metaphase cell lysates and decrease as the cell progresses through the cell-
cycle towards telophase. This result is consistent in repeats of this experiment. 
 
Figure 4-10 Phospho-specific antibody analysis of crude cell homogenate from 
synchronised GFP-FIP3 expressing HeLa cells 
HeLa cells stably expressing GFP-FIP3 were synchronised using a thymidine and 
nocodazole block, as detailed in section 2.4.5.1. Cells were homogenised using HPFEV 
buffer and a ball bearing homogeniser at metaphase (45 minutes) and telophase (90 and 110 
minutes), as detailed in section 2.4.8. Proteins were separated by SDS-PAGE, as detailed in 
section 2.2.2; transferred to nitrocellulose via western blotting, as detailed in section 2.2.3; 
detection of proteins was performed by immunodetection, as detailed in section 2.2.4. 
Crude homogenate was probed for pS102, pS281, pS348 and pS451. Data from a typical 
experiment is presented. The position of the Broad Range Prestained Protein Marker is 
illustrated. Immunoblots of GFP (Figure 4.10A) and GAPDH (Figure 4.10B) show equal 
loading of protein. Cyclin B1 expression (Figure 4.10C) is level in 45 and 60 minute 
fractions, but decreases as cells enter telophase. pS102 detects GFP-FIP3, the levels of 
which decrease from 45 minutes to 110 minutes post release (Figure 4.10D). It is unclear 
whether pS281 (Figure 4.10E), pS348 (Figure 4.10F) and pS451 (Figure 4.10G) detect GFP-
FIP3. Representative immunoblots from an experiment performed in duplicate are 
presented.   
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4.3.4 Density gradient analysis of FIP3’s association with HeLa 
membranes 
We hypothesised that phosphorylation or dephosphorylation regulates the 
association of FIP3 with cell membranes. In particular, evidence points to 
dephosphorylation of FIP3 enabelling the protein to interact with the cell 
membrane. We questioned whether dephosphorylation of FIP3 is simply allowing 
the protein to bind randomly to membranes or if it is coupled to a change in 
affinity of FIP3 for the membranes, perhaps by increasing its affinity for proteins 
such as Rab11. 
Recombinant baculovirus Sf9 cell expressed human FIP3 was incubated with 
either HeLa membranes or protein-free liposomes. These membranes (or 
vesicles) were then floated up through an Optiprep gradient. Fractions were 
collected and the distribution of proteins within the gradients was assayed by 
immunoblotting. A detailed description of the methods used is provided in 
section 2.4.9 of the materials and methods. This work was carried out with Prof. 
G.W. Gould. Fractions were separated by SDS-PAGE, as detailed in section 2.2.2. 
Proteins were transferred to nitrocellulose via Western Blotting, as detailed in 
section 2.2.3 and immunoblotted for FIP3, as detailed in section 2.2.4. The FIP3 
sample that had been incubated with HeLa membranes was blotted for Rab5, as 
a marker for the position of the membrane fraction in the gradient. Rab5 is a 
Rab GTPase found on early endosomes, phagosomes, caveosomes and the plasma 
membrane where it mediates various processes including endocytosis and 
endosome fusion of clathrin coated vesicles, macropinocytosis and maturation of 
early phagosomes (Stenmark, 2009). 
The resulting immunoblot is presented in figure 4.11, with the bottom and top of 
the Optiprep density gradient detailed. The experiment was repeated and the 
same results were obtained. In both the HeLa membrane and the protein-free 
liposome incubations, FIP3 is found at the bottom of the gradient. However, in 
the HeLa membrane incubation, Rab5 floated up through the gradient. If FIP3 
associated randomly with membranes, then we would expect it to bind to the 
membranes and float up the Optiprep density gradient and localise to the same 
fraction as Rab5. However FIP3 was not found in the same fraction as Rab5, thus 
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suggesting that FIP3 requires association with another protein (for example 
Rab11) to interact with membranes. 
 
Additionally, recombinant baculovirus Sf9 cell expressed FIP3 is not 
phosphorylated, as determined by proteomic analysis of the sample, discussed in 
section 3.3.6. It is hypothesised that FIP3 is phosphorylated in metaphase and 
cytosolic; dephosphorylation allows FIP3 to associate with the membranes in 
telophase. This experiment shows that dephosphorylated FIP3 does not randomly 
associate with cell membranes. Thus we suggest that the dephosphorylation 
event required for membrane association must in some way be coupled to a 
change in affinity for membranes, perhaps affinity for another protein, such as 
Rab11. 
 
Figure 4-11 Density gradient analysis of FIP3’s association with HeLa membranes 
Recombinant baculovirus Sf9 cell expressed FIP3 was incubated with either HeLa 
membranes or protein-free liposomes. These membranes (or vesicles) were then floated up 
through an Optiprep gradient. Fractions were collected and the distribution of proteins 
within the gradients was assayed by immunoblotting. A detailed description of the methods 
used is provided in section 2.4.9 of the materials and methods. Fractions were separated by 
SDS-PAGE, as detailed in section 2.2.2. Proteins were transferred to nitrocellulose via 
Western Blotting, as detailed in section 2.2.3 and immunoblotted for FIP3, as detailed in 
section 2.2.4. The FIP3 sample incubated with HeLa membranes was blotted for Rab5, as a 
marker for endocytic membranes. The bottom and top of the Optiprep density gradient is 
marked. Representative immunoblots from an experiment performed in duplicate are 
presented.   
 
Louise L. Collins, 2010  Chapter 4, 149 
 
4.3.5 Effect of kinase inhibition on GFP-FIP3 localisation in HeLa 
cells 
FIP3 has been identified as a phospho-protein (R. Prekeris, personal 
communication). We have shown that CDK1 phosphorylates recombinant FIP3 in 
vitro (discussed in section 3.3.6). We next sought to explore if CDK1 influences 
the localisation of FIP3. Initial studies have been performed, employing the use 
of kinase inhibitors to study the effect of kinase inhibition on the localisation of 
GFP-FIP3, stably expressed by HeLa cells. 
First we incubated non-synchronised GFP-FIP3 expressing HeLa cells, overnight, 
with a range of kinase inhibitors. These were 100µM Y-27632 (Uehata et al., 
1997;Ishizaki et al., 2000), 10µM PD 98059 (Dudley et al., 1995;Alessi et al., 
1995), 200µM BMI-1026 (Seong et al., 2003), 2µM ZM 447439 (Ditchfield et al., 
2003) and 0.15% (v/v) or 0.5% (v/v) DMSO. Details of inhibitors and their 
suppliers are listed in section 2.1.9. The concentrations were chosen from a 
review of the literature. Cells were plated onto ethanol sterilised glass 
coverslips and incubated for 24 hours in 5% (v/v) CO2 at 37°C. Following this, 
media was replaced with fresh media containing the inhibitors. After incubating 
for 24 hours, cells were fixed with 4% (w/v) ρ-formaldehyde and stained for 
alpha-tubulin and DAPI, as described in section 2.5. This work was performed in 
conjunction with Dr. J. Matheson. It was noted that the localisation of GFP-FIP3 
in telophase cells predominantly fell into one of two categories: early telophase 
(figure 4.12A) or late telophase (figure 4.12B). We sought to quantify the 
proportion of cells in each stage of telophase, for each inhibitor and DMSO 
control. The results are presented in figure 4.13. Treatment with DMSO resulted 
in 65 to 80% of telophase cells in late telophase. The Aurora B inhibitor, ZM 
447439, produced a similar effect. Inhibiting ROCK (Y-27632) or MEK (PD 98059) 
resulted in an equal proportion of cells in early and late telophase. Interestingly, 
inhibiting CDK1 with BMI-1026 resulted in only 30% of cells reaching late 
telophase. This perhaps suggests that by inhibiting CDK1 there is a mis-
localisation of GFP-FIP3 or a delay in cytokinesis. 
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A   
   
B   
   
   
Figure 4-12 Telophase localisations of GFP-FIP3 in HeLa cells 
HeLa cells were transfected with a GFP-FIP3 expressing plasmid (detailed in section 2.1.5), 
as decscribed in section 2.4.6. Cells were fixed with 4% (w/v) ρ-formaldehdye and processed 
for immunofluorescence 48 hours after transfection (section 2.5). Cells were stained for 
microtubules using a rat monoclonal antibody to α-Tubulin, followed by Alexa Fluor® 568 
(red channel). Mounted coverslips were analysed using a 63x Zeiss oil immersion objective 
on a Zeiss confocal microscope (Carl Zeiss, Germany) equipped with Zeiss LSM5 Pascal 
instrument. Zeiss Pascal software was used to collect and edit images. Panel A shows a 
GFP-FIP3 expressing HeLa cell in an early stage of telophase. Panel B shows a GFP-FIP3 
expressing HeLa cell in a late stage of telophase.  
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Figure 4-13 Effect of kinase inhibition on the localisation of GFP-FIP3 in non-synchronised 
HeLa cells 
Non-synchronised GFP-FIP3 stably expressing HeLa cells were grown on coverslips for 24 
hours, then incubated overnight with a range of kinase inhibitors. These were 100µM Y-
27632, 10µM PD 98059, 200µM BMI-1026, 2µM ZM 447439 and 0.15% (v/v) or 0.5% (v/v) 
DMSO. Cells were fixed with 4% (w/v) ρ-formaldehyde and stained for alpha-tubulin and 
DAPI. The proportion of GFP-FIP3 expressing telophase cells in either early telophase or 
late telophase was quantified. Approximately 200 cells per condition were counted. 
Inhibiting CDK1 with BMI-1026 resulted in approximately 30% of cells in late telophase, 
compared to the DMSO controls of 65-80%. Data from a single experiment is presented. 
 
We next sought to study the potential mis-localisation of GFP-FIP3 in CDK1-
treated HeLa cells further. HeLa cell stably expressing GFP-FIP3 were 
synchronised using a thymidine, nocodazole and MG132 block, as described in 
section 2.4.5.2 of the materials and methods (Petronczki et al., 2007). MG132, a 
reversible inhibitor of the proteosome, arrests cells in a metaphase-like state, 
and on release, cells enter a synchronous wave of anaphase. Following the two 
hour incubation with 10µM MG132 synchronised GFP-FIP3 expressing cells were 
harvested via shake off and washed with PBS, followed by warm media and 
plated onto ethanol sterilised glass coverslips. Cells were incubated for 10 
minutes, before a selection of kinase inhibitors were added. We used 50nM BMI-
1026, 50µM PD 98059 and a DMSO only control. Cells were incubated for 20, 30, 
45, 60, 70, 80 and 90 minutes (including the 10 pre-inhibitor incubation) before 
cells were fixed with 4% (w/v) ρ-formaldehdye and stained for alpha-tubulin and 
DAPI, as described in section 2.5. Again we quantified the proportion of cells in 
early or late telophase. This work was carried out in conjunction with Dr. J. 
Matheson and the data is presented in figure 4.14. Cells released from the block 
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for less than 60 minutes were not captured as they may have been washed away 
during the fixation procedure. Approximately 60 to 70% of cells treated with 
DMSO and released for 60 to 90 minutes were in late telophase. This was similar 
to the previous experiment. In PD 98059 treated cells, this decreased marginally 
to 50 to 60% in late telophase, a result similar to the previous experiment. 
Interestingly, in BMI-1026 treated cells released for 60 to 70 minutes, 
approximately 20% of cells were in late telophase. At 80 to 90 minutes post 
release, this increased to 30 to 40% of cells in late telophase. This is again 
similar to the previous experiment. 
These preliminary kinase inhibition studies have produced an interesting result. 
Our first experiment shows than an overnight incubation of non-synchronised 
GFP-FIP3 expressing HeLa cells with BMI-1026 (CDK1 inhibitor) resulted in 
approximately 30% cells in late telophase, in contrast to 65 to 80% of DMSO 
treated cells. Our next experiment developed this further by synchronising cells 
stably expressing GFP-FIP3 using a thymidine, nocodazole and MG-132 block. In 
Approximately 20 to 40% of cells were in late telophase following BMI-1026 
treatment. In contrast, 60 to 70% of DMSO cells were in late telophase. Such 
data suggests that CDK1 inhibition results in mis-localisation of GFP-FIP3 in HeLa 
cells or a delay in cytokinesis. 
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Figure 4-14 Effect of kinase inhibition on the localisation of GFP-FIP3 in synchronised HeLa 
cells 
HeLa cell stably expressing GFP-FIP3 were synchronised using a thymidine, nocodazole 
and MG-132 block, as described in section 2.4.5.2 of the materials and methods. 
Synchronised cells were harvested via shake plated onto ethanol sterilised glass 
coverslips. Cells were incubated for 10 minutes, before a selection of kinase inhibitors were 
added: 50nM BMI-1026, 50µM PD 98059 and a DMSO only control. Cells were incubated for 
60, 70, 80 and 90 minutes (including the 10 pre-inhibitor incubation) before coverslips were 
fixed with 4% (w/v) ρ-formaldehdye and stained for alpha-tubulin and DAPI, as described in 
section 2.5. The proportion of GFP-FIP3 expressing cells in early or late telophase was 
quantified. Approximately 200 cells per condition were counted. In BMI-1026 treated cells 
released for 60-70 minutes, approximately 20% of cells were in late telophase. At 80 to 90 
minutes post release, this increased slightly to 30 to 40%. In contrast, 60 to 70% of cells 
treated with DMSO and released for 60 to 90 minutes were in late telophase. Data from a 
single experiment is presented. 
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4.4 Conclusions  
The regulatory controls governing the spatial and temporal regulation of FIP3 
during mitosis are unknown. A potential candidate is phosphorylation, since 
phosphorylation is a commonly used control mechanism in mitotic regulation 
(Morgan, 2007). FIP3 has been identified as a phospho-protein (R. Prekeris, 
personal communication) and four potential phosphosites have been mapped 
(serines 102, 281, 348 and 451). During prometaphase and metaphase, FIP3 is 
cytosolic, but in telophase FIP3 becomes membrane associated. This work was 
performed by Prekeris et al., and subsequently replicated in this thesis. The 
association with membranes is dependent upon dephosphorylation of FIP3, as 
phosphatase treatment of cell extracts from metaphase results in FIP3 
associating with membranes, and FIP3 phosphorylation appears to decrease at 
telophase (R. Prekeris, personal communication). Such data offer the hypothesis 
that FIP3 is phosphorylated during early stages of the cell-cycle, and that 
dephosphorylation of FIP3 is the trigger for the association of FIP3 with 
membranes. This may have implications for the regulation of FIP3’s dynamics 
during the cell-cycle. 
To explore the role of phosphorylation in the regulation of FIP3’s dynamics, a 
panel of antibodies to serines 102, 281, 348 and 451 were generated. One 
antibody produced significant results. The antibody to pS102 detected 
baculovirus Sf9 insect cell expressed human FIP3 and CDK1 phosphorylated FIP3; 
this was competed for by the phospho-peptide from which the antibody was 
generated, thus signifying specificity. Interestingly, the antibody to pS102 
detected CDK1 phosphorylated FIP3, but pS281, p348 and pS451 did not. This 
may reflect on our previous findings (presented in section 3.3.6) that cyclin B-
CDK1 phosphorylates baculovirus Sf9 insect cell expressed human FIP3 at serine 
102, as tested in vitro. This antibody was used in the analysis of crude 
homogenate from synchronised GFP-FIP3 expressing HeLa cells, showing that 
serine 102 is phosphorylated in metaphase and becomes dephosphorylated as the 
cell progresses through to telophase. Further analysis of membrane and cytosol 
fractions from these cells reveal that cytosolic levels of pS102 peak in 
metaphase and decrease towards telophase to negligible levels. pS102 is absent 
in the membrane fraction. This work suggests that FIP3 may be directly 
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phosphorylated by CDK1 at serine 102 in early mitosis. This may affect the 
membrane and cytosol distribution of FIP3 by preventing membrane association 
of FIP3 in metaphase. Cyclin B1-CDK1 is inactivated at the metaphase/anaphase 
transition (Fung and Poon, 2005), which is reflected in the dephosphorylation of 
pS102 that we observe in the crude cell homogenate of HeLa cells in telophase. 
The phospho-specific antibody for pS102 was used in an attempt to study the 
localisation of this phosphorylated form of FIP3 during the cell-cycle, via 
immunofluorescence. However, this antibody did not produce good quality 
immunofluorescence labelling, and this was not pursued further. 
Preliminary kinase inhibition studies have produced an interesting result. 
Inhibition of CDK1 by the inhibitor BMI-1026 (Seong et al., 2003) resulted in a 
mis-localisation of GFP-FIP3 in HeLa cells compared to a DMSO control. Inhibition 
of CDK1 appeared to result in fewer cells displaying the late telophase 
distribution of GFP-FIP3, where the protein is found in the intracellular bridge at 
either side of the midbody. Instead more cells were found with GFP-FIP3 at the 
centrosomes and at either side of the intracellular bridge, which is characteristic 
for cells in an earlier stage of telophase. While this finding is preliminary, it was 
observed in multiple experiments and perhaps suggests that CDK1 may influence 
the localisation of FIP3. Interestingly, work from our lab has produced similar 
results for another kinase. On knockdown of Aurora B with RNAi, a similar mis-
localisation of GFP-FIP3 was observed (Simon et al., 2008). This work contains 
one caveat. CDK1 is chiefly responsible for the orchestration of mitosis (Nigg, 
2001) and perhaps by inhibiting the action of this kinase, other factors in the cell 
may have been disrupted, leading to mis-localisation of FIP3. Also important to 
note is that our work with CDK1 inhibition revealed a delay in mitosis, with more 
cells in the earlier stages of telophase. However, it is well documented that 
CDK1 inhibition by BMI-1026 forces cells to exit mitosis (Niiya et al., 
2005;Petronczki et al., 2007). 
This work does not reveal if the control of localisation of FIP3 by CDK1 is due to 
direct phosphorylation of FIP3 or an indirect one. Perhaps dephosphorylation 
alters the affinity of FIP3 for another protein such as Rab11. Significantly we 
found that dephosphorylated recombinant FIP3 does not interact randomly with 
HeLa membranes when subject to density gradient analysis. Thus we suggest 
that dephosphorylation required for membrane association must in some way be 
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coupled to a change in affinity for membranes, perhaps affinity for another 
protein, such as Rab11 (Prekeris et al., 2001;Eathiraj et al., 2006;Shiba et al., 
2006), ARF6 (Shin et al., 2001;Fielding et al., 2005), CYK-4 (Simon et al., 2008) 
and ASAP1 (Inoue et al., 2008) which have been found to interact with FIP3. 
The effect of kinase inhibition on the localisation of GFP-FIP3 warrants further 
analysis. The inhibitors could be used at different concentrations to the ones 
used in this study. A study of the effects of the ROCK inhibitor Y-27632 on HeLa 
cells demonstrated a positive correlation between the number of binuclear cells 
and the concentration of the inhibitor (Ishizaki et al., 2000). The concentration 
of BMI-1026 used in the first kinase inhibitor study may have been too high since 
we used BMI-1026 in the micromolar range, whereas other groups have used it in 
the nanomolar range (Seong et al., 2003;Petronczki et al., 2007). However, this 
was corrected in the second study. Further work should explore, via time lapse 
microscopy, of the effect of BMI-1026 on GFP-FIP3 localisation. Initial studies 
were made to analyse the effect of kinase inhibition on the membrane and 
cytosol ratio of GFP-FIP3. However, owing to time limitations this was not 
pursued further. 
In summary, during prometaphase and metaphase, FIP3 is cytosolic, but in 
telophase FIP3 becomes membrane associated. The antibody to pS102 
specifically detected baculovirus Sf9 insect cell expressed human FIP3 and CDK1 
phosphorylated FIP3, but antibodies to pS281, p348 and pS451 did not. Serine 
102 is phosphorylated in metaphase and becomes dephosphorylated as the cell 
progresses through to telophase. Cytosolic levels of pS102 peak in metaphase 
and decrease towards telophase to negligible levels. pS102 is absent in the 
membrane fraction. This work suggests that FIP3 may be directly phosphorylated 
by CDK1 at serine 102. Inhibition of CDK1 by the inhibitor BMI-1026 resulted in a 
mis-localisation of GFP-FIP3 in HeLa cells, as fewer cells displayed the late 
telophase distribution of GFP-FIP3, compared with the DMSO control. CDK1 
inhibition appeared to delay cytokinesis, causing more cells to display an earlier 
telophase distribution of GFP-FIP3. Thus we have explored the role of 
phosphorylation in the distribution of FIP3 to the membrane and cytosol and 
have identified serine 102 of FIP3 as potentially an important residue in this 
system. This may impact on the spatial and temporal regulation of FIP3 during 
the cell-cycle. However, many questions remain unanswered. Importantly, 
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questions still remain as to the mode of interaction between FIP3 and the 
membrane, and the role of phosphorylation in the cycling of FIP3 on and off the 
membrane.  Significantly, dephosphorylated recombinant FIP3 does not interact 
randomly with HeLa membranes, suggesting that dephosphorylation required for 
membrane association must in some way be coupled to a change in affinity for 
membranes, perhaps affinity for another protein, such as Rab11.  
    158 
 
5 Analysis of Rab11-FIP3 phosphosites 
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5.1 Introduction 
Rab11-FIP3 (FIP3) undergoes spatial and temporal regulation during mitosis 
(Wilson et al., 2005). A potential candidate for the regulation of FIP3 is 
phosphorylation, since phosphorylation is a commonly used control mechanism in 
mitotic regulation (Morgan, 2007). As discussed in chapters 3 and 4, work from a 
collaborating lab proposes that FIP3 phosphorylation and dephosphorylation may 
be a regulator of FIP3 localisation (R. Prekeris, personal communication) and 
mass spectrometry analysis of FIP3 immunoprecipitated from metaphase cells 
has identified four phosphorylation sites: serines 102, 281, 348 and 451. The 
significance of these phosphosites in the spatial and temporal regulation of FIP3 
during mitosis remains unknown. 
5.2 Aims 
This chapter aims to analyse the role of FIP3 phosphorylation at serines 102, 
281, 348 and 451 through the creation of phospho-null and phospho-mimetic 
mutants. Serines 102, 281, 348 and 451 were mutated to alanine (phospho-null) 
and aspartic acid (phospho-mimetic). These mutations were carried out in the 
pEGFP-N1 plasmid, containing the coding sequence for human FIP3. The aim was 
to study the role of the various phosphorylation sites of FIP3 through the analysis 
of the cell-cycle dependent subcellular localisation of each phospho-mutant 
protein. We also sought to determine whether mutation of any phosphosite had 
an effect on cytokinesis. 
5.3 Methods 
5.3.1 Site directed mutagenesis 
Mutants were generated via site directed mutagenesis (SDM). This was carried 
out in the context of pEGFP-N1 plasmid, containing the coding sequence for 
human FIP3 which had been cloned into the multiple cloning site of the plasmid 
via XhoI (N-terminus of FIP3) and EcoRI (C-terminus of FIP3). This plasmid is 
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hereafter referred to as GFP-FIP3 and is detailed in section 2.1.5 of the 
materials and methods. A schematic figure of the GFP-FIP3 plasmid is provided 
in figure 5.1 and includes restriction sites used throughout this work. 
 
Figure 5-1 Schematic figure of the GFP-FIP3 plasmid. 
The coding sequence of human FIP3 was cloned into the multiple cloning site of the pEGFP-
N1 plasmid via XhoI (N-terminus of FIP3) and EcoRI (C-terminus of FIP3). This plasmid is 
hereafter referred to as GFP-FIP3 and is detailed in section 2.1.5 of the materials and 
methods. Sites of digest by the restriction enzymes used in this work are detailed. 
 
SDM was carried out according to the QuickChange® method from Stratagene.  
SDM was initially performed using Pfu DNA polymerase (Promega) and then 
PfuTurbo DNA polymerase (Stratagene). However, no mutants were generated. 
Analysis of the DNA sequence reveals that FIP3 is GC rich, particularly at the N-
terminus where some of the potential phospho-sites are located. Addition of 
DMSO or glycerol into the SDM reaction mixture did not generate mutants. Next 
we investigated different polymerases. HotStarTaq DNA Polymerase (QIAGEN) 
yielded colonies on DpnI treated plates, but these proved to be wild-type. This is 
possibly due to this enzyme’s lack of 3' to 5' exonuclease proofreading ability. 
Advantage® GC Genomic LA Polymerase Mix from Clontech has proofreading 
ability and was used in this project to successfully generate mutants. The basic 
Louise L. Collins, 2010  Chapter 5, 161 
 
protocol is provided in section 2.3.1 of the materials and methods. However, 
this produced only some of the mutants required. Thus the modified protocols 
for phospho-mimetic and phospho-neutral mutants of serines 102, 281, 348 and 
451 are provided in section 5.3.4. 
5.3.2 Validation of mutant plasmids 
Various problems were encountered during the generation of the mutants. Some 
mutants had insertions or deletions of DNA in their sequence. In addition, some 
mutants were generated which did not fluoresce when transfected into HeLa 
cells. Thus, measures were undertaken to ensure the mutant plasmid DNA 
produced a FIP3 protein of the correct molecular weight, which fluoresced on 
expression in HeLa cells. 
Firstly, following mutagenesis, potential mutant DNA preparations were digested 
with XhoI and EcoRI to check for the presence of insertions or deletions in the 
DNA sequence. A protocol for digestion is detailed in section 2.3.5 of the 
materials and methods. DNA digestion products were separated by agarose gel 
electrophoresis, as detailed in section 2.3.7. Mutated GFP-FIP3 plasmids which 
contained a FIP3 insert of the correct length were transformed into HeLa cells, 
as outlined in section 2.4.6. Plasmids were transfected into cells grown on glass 
coverslips and processed for immunofluorescence by fixing with 4% (w/v) ρ-
formaldehyde and mounting onto glass slides, as detailed in section 2.5.1. This 
ensured that all potential mutant plasmids produced a GFP-tagged protein which 
fluoresced.  Plasmids were also transfected into HeLas and lysed, as detailed in 
section 2.4.7. Lysates were then separated by SDS-PAGE (2.2.2), transferred 
onto nitrocellulose via western blotting (2.2.3) and immunoblotted for GFP 
(2.2.4) to check the size of the expressed protein. If the plasmids were shown to 
produce a protein which expressed a fluorescent GFP tag and had the expected 
molecular weight, then one plasmid was sent for DNA sequencing (2.3.10) to 
ensure the generated plasmid was mutant. 
5.3.3 Cloning of BamHI fragments into GFP-FIP3 or pCR3.1 
For many of the mutants generated, insertions or deletions of DNA were present 
in the N-terminus of FIP3. These aberrations could be digested from the plasmid 
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by BamHI, which cuts the FIP3 sequence at position 738bp and is present in the 
MCS of pEGFP-N1, at the C-terminus of FIP3. This is detailed in figure 5.1. Thus 
the BamHI fragment containing the mutant could be ligated into wild type GFP-
FIP3. In addition, some mutants were generated using a plasmid constructed 
from the BamHI fragment of GFP-FIP3 and BamHI digested pCR3.1. On 
generation of a mutant from this construct, the BamHI fragment containing the 
mutant was ligated into wild type GFP-FIP3. A brief outline of the protocol used 
is provided below. 
The GFP-FIP3 plasmid containing the site of interest (‘insert’) and wild type 
GFP-FIP3 plasmid or pCR3.1 plasmid (’vector’) were digested with BamHI, 
according to section 2.3.5. The products of digestion were separated by agarose 
gel electrophoresis, as detailed in section 2.3.7. The bands corresponding to the 
vector (minus its BamHI fragment) and the insert were excised and DNA was 
extracted according to section 2.3.8. To prevent the re-ligation of linearised 
plasmid DNA, gel purified ‘vector’ DNA was treated with Shrimp Alkaline 
Phosphatase (section 2.3.9). ‘Insert’ and ‘vector’ DNA were ligated (section 
2.3.6) and the entire ligation transformed into Top10 cells (section 2.3.2). DNA 
was isolated from individual colonies via a small scale DNA preparation (section 
2.3.3).  
For the mutants which were constructed via ligation of BamHI fragments into 
fresh GFP-FIP3, the construct was digested with XhoI and EcoRI. This ensured 
that the modified FIP3 sequence did not contain any insertions or deletions of 
DNA. Plasmids of the correct length were digested with KpnI which cuts FIP3 at 
1305bp and at the MCS of pEGFP-N1, towards the C-terminus of FIP3. This is 
detailed in figure 5.1. KpnI digestion verified that the FIP3 fragment had been 
cloned into the fresh vector in the correct orientation. Following this, mutants 
were validated according to section 5.3.2. 
The plasmid constructed from the BamHI fragment of GFP-FIP3 and pCR3.1 was 
digested with BamHI to check for presence of the insert. This construct was then 
used in some SDM reactions and is hereafter referred to as BamHI-FIP3-pCR3.1. 
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5.3.4 Generation of phospho-mutant GFP-FIP3 plasmids 
5.3.4.1 Generation of GFP-FIP3-S102A and GFP-FIP3-S102D plasmids 
To generate GFP-FIP3-S102A we modified the basic SDM protocol provided in 
section 2.3.1 of the materials and methods: dNTPs were used at a concentration 
of 0.8mM each; primers were used at a concentration of 0.4µM each; 50ng of 
GFP-FIP3 was used as a template. The thermocycling conditions used for this 
SDM were as follows. 
94°C 3 min 
94°C 1 min 
55°C 30 sec  30 cycles 
68°C 16 min 
68°C 5 min 
4°C Hold 
 
Generation of GFP-FIP3-S102D proved to be challenging. Numerous attempts 
were made at modifying the basic SDM strategy, but this yielded no mutants. We 
next cloned XhoI/BstXI wild-type GFP-FIP3 fragment into XhoI/BstXI digested 
pCR3.1 and performed mutagenesis in this vector. BstXI digests GFP-FIP3 at 990 
bp. However, creating this plasmid did not help since we believe the problems 
encountered during SDM of FIP3 occurred in the GC rich N-terminal domain. Next 
we tried to use GFP-FIP3-S102A as template for SDM, but this did not yield 
mutants. GFP-FIP3-S102D was therefore made using GFP-FIP3 as the template by 
Dundee Cell Products Ltd, Dundee, UK. 
The mutated plasmids were verified, as detailed in section 5.3.2. 
 
5.3.4.2 Generation of GFP-FIP3-S281A and GFP-FIP3-S281D plasmids 
For GFP-FIP3-S281A we modified the basic SDM protocol provided in section 
2.3.1 of the materials and methods: dNTPs were used at a concentration of 
0.4mM each; primers were used at a concentration of 0.5µM each; 50ng GFP-FIP3 
was used as template. The thermocycling conditions used for SDM were as 
follows. 
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95°C 5 min 
95°C 1 min 
60°C 30 sec  30 cycles 
72°C 14 min 
72°C 5 min 
4°C Hold 
 
On verification of the mutant by DNA sequencing, we checked the DNA for any 
insertions or deletions. A double digest was performed using XhoI and EcoRI and 
the DNA products were separated by agarose gel electrophoresis, according to 
sections 2.3.5 and 2.3.7 of the materials and methods. This showed that there 
was a deletion of DNA as the XhoI/EcoRI fragment size was shorter than 
expected. A BamHI digest, which cuts the plasmid at 738bp of FIP3 and at the 
MCS, towards the C-terminus of FIP3, produced the expected insert. Thus the 
deletion of DNA had occurred N-terminal to 738bp. We cut out the BamHI 
fragment which contained the mutant and ligated it into fresh GFP-FIP3. This 
method is outlined in section 5.3.3.  
For GFP-FIP3-S281D we modified the basic SDM protocol provided in section 
2.3.1 of the materials and methods: dNTPs were used at a concentration of 
0.8mM each; primers were used at a concentration of 0.8µM each; 50ng 
template was used. The thermocycling conditions used for site directed 
mutagenesis were as follows. 
95°C 5 min 
95°C 1 min 
60°C 1 min  30 cycles 
72°C 20 min 
72°C 5 min 
4°C Hold 
 
The mutated plasmids were verified, as detailed in section 5.3.2. 
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5.3.4.3 Generation of GFP-FIP3-S348A and GFP-FIP3-S348D plasmids 
Various attempts were made at generating GFP-FIP3-S348A, each of which 
produced insertions of DNA towards the N-terminus of FIP3. To resolve this issue, 
we cloned a BamHI fragment from the wild-type GFP-FIP3 plasmid into BamHI 
digested pCR3.1 vector and performed mutagenesis in the absence of the N-
terminus of FIP3. The methods used to produce the BamHI-FIP3-pCR3.1 construct 
are detailed in section 5.3.3. We modified the basic SDM protocol provided in 
section 2.3.1 of the materials and methods to the following: dNTPs were used at 
a concentration of 0.4mM each; primers were used at a concentration of 0.4µM 
each; 50ng BamHI-FIP3-pCR3.1 was used as a template. 
The thermocycling conditions used for SDM were as follows. 
94°C 1 min 
94°C 30 sec 
60°C 30 sec  16 cycles 
72°C 6 min 
72°C 5 min 
4°C Hold  
 
Once the mutagenesis was confirmed to have generated the S348A mutant, we 
digested out the BamHI fragment of the mutant and ligated it into fresh GFP-
FIP3. The protocol for this is detailed in section 5.3.3.  
To generate GFP-FIP3-S348D we modified the basic SDM protocol provided in 
section 2.3.1 of the materials and methods: dNTPs were used at a concentration 
of 0.4mM each; primers were used at a concentration of 0.4µM each; 50ng GFP-
FIP3 template was used.  
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The thermocycling conditions used for SDM were as follows. 
94°C 1 min 
94°C 30 sec 
60°C 30 sec  30 cycles 
72°C 14 minutes 
72°C 5 min 
4°C Hold  
 
The GFP-FIP3-S348D plasmid generated a FIP3 protein which had a smaller than 
expected molecular weight, as analysed by SDS-PAGE. On digestion of the 
plasmid with BamHI, it was shown that the deletion of DNA occurred in the N-
terminus of FIP3. Thus we cut out the BamHI fragment of the mutant and ligated 
it into fresh GFP-FIP3, as described in section 5.3.3.  
The mutated plasmids were verified, as detailed in section 5.3.2.  
5.3.4.4 Generation of GFP-FIP3-S451A and GFP-FIP3-S451D plasmids 
Generation of phospho-neutral and phospho-mimetic mutants of serine 451 from 
GFP-FIP3 proved challenging, since all mutants made contained insertions or 
deletions of DNA towards the N-terminus of FIP3. To resolve this issue, we 
cloned a BamHI fragment from the wild-type GFP-FIP3 plasmid into BamHI 
digested pCR3.1 vector and performed mutagenesis in the absence of the N-
terminus of FIP3. The methods used to produce the BamHI-FIP3-pCR3.1 construct 
are detailed in section 5.3.3. 
To generate GFP-FIP3-S451A we modified the basic SDM protocol provided in 
section 2.3.1 of the materials and methods to the following: dNTPs were used at 
a concentration of 0.4mM each; primers were used at a concentration of 0.25µM 
each; 25ng BamHI-FIP3-pCR3.1 was used as a template. The thermocycling 
conditions used for SDM were as follows. 
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95°C  5 min 
95°C 1 min 
60°C 30 sec  16 cycles 
68°C 12 min 
68°C 10 min 
4°C Hold 
 
To generate GFP-FIP3-S451D we modified the basic SDM protocol provided in 
section 2.3.1 of the materials and methods to the following: dNTPs were used at 
a concentration of 0.4mM each; primers were used at a concentration of 0.25µM 
each; 25ng BamHI-FIP3-pCR3.1 was used as a template. The thermocycling 
conditions used for SDM were as follows. 
94°C 5 min 
94°C 1 min 
60°C 30 sec  30 cycles 
72°C 12 min 
72°C 10 min 
4°C Hold 
 
The mutated plasmids were verified, as detailed in section 5.3.2. 
5.4 Results 
5.4.1 Restriction digest analysis of phospho-mutant GFP-FIP3 
plasmids 
To ensure that the SDM protocol had not introduced unwanted insertions or 
deletions into the FIP3 sequence, the phospho-mutant GFP-FIP3 plasmids were 
subject to a restriction digest. The Prekeris lab cloned human FIP3 into the 
pEGFP-N1 plasmid using XhoI (at the N-terminus of FIP3) and EcoRI (at the C-
terminus of FIP3), thus digestion with these enzymes should produce full length 
fragments of FIP3. Restriction digests were carried out according to section 
2.3.5 of the materials and methods, using 1.5µg of plasmid DNA. For comparison, 
GFP-FIP3 and GFP-FIP3-I737E were also digested. In brief, plasmids were 
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incubated with XhoI and EcoRI for two hours at 37ºC and DNA fragments 
separated and visualised via agarose gel electrophoresis (section 2.3.7). 
Figure 5.2 shows the resulting DNA fragment pattern for GFP-FIP3-S102A and 
GFP-FIP3-S102D plasmids. In all DNA samples digested, FIP3 produced a fragment 
size between the 2 to 3kb markers, as expected, since the coding sequence of 
human FIP3 is approximately 2270bp. The pEGFP-N1 vector (4.7kb) appeared at 
the 5kb marker, as expected. The band of approximately 8kb is uncut plasmid. 
Thus, SDM did not introduce any insertions or deletions into the sequence of the 
GFP-FIP3-S102A and GFP-FIP3-S102D plasmids. The remaining mutant pairs 
produced identical DNA fragment patterns and are therefore not presented. 
 
Figure 5-2 Restriction digest analysis of GFP-FIP3-S102A and GFP-FIP3-S102D plasmids 
GFP-FIP3-S102A and GFP-FIP3-S102D plasmids were subject to restriction digests to 
confirm FIP3 fragment size. Restriction digests were carried out according to section 2.3.5, 
using 1.5µg of plasmid. For comparison, GFP-FIP3 and GFP-FIP3-I737E were also digested. 
Plasmids were incubated with 10u XhoI and 10u EcoRI for two hours at 37ºC and DNA 
fragments separated and visualised via agarose gel electrophoresis, according to section 
2.5.7. Lane allocations are as follows: Lane 2, GFP-FIP3-S102A; Lane 3, GFP-FIP3-S102D; 
Lane 4, GFP-FIP3; Lane 5, GFP-FIP3-I737E. Lane 1 contains the 1kb DNA ladder, with the 
positions of the markers indicated. The position of FIP3 is marked. In all DNA samples 
digested FIP3 produces a fragment size between the 2-3kb markers, as expected, since the 
coding sequence of human FIP3 is 2270kb. Thus, SDM did not introduce any insertions or 
deletions into the FIP3 sequence of the mutants. 
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5.4.2 Immunoblot analysis of HeLa lysates from cells expressing 
phospho-mutant GFP-FIP3 plasmids 
To check that the phospho-mutant GFP-FIP3 plasmids expressed their mutated 
FIP3 proteins at the correct molecular weight, the plasmids were transfected 
into HeLa cells, as outlined in section 2.4.6. In addition to the phospho-mutant 
GFP-FIP3 plasmids, wild type GFP-FIP3 and GFP-FIP3-I737E were transfected into 
HeLa cells. Two controls were set up: one with only the transfection reagent and 
one with untransfected cells. Cells were lysed following 24, 48 and 72 hours 
transfection (section 2.4.7). Samples were separated by SDS-PAGE (section 
2.2.2), transferred onto nitrocellulose (section 2.2.3) and probed for GFP-FIP3 
(section 2.2.4). As a loading control, the bottom half of the membrane, below 
the 47.5kDa marker, was probed for GAPDH.  
The resulting immunoblots for the serine 102 phospho-mutant pair are shown in 
figure 5.3. GFP-FIP3-S102A and GFP-FIP3-S102D run at the same molecular 
weight as GFP-FIP3 and GFP-FIP3-I737E. Immunoblots for the serine 281 (figure 
5.4) and serine 348 (figure 5.5) phospho-mutant pairs show that GFP-FIP3-S281A, 
GFP-FIP3-S281D, GFP-FIP3-S348A and GFP-FIP3-S348D run at the same molecular 
weight as GFP-FIP3 and GFP-FIP3-I737E.  
Figure 5.6 presents the immunoblots from the serine 451 phospho-mutant pair. 
GFP-FIP3-S451A and GFP-FIP3-S451D run at the same molecular weight as GFP-
FIP3 and GFP-FIP3-I737E. Interestingly, GFP-FIP3-S451A is expressed at much 
lower levels than the other GFP-FIP3 plasmids. This result was repeated in three 
separate transfections, using different preparations of DNA. Additionally, levels 
of GFP-FIP3-S451A decrease from the 24 hour transfection to the 72 hour 
transfection. GAPDH levels for the GFP-FIP3-S451A transfection are equal to that 
of the other plasmid transfections and show no decrease in signal from 24 to 72 
hours. 
Phospho-mutant GFP-FIP3 plasmids were also transfected into CHO cells and 
immunoblot analysis produced identical results as those from HeLa cells (data 
not shown). 
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Figure 5-3 Immunoblot analysis of HeLa lysates from cells expressing GFP-FIP3-S102A and 
GFP-FIP3-S102D plasmids 
To check that GFP-FIP3-S102A (Lane 1) and GFP-FIP3-S102D (Lane 2) plasmids expressed 
their mutated FIP3 proteins at the correct molecular weight, the plasmids were transfected 
into HeLa cells. Control transfections included GFP-FIP3 (Lane 3) and GFP-FIP3-I737E (Lane 
4), Lipofectamine 2000 only (Lane 5) and untransfected cells (Lane 6). The protocol for 
which is detailed in section 2.4.6 of the materials and methods. Cells were lysed at 24 
(Figures 5.3A and 5.3D), 48 (Figures 5.3B and 5.3E) and 72 (Figures 5.3C and 5.3F) hours 
after transfection. The protocol for which is detailed in section 2.4.7. Protein lysates were 
separated by SDS-PAGE, as detailed in section 2.2.2, and then transferred onto 
nitrocellulose via Western Blotting, as outlined in section 2.2.3. Following Western Blotting 
the membrane was cut in half at the 47.5kDa marker. The half of the membrane above 
47.5kDa was probed for GFP (top panel). As a loading control, the half of the membrane 
below the 47.5kDa marker was probed for GAPDH (bottom panel). A protocol for this is 
provided in section 2.2.4. The resulting immunoblots are presented, with the positions of 
GFP and GAPDH labelled. The position of the Broad Range Prestained Protein Marker is 
illustrated. GFP-FIP3-S102A and GFP-FIP3-S102D run at the same molecular weight as GFP-
FIP3 and GFP-FIP3-I737E. Representative immunoblots from an experiment performed in 
duplicate are presented.   
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Figure 5-4 Immunoblot analysis of HeLa lysates from cells expressing GFP-FIP3-S281A and 
GFP-FIP3-S281D plasmids (figure legend as per figure 5.3). Representative immunoblots 
from an experiment performed in duplicate are presented.   
 
Figure 5-5 Immunoblot analysis of HeLa lysates from cells expressing GFP-FIP3-S348A and 
GFP-FIP3-S348D plasmids (figure legend as per figure 5.3). Representative immunoblots 
from an experiment performed in duplicate are presented.   
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Figure 5-6 Immunoblot analysis of HeLa lysates from cells expressing GFP-FIP3-S451A and 
GFP-FIP3-S451D plasmids (figure legend as per figure 5.3). Representative immunoblots 
from an experiment performed in triplicate are presented.   
 
5.4.3 Immunofluorescence analysis of HeLa cells expressing 
phospho-mutant GFP-FIP3 plasmids 
To analyse the distribution of phospho-mutant GFP-FIP3, plasmids were 
transfected into HeLa cells, which allowed the analysis of the localisation of 
phospho-mutant proteins through the cell-cycle, owing to their GFP tags. HeLa 
cells were transfected with plasmid DNA (section 2.4.6). In addition to phospho-
mutant GFP-FIP3 plasmids, wild type GFP-FIP3 and GFP-FIP3-I737E were also 
transfected into cells. Two controls were set up: one with the transfection 
reagent only and one with untransfected cells. Cells were fixed with 4% (w/v) ρ-
formaldehdye and processed for immunofluorescence 24, 48 and 72 hours after 
transfection (section 2.5). Cells were stained for microtubules using a rat 
monoclonal antibody to α-Tubulin, followed by Alexa Fluor® 568. For nuclear 
staining, cells were stained with DAPI. Mounted coverslips were analysed using a 
63x Zeiss oil immersion objective on a Zeiss confocal microscope (Carl Zeiss, 
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Germany) equipped with Zeiss LSM5 Pascal instrument. Zeiss Pascal software was 
used to collect and edit images.  
The localisation of each phospho-mutant GFP-FIP3 was identical following 24, 48 
and 72 hours expression, thus data for the 24 hour and 72 hour time points are 
not included, owing to space constrains. Images of HeLa cells expressing 
phospho-mutant GFP-FIP3 plasmids for 48 hours, along with the various controls, 
are presented at the end of this chapter in figures 5.11 to 5.28. Images were 
taken of cells in interphase (figures 5.11 to 5.13), metaphase (figures 5.14 to 
5.16), anaphase (figures 5.17 to 5.19), early telophase (figures 5.20 to 5.22), 
and late telophase (figures 5.23 to 5.25). These images represent the majority of 
cells viewed.  
GFP-FIP3 is found on membranes at the centrosome in interphase and the 
duplicated centrosomes in metaphase. In addition, GFP-FIP3 is located on 
endosomal membrane structures in the cytosol. By anaphase, the majority of 
GFP-FIP3 is concentrated at the centrosomes. In early telophase, GFP-FIP3 is 
found again at the centrosomes, but the beginnings of trafficking to the furrow 
are evident as GFP-FIP3 begins to concentrate in pools associated with the minus 
ends of the microtubules forming the spindle midzone. In late telophase GFP-
FIP3 traffics into the intracellular bridge and is found on either side of the 
midbody. The Rab11 binding defective mutant of FIP3, GFP-FIP3-I737E, shows 
diffuse cytosolic staining throughout the cell-cycle, as expected. GFP-FIP3-
S102A, GFP-FIP3-S102D, GFP-FIP3-S281A, GFP-FIP3-S281D, GFP-FIP3-S348A, GFP-
FIP3-S348D and GFP-FIP3-S451D show the same localisation through the cell-
cycle as the wild type GFP-FIP3 protein. They localise to the centrosomes in 
interphase and metaphase and then traffic into the intracellular bridge, on 
either side of the midbody, by late telophase.  
While GFP-FIP3-S451D shows the same localisation through the cell-cycle as the 
wild type GFP-FIP3 protein, GFP-FIP3-S451A produced an interesting result. As 
shown in section 5.4.2, GFP-FIP3-S451A is expressed at much lower levels than 
the other GFP-FIP3 plasmids. Additionally, levels of GFP-FIP3-S451A decrease 
from the 24 hour transfection to the 72 hour transfection. However, GAPDH 
levels for the GFP-FIP3-S451A transfection are equal to that of the other plasmid 
transfections and show no decrease in signal from 24 to 72 hours. Coverslips 
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from these transfections were sparse and patches of cells rarely expressed GFP-
FIP3-S451A. In the cells which did express GFP-FIP3-S451A, the cells appeared 
unhealthy and the protein did not accumulate in the same way as the wild type 
protein. Examples of average fields of view have been presented in figures 5.26 
to 5.28 at the end of this chapter.  
Phospho-mutant GFP-FIP3 plasmids were also transfected into CHO cells and 
immunofluorescence analysis produced similar results, however these are not 
presented owing to space constraints. Thus, on expression of phospho-mutant 
GFP-FIP3 plasmids for serines 102, 281 and 348 in HeLa and CHO cells, no 
apparent effect was observed on the cell-cycle dependent localisation of these 
mutated proteins. Expression of the phospho-mimetic form of serine 451 had no 
apparent effect on the cell-cycle dependent localisation of the protein. 
However, expression of the phospho-neutral form of serine 451 produced a 
dramatic effect as very few cells expressed the plasmid. The cells which did so 
were unhealthy and the protein did not accumulate in the same way as the wild 
type protein. 
5.4.4 Binuclear cell count analysis of HeLa cells expressing 
phospho-mutant GFP-FIP3 plasmids 
We next sought to determine the role of phosphorylation at serine 102, 281, 348 
and 451 of FIP3 in cytokinesis. As a crude estimate of defects in cytokinesis, a 
binuclear cell count is widely used in the field. HeLa cells expressing phospho-
mutant GFP-FIP3 plasmids from section 5.4.3 were used. The number of 
binuclear cells and total cells expressing GFP-FIP3 (or a mutant of) were counted 
in ten fields of view for each transfection condition. From this the average 
percentage of binuclear cells per field of view was calculated.  
The binuclear cell count for serine 102 at the 48 hour time point is presented in 
figure 5.7. As expected, GFP-FIP3-I737E produced an increased binuclear 
phenotype in HeLa cells (approximately 4%). Binucleate counts for GFP-FIP3-
S102A and GFP-FIP3-S102D plasmids were marginally higher (approximately 1.5%) 
to those of the controls (approximately 0.5 to 1%), but did not reach the levels 
observed for GFP-FIP3-I737E.  
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The binuclear cell count for serine 281 at 24 hours is presented in figure 5.8. As 
expected, GFP-FIP3-I737E produced an increased binuclear phenotype in HeLa 
cells (approximately 4.5%). Binucleate counts for GFP-FIP3-S281A and GFP-FIP3-
S281D plasmids (approximately 2.5%) were marginally higher than those of the 
controls (between 1 and 1.5%).  
The binuclear cell count for serine 348 at the 72 hour time point is presented in 
figure 5.9. As expected, GFP-FIP3-I737E produced an increased binuclear 
phenotype in HeLa cells (approximately 5%). Binucleate counts for GFP-FIP3-
S348A and GFP-FIP3-S348D plasmids (between 0.5 to 1.0%) were similar to those 
of the controls (between 1.0 to 1.5%).  
The binuclear cell count for serine 451 for 24 hours is presented in figure 5.10. 
Binuclear cells for GFP-FIP3-S451A could not be performed as very few cells 
expressing the plasmid were present on the coverslips and the ones which did 
express were often unhealthy. As expected, GFP-FIP3-I737E produced an 
increased binuclear phenotype in HeLa cells (approximately 4%). The binucleate 
count for the GFP-FIP3-S451D plasmid (2.5%) was similar to those of the controls 
(0.5 to 3%). 
Phospho-mutant GFP-FIP3 plasmids were also transfected into CHO cells, which 
produced similar results and therefore data is not presented, owing to space 
constraints. In summary, on expression of phospho-mutant GFP-FIP3 plasmids of 
serines 102, 281 and 348, no discernible effect on cytokinesis was observed via a 
binuclear cell count. Expression of the phospho-mimetic form of serine 451 had 
no apparent effect on cytokinesis. However, expression of the phospho-neutral 
form of serine 451 produced a dramatic effect on the cell, as very few cells 
expressed the plasmid and the cells which did so were unhealthy. As a result, 
any effect on cytokinesis by GFP-FIP3-S451A could not be shown by this method. 
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Figure 5-7 Binuclear cell count of HeLa cells expressing GFP-FIP3-S102A and GFP-FIP3-
S102D plasmids for 48 hours. Approximately 500 cells per condition were counted. Data 
from a single experiment is presented. 
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Figure 5-8 Binuclear cell count of HeLa cells expressing GFP-FIP3-S281A and GFP-FIP3-
S281D plasmids for 24 hours. Approximately 500 cells per condition were counted. Data 
from a single experiment is presented. 
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Figure 5-9 Binuclear cell count of HeLa cells expressing GFP-FIP3-S348A and GFP-FIP3-
S348D plasmids for 72 hours. Approximately 500 cells per condition were counted. Data 
from a single experiment is presented. 
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Figure 5-10 Binuclear cell count of HeLa cells expressing GFP-FIP3-S451A and GFP-FIP3-
S451D plasmids for 24 hours. Approximately 500 cells per condition were counted. Data 
from a single experiment is presented. 
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5.5 Conclusions 
FIP3 undergoes spatial and temporal regulation during mitosis (Wilson et al., 
2005). A potential candidate for the control of FIP3 dynamics is phosphorylation, 
since phosphorylation is a commonly used control mechanism in mitotic 
regulation (Morgan, 2007). As discussed in chapters 3 and 4, work from a 
collaborating lab proposes that FIP3 phosphorylation and dephosphorylation may 
be a regulator of FIP3 localisation (R. Prekeris, personal communication) and 
mass spectrometry analysis of FIP3 immunoprecipitated from metaphase cells 
has identified four phosphorylation sites: serines 102, 281, 348 and 451. The 
significance of these phosphosites in the spatial and temporal regulation of FIP3 
during mitosis remains unknown. The aim of this chapter was to analyse the role 
of phosphorylation at serines 102, 281, 348 and 451 by creating alanine 
(phospho-null) and aspartic acid (phospho-mimetic) mutant FIP3. These 
mutations were carried out in the pEGFP-N1 plasmid, containing the coding 
sequence for human FIP3. The aim was to study the role of the various 
phosphorylation sites of FIP3 through the analysis of the cell-cycle dependent 
subcellular localisation of each phospho-mutant. We also performed binuclear 
cell counts to look for cytokinesis defects resulting from mutation of the various 
phosphosites. Ideally, we sought to analyse the membrane and cytosol ratios of 
these mutant proteins, but time constraints prevented this. 
In considering the potential functions of phosphorylation at serines 102, 281, 348 
and 451, it is important to explore where these sites are located within FIP3. 
The family of FIP proteins is characterised by a highly conserved Rab11-binding 
domain (RBD) of 20 amino acids located at the C-terminus of the protein 
(Prekeris et al., 2001), the minimal area of which encompasses residues 733 to 
756 of FIP3 (Shiba et al., 2006). The structure of FIP3 in its entirety is not yet 
known. The crystal structure of the FIP3-RBD (695 to 756 amino acids) in 
complex with Rab11 reveals that amphiphillic helices from two FIP3-RBDs form a 
parallel coiled-coil homodimer. This creates two symmetrical interfaces for 
binding the switch regions of two Rab11 molecules, thus forming a 
heterotetrameric complex (Eathiraj et al., 2006;Shiba et al., 2006). Thus our 
phosphosites fall outside of the reported homodimerisation domain and RBDs. 
However, it is important to note that points of contact between the two FIP3 
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proteins may exist out with the RBD. Indeed, prediction software has shown that 
FIP3 has an extensive α-helical coiled-coil region between residues 463 and 692 
(Wallace et al., 2002;Horgan et al., 2007). Perhaps future research may identify 
other points of dimerisation in the regions of the phosphosites investigated in 
this thesis. Analysis of the amino acid sequence reveals that FIP3 also contains 
two EF-hand domains (Prekeris et al., 2001) at approximately 202 to 237 and 234 
to 269 amino acids (The UniProt Consortium, 2009). EF-hand domains are 
involved in calcium binding (Grabarek, 2006). Also important to note is the 
proline rich region found at the N-terminus of FIP3 (Prekeris et al., 2001), 
encompassing amino acids 5 to 197 (The UniProt Consortium, 2009). Interestingly 
serine 102 is located within this proline rich region; this type of region is known 
to mediate a large number of protein to protein interactions (Kay et al., 2000).  
It has been proposed that the FIP3-Rab11 complex plays a key role in cytokinesis 
by delivering and targeting recycling endosomes to the cleavage furrow and 
midbody (Wilson et al., 2005;Fielding et al., 2005). FIP3 may act as a scaffold in 
the recruitment of proteins to the recycling endosomes at the centrosome. An 
ever increasing list of proteins has been found to interact with FIP3. Directly N-
terminal to the RBD is the Arf binding domain (ABD), which involves amino acids 
650 to 695 (Fielding et al., 2005;Shiba et al., 2006;Schonteich et al., 2007). N-
terminal to this is the CYK-4 binding domain which is thought to encompass 
amino acids 441 to 610 (Simon et al., 2008). Serine 451 lies just within this 
region. Recently, Kinesin I has been found to interact with FIP3, which is 
essential for cytokinesis (Simon and Prekeris, 2008). Also, Arf GTPase Activating 
Protein ASAP1 is thought to interact with amino acids 565 to 650 of FIP3, within 
the coiled-coil domain (Inoue et al., 2008). Perhaps future research may identify 
proteins which interact with FIP3 in the regions of the phosphosites investigated 
in this thesis.  
On transfection into HeLa cells, the cell-cycle dependent localisation of the wild 
type GFP-FIP3 plasmid was as expected. In interphase, metaphase and early 
anaphase, FIP3 localised to endosomal membrane structures in the cytosol 
(Wilson et al., 2005). Data from this thesis shows that in addition to this, a pool 
of GFP-FIP3 is concentrated at endosomal membranes at the centrosome in 
interphase and metaphase. This has also been observed via immunofluorescence 
of fixed HeLa cells using an antibody for FIP3, where a pool of FIP3 associates 
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with the centrosome throughout the cell-cycle, in addition to the pool of FIP3 
which is dynamic (Wilson et al., 2005). Real-time microscopy shows a rapid 
redistribution of GFP-FIP3 to the centrosomes during late anaphase, following 
furrow initiation. We also observe a concentration of GFP-FIP3 at the 
centrosomes during anaphase. At late cytokinesis, FIP3 relocates to the cleavage 
furrow and midbody and on separation of the two daughter cells, FIP3 relocates 
to the centrosome (Wilson et al., 2005). We have presented the dynamic 
relocalisation of GFP-FIP3 in stages: anaphase, where GFP-FIP3 is associated 
with the centrosomes; early telophase, where GFP-FIP3 associates with 
centrosomes, but begins to concentrate in pools associated with the minus ends 
of the microtubules forming the spindle midzone; late telophase, where GFP-
FIP3 traffics into the intracellular bridge and can be found at either side of the 
midbody.  
The majority of the plasmids constructed for this thesis localised in the same 
manner as wild type GFP-FIP3. The localisations of GFP-FIP3-S102A/D, GFP-FIP3-
S281A/D, GFP-FIP3-S348A/D and GFP-FIP3-S451D mirrored that of the wild type 
protein. In addition, these plasmids did not demonstrate a disruption in 
cytokinesis as their binuclear counts in HeLa and CHO cells did not differ greatly 
to the binuclear counts produced by the wild type plasmid and the transfection 
controls. Thus it would appear that when mutated singly, the potential phospho-
sites of serines 102, 281, 348 and 451 (aspartic acid mutation only) have no 
significant effect on the spatial and temporal regulation of FIP3 during mitosis. 
However, before discounting these phospho-sites there is one note of caution 
which arises on consideration of the binuclear counts from the mutant of FIP3 
defective in binding to Rab11, GFP-FIP3-I737E. On transfection of this plasmid 
into HeLa and CHO cells, GFP-FIP3-I737E showed diffuse cytosolic staining 
throughout the cell cycle, as expected (Wilson et al., 2005). In this thesis, only a 
slightly higher binuclear phenotype to that of the controls was observed. 
Previously GFP-FIP3-I737E was reported to produce a binuclear cell count of 40% 
in HeLa cells (Wilson et al., 2005). It was for that reason that transfections were 
repeated in CHO cells, but the binclear counts were similar to those from HeLa 
cells. In addition, phospho-mutant proteins were expressed in HeLas, with a 
background of endogenous FIP3. Ongoing work in the lab aims to create a FIP3 
knockdown system in HeLa cells. 
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A binuclear count is used widely in the field to quantify mitotic defects. 
However, it is in itself limited as it does not take into account cells which are 
connected by an intracellular bridge and appear normal, but will regress. Some 
research groups take into account cells attached by a midbody, in addition to 
the standard binuclear cell (Bajorek et al., 2009). Thus, in addition to counting 
binuclear cells, we also counted separately cells in telophase. However, this did 
not reveal any difference between the mutants and the controls. Time lapse 
microscopy revealed the importance of FIP3 in cytokinesis as knockdown of FIP3 
produced a delay in cytokinesis, leading to apoptosis (Wilson et al., 2005). Thus 
to ensure that potential defects in mitosis are not overlooked, time lapse 
microscopy should be performed on cells transfected with these plasmids. 
Another potential reason for the lack of cytokinesis defects following mutation 
of these phosphosites is the fact that these sites were mutated singly. Multisite 
phosphorylation is a commonly recognised control of protein behaviour (Cohen, 
2000). Further work to produce double/triple/quadruple mutants for these four 
sites would explore the role of these four phosphosites further.  
The one plasmid which produced a phenotype different to that of the wild type 
plasmid was GFP-FIP3-S451A. GFP-FIP3-S451D shows the same localisation 
through the cell cycle as the wild type GFP-FIP3 protein. However, GFP-FIP3-
S451A produced an interesting result. As shown in section 5.4.2, GFP-FIP3-S451A 
is expressed at much lower levels than the other GFP-FIP3 plasmids. 
Additionally, levels of GFP-FIP3-S451A decreased from the 24 hour transfection 
to the 72 hour transfection. However, GAPDH levels for the GFP-FIP3-S451A 
transfection are equal to that of the other plasmid transfections and show no 
decrease in signal from 24 to 72 hours. Coverslips from these transfections were 
sparse and patches of cells rarely expressed GFP-FIP3-S451A. In the cells which 
did express GFP-FIP3-S451A, the cells appeared unhealthy and the protein did 
not accumulate in the same way as the wild type plasmid. Very few cells which 
expressed GFP-FIP3-S451A were present on the coverslips to allow the cell-cycle 
localisation of this protein to be recorded. However, GFP-FIP3-S451A did not 
appear to concentrate at the centrosomes of interphase cells. It is important to 
note that GFP-FIP3-S451A did not produce the same phenotype as GFP-FIP3-
I737E as it was not diffusely cytosolic.  
Louise L. Collins, 2010  Chapter 5, 182 
 
The localisation of this protein should be studied in more depth. It would be 
interesting to determine if this mutation resulted in apoptosis of the cells. 
Mitotic catastrophe resulting from expression of phospho-mimetic mutations of 
CK2 has been previously reported (St Denis et al., 2009). Again time lapse 
microscopy would potentially reveal more about this phospho-mutant. The only 
clues for the potential role of this site in the regulation of FIP3 come from the 
domain structure of FIP3, as a CYK-4 binding domain has been mapped to amino 
acids 441-610 (Simon et al., 2008). FIP3 interacts with CYK-4 of the 
centralspindlin complex at the midbody, and is responsible for recruiting 
recycling endosomes to this area (Simon and Prekeris, 2008). Owing to time 
constrains GFP-FIP3-S451A was not investigated further, thus the significance of 
CYK-4 binding remains conjecture. Another possibility is that this mutation may 
have affected the processing of the protein. 
In summary, the aim of this chapter was to analyse the role of FIP3 
phosphorylation at serines 102, 281, 348 and 451 by creating phospho-null and 
phospho-mimetic mutants in the context of GFP-FIP3. The majority of the 
plasmids constructed for this thesis localised in the same way as wild type GFP-
FIP3 and did not disrupt cytokinesis. This would suggest that phosphorylation at 
serines 102, 281, 348, 451 has no relevance in the spatial and temporal 
regulation of FIP3 during mitosis. However, these sites should not be discounted 
as perhaps the reality is more complex than this work accounts for; perhaps 
multisite phosphorylation is required in the regulation of FIP3’s dynamics. 
However, mutation of serine 451 to alanine produced an interesting phenotype. 
Very few cells expressed this protein. The ones which did so were often 
unhealthy and the protein failed to localise as was expected. Therefore, 
mutation of serine 451 to alanine may not shed light on the role of 
phosphorylation in the spatial and temporal regulation of FIP3 during mitosis, 
but it does warrant further investigation as to the importance of this mutation in 
the expression of the protein and the survival of the cell.  
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Figure 5-11 Immunofluorescence analysis of HeLa cells in interphase expressing GFP-FIP3-
S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in interphase expressing GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-12 Immunofluorescence analysis of HeLa cells in interphase expressing GFP-FIP3-
S348A/D and GFP-FIP3-S451A/D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in interphase expressing GFP-FIP3-S348A/D and GFP-FIP3-S451A/D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-13 Immunofluorescence analysis of HeLa cells in interphase expressing wild-type 
GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to Lipofectamine 2000 only and 
untransfected controls, for 48 hours.  
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in interphase expressing wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition 
to control transfections, for 48 hours. These images represent the majority of cells viewed. 
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Figure 5-14 Immunofluorescence analysis of HeLa cells in metaphase expressing GFP-FIP3-
S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in metaphase expressing GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-15 Immunofluorescence analysis of HeLa cells in metaphase expressing GFP-FIP3-
S348A/D and GFP-FIP3-S451D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in metaphase expressing GFP-FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-16 Immunofluorescence analysis of HeLa cells in metaphase expressing wild-type 
GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to Lipofectamine 2000 only and 
untransfected controls, for 48 hours.  
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in metaphase expressing wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition 
to control transfections, for 48 hours. These images represent the majority of cells viewed. 
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Figure 5-17 Immunofluorescence analysis of HeLa cells in anaphase expressing GFP-FIP3-
S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in anaphase expressing GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-18 Immunofluorescence analysis of HeLa cells in anaphase expressing GFP-FIP3-
S348A/D and GFP-FIP3-S451D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in anaphase expressing GFP-FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-19 Immunofluorescence analysis of HeLa cells in anaphase expressing wild-type 
GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to Lipofectamine 2000 only and 
untransfected controls, for 48 hours.  
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in anaphase expressing wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition 
to control transfections, for 48 hours. These images represent the majority of cells viewed. 
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Figure 5-20 Immunofluorescence analysis of HeLa cells in early telophase expressing GFP-
FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in early telophase expressing GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 
48 hours. These images represent the majority of cells viewed. 
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Figure 5-21 Immunofluorescence analysis of HeLa cells in early telophase expressing GFP-
FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in early telophase expressing GFP-FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-22 Immunofluorescence analysis of HeLa cells in early telophase expressing wild-
type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to Lipofectamine 2000 only and 
untransfected controls, for 48 hours.  
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in early telophase expressing wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in 
addition to control transfections, for 48 hours. These images represent the majority of cells 
viewed. 
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Figure 5-23 Immunofluorescence analysis of HeLa cells in late telophase expressing GFP-
FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in late telophase expressing GFP-FIP3-S102A/D and GFP-FIP3-S281A/D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-24 Immunofluorescence analysis of HeLa cells in late telophase expressing GFP-
FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 hours. 
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in late telophase expressing GFP-FIP3-S348A/D and GFP-FIP3-S451D plasmids for 48 
hours. These images represent the majority of cells viewed. 
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Figure 5-25 Immunofluorescence analysis of HeLa cells in late telophase expressing wild-
type GFP-FIP3 and GFP-FIP3-I737E plasmids, in addition to Lipofectamine 2000 only and 
untransfected controls, for 48 hours.  
HeLa cells were transfected with plasmid DNA or the relevant controls (section 2.4.6). Cells 
were fixed with 4% (w/v) ρ-formaldehdye and processed for immunofluorescence 48 hours 
after transfection (section 2.5). Cells were stained for microtubules using a rat monoclonal 
antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). This figure details HeLa 
cells in late telophase expressing wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids, in 
addition to control transfections, for 48 hours. These images represent the majority of cells 
viewed. 
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Figure 5-26 Immunofluorescence analysis of HeLa cells expressing GFP-FIP3-S451A/D plasmids for 48 hours. Cells were stained for microtubules using a 
rat monoclonal antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). These images represent an average field of view. 
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Figure 5-27 Immunofluorescence analysis of HeLa cells expressing wild-type GFP-FIP3 and GFP-FIP3-I737E plasmids for 48 hours. Cells were stained for 
microtubules using a rat monoclonal antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). These images represent an average field of view. 
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Figure 5-28 Immunofluorescence analysis HeLa cells treated with control transfections for 48 hours. Cells were stained for microtubules using a rat 
monoclonal antibody to α-Tubulin, followed by Alexa Fluor® 568 (red channel). These images represent an average field of view. 
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6 Discussion 
Cytokinesis involves abscission of the intracellular bridge between two daughter 
cells, thus completing mitosis (Steigemann and Gerlich, 2009). The cellular 
dynamics at the midbody resulting in abscission are the subject of intense 
investigation. However, recent research has placed membrane traffic at the 
heart of mammalian cytokinesis (Albertson et al., 2005;Barr and Gruneberg, 
2007;Prekeris and Gould, 2008;Ai and Skop, 2009). Understanding the 
mechanisms of cytokinesis is of importance since failure of cytokinesis results in 
genomic instability and tumourigenesis (Fujiwara et al., 2005). 
Time-lapse microscopy of HeLa cells expressing GFP-FIP3 has shown that FIP3 
undergoes spatial and temporal dynamics during mitosis (Wilson et al., 2005). 
During metaphase and early anaphase FIP3 is largely cytosolic with some 
localised to endosomal membrane structures. During late anaphase, following 
furrow initiation, FIP3 localises to the centrosome. At late cytokinesis, FIP3 
relocates to the cleavage furrow and midbody. On separation of daughter cells, 
FIP3 relocates to the centrosome. It has been proposed that FIP3 in complex 
with Rab11 plays a key role in the delivery and targeting of recycling endosomes 
to the furrow; this is essential for completion of cytokinesis (Wilson et al., 
2005;Fielding et al., 2005).  
The regulatory mechanisms governing the spatial and temporal dynamics of FIP3 
during mitosis are unknown. The cell-cycle is regulated by a network of protein 
kinases which control the activity, localisation and interactions of proteins 
involved in cell-cycle progression (Nigg, 2001). This work aimed to determine if 
FIP3 can be phosphorylated by the mitotic kinases and whether this has an 
impact on its spatial and temporal dynamics. Work from a collaborating lab 
suggests that FIP3 is a phospho-protein, which can exist in different, reversible 
phosphorylation states (R. Prekeris, personal communication). Proteomic 
analysis of FIP3 immunoprecipitated from metaphase cells identified the serines 
102, 281, 348 and 451 as sites of phosphorylation (R. Prekeris, personal 
communication). 
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We first sought to determine whether candidate cell-cycle kinases phosphorylate 
FIP3 in vitro and found that FIP3 was phosphorylated by cyclin B-CDK1, Plk1, 
Aurora A and weakly by Aurora B. A proteomic approach showed that within the 
limits of our experimental approach, only cyclin B-CDK1 phosphorylated FIP3 
significantly, at serine 102. This parallels the site identified by Prekeris et al., in 
metaphase HeLa lysates. Analysis of the amino acid sequence surrounding serine 
102 identifies it as a potential target of the CDKs, owing to the presence of a 
proline residue immediately following the phospho-serine (Shetty et al., 
1993;Brown et al., 1999;Ubersax and Ferrell Jr, 2007). This work does not 
discount the role of the Plk1, Aurora A, Aurora B or other mitotic kinases in the 
regulation of FIP3. 
Analysis of the role of phosphorylation in the membrane and cytosol distribution 
of FIP3 throughout the cell-cycle has shown that phosphorylation and 
dephosphorylation of FIP3 during mitosis may regulate FIP3 association with 
membranes (unpublished data from the Prekeris and Gould labs). Synchronised 
HeLa cells fractionated at metaphase and telophase show that during 
prometaphase and metaphase, FIP3 is predominantly cytosolic. FIP3 is 
membrane associated in telophase cells. This work was performed by Prekeris et 
al., and subsequently replicated in this thesis. This association of FIP3 with 
membranes is dependent upon dephosphorylation of FIP3, as phosphatase 
treatment of cell extracts from metaphase results in FIP3 associating with 
membranes. Interestingly, FIP3 phosphorylation appears to decrease at 
telophase (R. Prekeris, personal communication). Such data offer the hypothesis 
that FIP3 is phosphorylated during early stages of the cell-cycle, and that 
dephosphorylation of FIP3 is the trigger for the association of FIP3 with 
membranes. This may have implications for the regulation of FIP3’s dynamics 
during the cell-cycle. 
We sought to explore further the role that phosphorylation plays in the 
membrane association of FIP3. A phospho-specific antibody to serine 102 (pS102) 
detected CDK1 phosphorylated FIP3. This further supports our findings that 
cyclin B-CDK1 phosphorylates FIP3 at serine 102. Screening of crude cell lysates 
from synchronised HeLa cells shows that serine 102 is phosphorylated in 
metaphase and becomes dephosphorylated as the cell progresses through to 
telophase. Further analysis of membrane and cytosol fractions from these cells 
Louise L. Collins, 2010  Chapter 6, 203 
 
reveal that cytosolic levels of pS102 peak in metaphase and decrease towards 
telophase to negligible levels. pS102 is absent in the membrane fraction. This 
work suggests that FIP3 may be directly phosphorylated by CDK1 at serine 102 in 
early mitosis. This may affect the membrane and cytosol distribution of FIP3 by 
preventing membrane association of FIP3 in metaphase.  
Dephosphorylated FIP3 does not associate randomly with HeLa membranes or 
protein-free liposomes, as assayed by density gradient fractionation. Thus we 
suggest that the dephosphorylation event required for membrane association 
must in some way be coupled to a change in affinity for membranes, perhaps 
affinity for another protein. Proteins known to interact with FIP3 include Rab11 
(Prekeris et al., 2001;Eathiraj et al., 2006;Shiba et al., 2006), ARF6 (Shin et al., 
2001;Fielding et al., 2005), CYK-4 (Simon et al., 2008) and ASAP1 (Inoue et al., 
2008). Interestingly, Rab11 knock-down with RNAi results in translocation of FIP3 
from the membranes to the cytosol, suggesting that the Rab11 mediates the 
association of FIP3 with endosomes (Wilson et al., 2005). The link between FIP3 
and the cell membrane and how this is modulated via phosphorylation warrants 
further investigation. Interestingly serine 102 is located within this proline rich 
region of FIP3; this type of region is known to mediate a large number of protein 
to protein interactions (Kay et al., 2000).  
The role of phosphorylation at serines 102, 281, 348 and 451 of FIP3 was 
investigated by creating phospho-null and phospho-mimetic mutants in the 
context of GFP-FIP3. It would appear that when mutated singly the potential 
phospho-sites of serines 102, 281, 348 and 451 (phospho-mimetic mutant only for 
serine 451) have no significant effect on the spatial and temporal regulation of 
FIP3 during mitosis as their localisations mirror that of the wild type GFP-FIP3 
protein. Mutations of these phospho-sites had no effect on cytokinesis, as 
assayed via binuclear cell counts. However, this requires further analysis. 
Ongoing work in our lab aims to create a FIP3 knockdown system in HeLa cells 
which would allow the phospho-mutants to be expressed in the absence of 
endogenous FIP3. Also, to ensure that potential defects in mitosis are not 
overlooked, time lapse microscopy could be performed on cells expressing GFP-
FIP3 phospho-mutants. Further work to produce double/triple/quadruple 
mutants for these four sites would explore the role of these phospho-sites 
further. It would also be of interest to analyse the membrane and cytosol ratios 
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of these GFP-FIP3 phospho-mutants. A phospho-null mutation of serine 451 
produced an interesting phenotype. Very few cells expressed this protein. The 
ones which did so were often unhealthy and the protein failed to localise in the 
same way as wild-type GFP-FIP3. The role of phosphorylation at serine 451 
warrants further investigation. Mitotic catastrophe resulting from expression of a 
phospho-mimetic form of CK2 has been previously reported (St Denis et al., 
2009). 
Preliminary kinase inhibition studies show that inhibition of CDK1 by the 
inhibitor BMI-1026 results in a mis-localisation of GFP-FIP3 in HeLa cells. This 
could also be interpreted as a delay in cytokinesis, since CDK1 inhibition resulted 
in more cells displaying GFP-FIP3 in a localisation characteristic of an earlier 
stage of telophase, compared to the controls. However, since CDK1 is chiefly 
responsible for the orchestration of mitosis (Nigg, 2001), perhaps inhibiting the 
action of this kinase disrupts other factors in the cell, leading to mis-localisation 
of FIP3. Interestingly, knockdown of Aurora B with RNAi results in a similar mis-
localisation of GFP-FIP3 (Simon et al., 2008). Further work could employ the use 
of time lapse microscopy to study the effect of BMI-1026 on GFP-FIP3 
localisation. Owing to the growing number of small molecule inhibitors of 
mitotic kinases, the role of other kinases such as Plk1 and Aurora B in GFP-FIP3 
localisation could be examined by time lapse microscopy, allowing their roles in 
late mitosis to be examined by avoiding their earlier cell-cycle functions 
(Petronczki et al., 2007). Also these inhibitors could be used to analyse the 
effect of kinase inhibition on the membrane and cytosol distribution of FIP3.  
This work opens up another avenue of research. FIP3 is a phospho-protein and 
the current thinking suggests that dephosphorylation of FIP3 in late anaphase 
results in its association with membranes. The next step would be to identify the 
phosphatase responsible for this event. The role of phosphatases in the spatial 
and temporal regulation of mitosis is as important as that of the kinases, 
although less well studied (Bollen et al., 2009). 
In summary, FIP3 undergoes spatial and temporal dynamics during mitosis 
(Wilson et al., 2005;Fielding et al., 2005). The current working model suggests 
that Rab11 recruits FIP3 onto recycling endosome-derived vesicles at the 
centrosome. In telophase FIP3-Rab11 vesicles traffic to the furrow and at later 
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stages the midbody. These vesicles are directed along the microtubules of the 
mitotic spindle, possibly via the motor protein kinesin I. These vesicles are 
tethered to the midbody prior to abscission via interactions with ARF6, Rab11, 
CYK-4 and components of the Exocyst. These vesicles may serve as an 
organisation platform for the assembly of the abscission machinery or they may 
deliver the cargo required for abscission. FIP3-Rab11 vesicles may also be 
involved in a compound fusion event which seals the intracellular bridge, thus 
resolving the two daughter cells (Prekeris and Gould, 2008). 
Work from this thesis has added a new dimension to this model. FIP3 dynamics 
may be regulated by phosphorylation, potentially by CDK1. CDK1 in complex 
with its regulatory subunit, cyclin B1, is chiefly responsible for the orchestration 
of mitosis (Nigg, 2001). Cyclin B1-CDK1 activity peaks in the early stages of 
mitosis and is inactivated via degradation of cyclin B as the last chromosome 
lines up on the metaphase plate, just after inactivation of the spindle-assembly 
checkpoint (Clute and Pines, 1999). Cyclin B1-CDK1 negatively regulates many of 
the protein complexes required for cytokinesis, until anaphase onset when the 
sister chromatids have successfully separated and CDK1 is inactivated (Barr and 
Gruneberg, 2007). Interestingly, phosphorylation by CDK1 can affect the 
membrane and cytosol distribution of proteins involved in mitosis: cyclin B1-
CDK1 phosphorylation of the microtubule motor cytoplasmic dynein releases the 
protein from membranes, in vitro (Addinall et al., 2001). 
Work from our lab and Prekeris et al., suggests that during prometaphase and 
metaphase FIP3 is phosphorylated, preventing its association with endosomes. 
FIP3 is dephosphorylated in late anaphase, allowing it to associate with 
endosomes and subsequently traffic to the furrow and midbody. We suggest that 
CDK1 phosphorylates FIP3 in the early stages of mitosis, at serine 102. This 
perhaps modulates the affinity of FIP3 for another protein which recruits it to 
vesicles derived from the recycling endosome at the centrosome. Recent 
research has placed membrane traffic at the heart of mammalian cytokinesis 
and data from this thesis suggests that membrane dynamics may be regulated by 
the orchestrators of mitosis: the cell-cycle kinases. 
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7 Appendix 
7.1 Rab11-FIP3 Proteomic Data 
7.1.1 Rab11-FIP3 solution analysed via nLC-ESI-MS/MS by Sir 
Henry Wellcome Functional Genomics Facility (SHWFGF), 
University of Glasgow 
Protein  Score Database 
Accession 
Number 
Rab11-family interacting protein 3  1602 gi 7662234 
Beta tubulin 580 gi 135490 
Beta tubulin 538 gi 57429 
Beta tubulin 531 gi 12851187 
Beta tubulin 502 gi 49456871 
Beta tubulin 495 gi 90075322 
Alpha tubulin  466 gi 2843123 
Beta tubulin 452 gi 223486 
Beta tubulin 450 gi 149440634 
Beta tubulin 440 gi 74212109 
Beta tubulin 431 gi 223429 
Rab11-family interacting protein 3 418 gi 26006197 
Alpha tubulin 343 gi 66730465 
Alpha tubulin 323 gi 135435 
Alpha tubulin 305 gi 114649125 
Alpha tubulin 293 gi 74186501 
Alpha tubulin 266 gi 119878872 
Hsp70 252 gi 428 
Rab11-family interacting protein 3 236 gi 126335383 
Rab11-family interacting protein 3 200 gi 116667015 
Hsp70 198 gi 640325 
Hsp70 187 gi 62897129 
Beta tubulin 170 gi 225480 
Alpha tubulin 163 gi 73960249 
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Alpha tubulin 146 gi 149626356 
Trypsin precursor 125 gi 136429 
Histone H2B 107 gi 76630991 
Histone H2B  103 gi 1568557 
Histone H2B  102 gi 28173554 
Beta tubulin  97 gi 114575797 
Ribosomal protein S3 92 gi 32532 
Alpha tubulin 88 gi 10436240 
Ribosomal protein L9 82 gi 607793 
Ribosomal protein S15a  81 gi 55586139 
T-complex protein 1 subunit eta (TCP-1-eta)  81 gi 549060 
Beta actin 74 gi 89257929 
PREDICTED: actin, gamma 1 propeptide  65 gi 114670968 
PREDICTED: similar to complement receptor (Cr2) 63 gi 119923979 
Beta tubulin 62 gi 2144007 
Ribosomal protein S9  62 gi 146424326 
Alpha tubulin 61 gi 119587277 
PREDICTED: similar to laminin, alpha 2  60 gi 149636827 
Ribosomal protein S4  60 gi 4432939 
PREDICTED: similar to serine/threonine protein 
phosphatase 2A, 55 kDa regulatory subunit B, alpha 
isoform (PP2A, subunit B, B-alpha isoform)  
58 gi 73993713 
Translation elongation factor 1 alpha  58 gi 31092 
Abnormal spindle-like microcephaly-associated 
protein  
57 gi 38155726 
PREDICTED: similar to golgi autoantigen, golgin 
subfamily a, 4  
54 gi 109484079 
PIG48 (proliferation-inducing gene 48) 52 gi 46411195 
rCG39164  51 gi 149015707 
PREDICTED: similar to phospholipase C-beta-3  51 gi 119919228 
PREDICTED: similar to macrophin 1  50 gi 149608639 
Serine/threonine protein phosphatase 2A, 55 kDa 
regulatory subunit B, beta isoform (PP2A, subunit 
B, B-beta isoform)                       
50 gi 26347737 
PREDICTED: similar to tubulin tyrosine ligase-like 
family, member 6  
49 gi 109488871 
PREDICTED: similar to copper-transporting ATPase 49 gi 149730284 
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Table 7.1 Protein identification of recombinant FIP3 solution by nLC-ESI-MS/MS, searching 
the Mammalia database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 49 indicate 
homology or extensive identity (p<0.05). Protein hits of interest are marked with a star. 
 
Protein  Score Database 
Accession 
Number 
Beta tubulin 379 gi 24655737 
Alpha tubulin  356 gi 17136564 
Beta tubulin 224 gi 158743 
Beta tubulin 131 gi 21428640 
TCP-1eta chaperonin  118 gi 24645179 
TCP1 chaperonin 109 gi 125775778 
Heat shock cognate 4 83 gi 157665 
Heat shock protein cognate 72 82 gi 157658 
Histone H2b  71 gi 7436 
Ribosomal protein L9  70 gi 1208910 
Ribosomal protein S3  62 gi 296094 
Ribosomal protein S3  62 gi 38048231 
Kinesin heavy chain 62 gi 157778 
TCP1 Chaperonin 60 gi 125778070 
Heat shock protein cognate 1, isoform A  58 gi 17647515 
Ribosomal protein S10a 58 gi 21357663 
Acetyl CoA carboxylase 52 gi 24586458 
Ribosomal protein S19  50 gi 396531 
Actin 48 gi 156763 
Actin 47 gi 156773 
Ribosomal protein S9, isoform A  46 gi 24661707 
DGP-1 protein   46 gi 5764409 
Ribosomal protein S2  44 gi 288084 
Ribosomal protein L17, isoform D  44 gi 18921137 
N-acetyltransferase 1, isoform B (NAT1) 43 gi 22026966 
RNA helicase 43 gi 157594 
Innexin 42 gi 125981821 
Ribosomal protein S4 41 gi 440853 
Ribosomal protein S9 41 gi 125808610 
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Ribosomal protein S15Aa, isoform D  40 gi 17975567 
Table 7.2 Protein identification of recombinant FIP3 solution by nLC-ESI-MS/MS, searching 
the Drosophila database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 39 indicate 
homology or extensive identity (p<0.05). Protein hits of interest are marked with a star. 
 
7.1.2 Rab11-FIP3 gel slices analysed via nLC-ESI-MS/MS by Sir 
Henry Wellcome Functional Genomics Facility (SHWFGF), 
University of Glasgow 
Protein  Score Database 
Accession 
Number 
Rab11-family interacting protein 3  1868 gi 7662234 
Rab11-family interacting protein 3 775 gi 119916632 
Rab11-family interacting protein 3 583 gi 149750990 
Alpha tubulin  536 gi 2843123 
Alpha tubulin  505 gi 46409270 
Beta tubulin 486 gi 135490 
Beta tubulin  479 gi 224839 
Beta tubulin 470 gi 12851187 
Beta tubulin 453 gi 49456871 
Beta tubulin  448 gi 40018568 
Alpha tubulin  441 gi 135435 
Beta tubulin 426 gi 90080399 
Alpha tubulin  421 gi 66730465 
Beta tubulin 408 gi 149440634 
Hsp70 364 gi 126326875 
Alpha tubulin 350 gi 74186501 
Alpha tubulin 350 gi 119878872 
Heat shock-related 70 kDa protein 2  338 gi 123621 
Rab11-family interacting protein 3 332 gi 126335383 
Beta tubulin 323 gi 223429 
Hsp70 306 gi 640325 
Alpha tubulin  287 gi 149626356 
Alpha tubulin  283 gi 77539752 
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Chain E, Leech-Derived Tryptase Inhibitor TRYPSIN 
COMPLEX 
282 gi 3318722 
Trypsin precursor 272 gi 136429 
Hsp70 227 gi 62897129 
Alpha tubulin 179 gi 73960249 
Rab11-family interacting protein 3 164 gi 116667015 
Beta tubulin 151 gi 225480 
Alpha tubulin 134 gi 57099745 
Ribosomal protein S3 117 gi 32532 
Beta tubulin 103 gi 114575797 
78 kDa glucose-regulated protein precursor (GRP78 
precursor) 
90 gi 386758 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 2  
83 gi 15341763 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 1 
80 gi 119585235 
Ribosomal protein L9 76 gi 607793 
Alpha tubulin 64 gi 10436240 
40S Ribosomal protein S3  60 gi 73982323 
Chaperonin containing t-complex polypeptide 1, 
delta subunit; CCT-delta 
56 gi 126303810 
TCP1 Chaperonin 53 gi 201723 
 rCG39164  52 gi 149015707 
Eukaryotic translation initiation factor 3, subunit 
10 
51 gi 114326234 
Fatty acid coenzyme A ligase 5  49 gi 6174877 
Cytochrome b  48 gi 22652250 
Table 7.3 Protein identification of recombinant FIP3 gel slice 1 by nLC-ESI-MS/MS searching 
the Mammalia database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 48 indicate 
homology or extensive identity (p<0.05). 
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Protein  Score Database 
Accession 
Number 
Beta tubulin 234 gi 24655737 
Alpha tubulin 223 gi 17136564 
Beta tubulin 166 gi 860916 
Hsp70 159 gi 125778264 
Beta tubulin 148 gi 158749 
Beta tubulin 131 gi 158743 
Heat shock protein cognate 72 125 gi 157658 
Beta tubulin 85 gi 21428640 
Ribosomal protein S3 82 gi 38048231 
TCP1 gamma chaperonin 78 gi 125775778 
Ribosomal protein L9  76 gi 1208910 
GA15060-PA  67 gi 125776432 
Moira (contains DNA binding domain) 67 gi 4220848 
Heat shock protein 68  63 gi 34420080 
Heat shock protein cognate 1, isoform A  63 gi 17647515 
Heat shock protein Hsp70c  63 gi 38325846 
Heat shock protein 68 short form  63 gi 34420086 
Heat shock protein 68 long form  63 gi 34420082 
TCP1 chaperonin 62 gi 125778070 
RNA helicase 58 gi 157594 
RE65203p 54 gi 17946379 
T complex protein 53 gi 158534 
eIF3-S9, isoform B 48 gi 19922458 
eIF3-S8  47 gi 19922464 
CG11198-PA, isoform A  47 gi 24586458 
AT15052p  44 gi 18446976 
LD07301p  41 gi 16768826 
Table 7.4 Protein identification of recombinant FIP3 gel slice 1 by nLC-ESI-MS/MS searching 
the Drosophila database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 38 indicate 
homology or extensive identity (p<0.05). 
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Protein  Score Database 
Accession 
Number 
Rab11-family interacting protein 3 1292 gi 7662234 
Rab11-family interacting protein 3 653 gi 119916632 
Beta tubulin 546 gi 135490 
Beta tubulin 529 gi 224839 
Alpha tubulin 514 gi 2843123 
Beta tubulin 506 gi 12851187 
Beta tubulin 504 gi 49456871 
Beta tubulin 501 gi 5174735 
Alpha tubulin 412 gi 66730465 
Beta tubulin 404 gi 149440634 
Beta tubulin 399 gi 223429 
Alpha tubulin 396 gi 135435 
Beta tubulin 391 gi 74212109 
Chain E, Leech-Derived Tryptase Inhibitor TRYPSIN 
COMPLEX 
331 gi 3318722 
Alpha tubulin 326 gi 74186501 
Alpha tubulin 290 gi 119878872 
Alpha tubulin 277 gi 149626356 
Beta tubulin 272 gi 126321861 
Beta tubulin 232 gi 73962097 
Beta tubulin 213 gi 10433717 
Alpha tubulin 178 gi 73951159 
Alpha tubulin 147 gi 73960249 
Beta tubulin 126 gi 225480 
Ribosomal protein S3  109 gi 6755372 
Beta tubulin 98 gi 147223311 
T-complex protein 1 isoform b (TCP1b) 92 gi 57863259 
PREDICTED: similar to retinoblastoma binding 
protein 4, isoform 5  
81 gi 88982346 
Ribosomal protein L9 76 gi 607793 
Translation elongation factor EF-1 alpha  75 gi 31092 
Alpha tubulin 69 gi 10436240 
PREDICTED: similar to BMK1 alpha kinase  68 gi 126334010 
Alpha tubulin 57 gi 13376181 
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PREDICTED: similar to laminin, alpha 2  55 gi 149636827 
Solute carrier family 25, member 41 54 gi 115495681 
Replication factor C (activator 1) 2, isoform CRA_c  52 gi 148687478 
rCG40478, isoform CRA_e  52 gi 149068843 
Table 7.5 Protein identification of recombinant FIP3 gel slice 2 by nLC-ESI-MS/MS searching 
the Mammalia database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 49 indicate 
homology or extensive identity (p<0.05). Protein hits of interest are marked with a star. 
 
Protein  Score Database 
Accession 
Number 
Beta tubulin 273 gi 24655737 
Alpha tubulin 200 gi 17136564 
Beta tubulin 181 gi 860916 
Beta tubulin 169 gi 158749 
Beta tubulin 135 gi 158743 
Alpha tubulin 116 gi 17865841 
Beta tubulin 87 gi 21428640 
Ribosomal protein S3  78 gi 296094 
Ribosomal protein L9  76 gi 1208910 
TCP1 Chaperonin 73 gi 125810511 
t-complex polypeptide 1  68 gi 7716854 
TCP1 Chaperonin 64 gi 125775778 
Lasp protein  58 gi 27526238 
CG11198-PA, isoform A  54 gi 24586458 
GA11482-PA  52 gi 125777031 
RNA helicase 51 gi 157594 
Int6 homologue  50 gi 17137592 
Chromatin assembly factor 1 subunit  46 gi 17933648 
Elongation factor 1-alpha (EF-1-alpha)  42 gi 7915 
Table 7.6 Protein identification of recombinant FIP3 gel slice 2 by nLC-ESI-MS/MS searching 
the Drosophila database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 38 indicate 
homology or extensive identity (p<0.05). 
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Protein  Score Database 
Accession 
Number 
Rab11-family interacting protein 3  1088 gi 7662234 
Rab11-family interacting protein 3 564 gi 119916632 
Keratin 424 gi 1346343 
Keratin 420 gi 109096823 
Chain E, Leech-Derived Tryptase Inhibitor TRYPSIN 
COMPLEX 
402 gi 3318722 
Ribosomal protein S3 143 gi 6755372 
Beta actin  138 gi 49868 
Keratin 129 gi 453155 
Keratin 127 gi 547754 
PREDICTED: similar to casein kinase II alpha 1 
subunit isoform a isoform 1  
121 
gi 73991517 
Keratin 116 gi 81891716 
Keratin 102 gi 4159806 
Keratin 99 gi 45597458 
PREDICTED: similar to casein kinase II alpha 1 
subunit isoform b  
98 
gi 114603982 
Ribosomal protein L9 92 gi 607793 
Keratin 90 gi 119892108 
Ribosomal protein L9 83 gi 109503459 
Keratin 80 gi 47059013 
Keratin 76 gi 148747492 
Keratin 73 gi 52789 
Keratin 69 gi 398168 
Alpha tubulin 69 gi 2843123 
Alpha actin  64 gi 49864 
Keratin 64 gi 115528975 
Beta actin  61 gi 27687455 
Beta actin 61 gi 57043600 
PREDICTED: similar to laminin, alpha 2  61 gi 149636827 
Beta tubulin 59 gi 57429 
Trypsin 10 58 gi 84781771 
Alpha tubulin 57 gi 66730465 
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Keratin 4 56 gi 148356276 
Cationic trypsinogen  56 gi 27465583 
PREDICTED: similar to ribosomal protein S6 kinase, 
52kDa, polypeptide 1  
54 
gi 73960898 
PREDICTED: hypothetical protein  51 gi 119914297 
PREDICTED: astrotactin  51 gi 114565537 
Transition protein  51 gi 110056 
PREDICTED: hypothetical protein 51 gi 126307650 
Table 7.7 Protein identification of recombinant FIP3 gel slice 3 by nLC-ESI-MS/MS searching 
the Mammalia database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 48 indicate 
homology or extensive identity (p<0.05). Protein hits of interest are marked with a star. 
 
Protein  Score Database 
Accession 
Number 
Ribosomal protein S3  83 gi 296094 
CKII-alpha  78 gi 17016246 
Ribosomal protein L9  70 gi 1208910 
GA17990 (Superfamily II RNA helicase)  52 gi 125984810 
Actin 49 gi 156773 
Trip1 44 gi 17648041 
Hu-li tai shao protein (homolog of adducin) 39 gi 157747 
CG32528   39 gi 24643390 
Table 7.8 Protein identification of recombinant FIP3 gel slice 3 by nLC-ESI-MS/MS searching 
the Drosophila database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 38 indicate 
homology or extensive identity (p<0.05). Protein hits of interest are marked with a star. 
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Protein  Score Database 
Accession 
Number 
Chain E, Leech-Derived Tryptase Inhibitor TRYPSIN 
COMPLEX 
331 gi 3318722 
Trypsin precursor 306 gi 136429 
Rab11-family interacting protein 3  246 gi 7662234 
Ribosomal protein S3 221 gi 6755372 
Keratin  192 gi 146741486 
Keratin 133 gi 73996498 
Keratin 110 gi 126343630 
Keratin 4 103 gi 148356276 
Keratin  74 gi 113420086 
Trypsin 10  60 gi 84781771 
Keratin  57 gi 148672070 
BBC1  56 gi 29383 
Acetyl-CoA carboxylase 2 54 gi 40019048 
Ribosomal protein L9 53 gi 607793 
Sema domain, seven thrombospondin repeats (type 
1 and type 1-like), transmembrane domain (TM) 
and short cytoplasmic domain, (semaphorin) 5B  
52 gi 109493368 
Acetyl-CoA carboxylase  52 gi 2138330 
PREDICTED: similar to aortic preferentially 
expressed gene 1  
52 gi 113413482 
PREDICTED: similar to Acetyl-CoA carboxylase 2  50 gi 149720500 
PREDICTED: similar to phospholipase C, beta 3 
(phosphatidylinositol-specific) isoform 6  
50 gi 73983251 
Ribosomal protein S9 isoform 2 50 gi 55661270 
hCG41114, isoform CRA d  49 gi 119580811 
Table 7.9 Protein identification of recombinant FIP3 gel slice 4 by nLC-ESI-MS/MS searching 
the Mammalia database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 49 indicate 
homology or extensive identity (p<0.05) 
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Protein  Score Database 
Accession 
Number 
Ribosomal protein S3  114 gi 17136324 
Ribosomal protein S10a  64 gi 21357663 
Ribosomal protein L9  53 gi 1208910 
Ribosomal protein S9, isoform A 53 gi 24661707 
Ribosomal protein S16  43 gi 19922746 
Phospholipase C 40 gi 158131 
Table 7.10 Protein identification of recombinant FIP3 gel slice 4 by nLC-ESI-MS/MS 
searching the Drosophila database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 38 indicate 
homology or extensive identity (p<0.05). 
 
Protein  Score Database 
Accession 
Number 
Keratin 583 gi 1346343 
Chain E, Leech-Derived Tryptase Inhibitor TRYPSIN 
COMPLEX 
335 gi 3318722 
Trypsin precursor 314 gi 136429 
Keratin 277 gi 453155 
Keratin 151 gi 73996498 
Keratin 140 gi 148356276 
Keratin 122 gi 126343630 
Rab11-family interacting protein 3  122 gi 7662234 
Keratin 113 gi 114644554 
Keratin 112 gi 149714742 
Keratin 105 gi 149417889 
Keratin 101 gi 57012352 
Ribosomal protein S9 isoform 2 99 gi 55661270 
Keratin 89 gi 81891716 
Ribosomal protein S23 84 gi 3088342 
PREDICTED: similar to calmodulin  84 gi 149255339 
Keratin 82 gi 109099462 
Keratin 78 gi 46485130 
Keratin  75 gi 24753845 
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Keratin 75 gi 109096855 
Keratin 71 gi 62122767 
Keratin 69 gi 52789 
Ribosomal protein L31 66 gi 1655596 
Histone H2A.2  59 gi 31979 
Ribosomal protein L9 59 gi 607793 
Keratin 58 gi 547754 
Keratin 57 gi 27764561 
Histone cluster 1, H2ba 57 gi 24586679 
Keratin 53 gi 73996461 
Histone H2B 53 gi 119879706 
PREDICTED: hypothetical protein  52 gi 126341903 
Keratin 52 gi 398168 
Table 7.11 Protein identification of recombinant FIP3 gel slice 5 by nLC-ESI-MS/MS 
searching the Mammalia database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 49 indicate 
homology or extensive identity (p<0.05). 
 
Protein  Score Database 
Accession 
Number 
Ribosomal protein S23  84 gi 22024141 
Ribosomal protein S16  77 gi 19922746 
60S ribosomal protein L31 66 gi 6094051 
Chain A, Solution Structure of a Calmodulin-Target 
Peptide Complex By Multidimensional Nmr 
64 gi 494737 
Similar to Drosophila melanogaster Ribosomal 
protein L9  
59 gi 38047669 
Ribosomal protein S9, isoform A  56 gi 24661707 
Ribosomal protein S10a 55 gi 21357663 
CG32275-PA  43 gi 24656683 
Table 7.12 Protein identification of recombinant FIP3 gel slice 5 by nLC-ESI-MS/MS 
searching the Drosophila database, performed by SHWFGF, University of Glasgow. 
Individual ion scores greater than the probability based MASCOT cut off score of 39 indicate 
homology or extensive identity (p<0.05). 
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7.1.3 Rab11-FIP3 gel slices analysed via LC-MS/MS by Aberdeen 
Proteomics, University of Aberdeen 
Sample 
Details 
Summary of Sample Results 
from Human database 
Summary of Sample Results from 
Spodoptera Frugiperda database 
Gel 
Slice 1 
gi 30411061  
Rab11 family interacting 
protein 3 (class II)  
No hits 
Gel 
Slice 2 
gi 386854  
Type II keratin subunit 
protein 
No hits 
Gel 
Slice 3 
gi 7662234  
Rab11-family interacting 
protein 3 
No Hits 
Gel 
Slice 4 
gi 7662234  
Rab11-family interacting 
protein 3 
No Hits 
Gel 
Slice 5 
gi 7662234  
Rab11-family interacting 
protein 3 
No Hits 
Gel 
Slice 6 
gi 7662234  
Rab11-family interacting 
protein 3 
gi 12585261 
Heat shock 70 kDa protein cognate 
4 (Hsc 70-4)  
Gel 
Slice 7 
gi 7662234  
Rab11-family interacting 
protein 3 
No Hits 
Gel 
Slice 8 
gi 4507729  
Tubulin, beta 2  
gi 121987496 
Tubulin beta-1 chain 
Gel 
Slice 9 
gi 7662234  
Rab11-family interacting 
protein 3 
gi 91091212 
PREDICTED: similar to tar RNA 
binding protein 
Gel 
Slice 10 
gi 7662234 
Rab11-family interacting 
protein 3 
No Hits 
Gel 
Slice 11 
gi 7765076 
S3 ribosomal protein  
gi 16566719 
Ribosomal protein S3 
Gel 
Slice 12 
gi 7662234  
Rab11-family interacting 
protein 3 
gi 74844658 
40S ribosomal protein S4 
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Gel 
Slice 13 
gi 607793 
Ribosomal protein L9 
gi 21759393 
60S ribosomal protein L9 
Gel 
Slice 14 
No Significant Hits No Significant Hits 
Gel 
Slice 15 
gi 1655596  
Ribosomal protein L31  
gi 51701794 
60S ribosomal protein L31 
Gel 
Slice 16 
No Significant Hits 
 
No Significant Hits 
 
Table 7.13 Protein identification of recombinant FIP3 gel slices by LC-MS/MS searching 
Human and Spodoptera Frugiperda databases, performed by Aberdeen Proteomics at the 
University of Aberdeen. The major FIP3 band is found in gel slice 4. 
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